var title_f12_3_12336="Posterior vaginal wall prolapse 1";
var content_f12_3_12336=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F73011&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F73011&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Repair of posterior vaginal wall prolapse",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 372px; height: 492px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A triangular shaped incision is made in the perineal body.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Walters, MD, Karram, MM. Urogynecology and reconstructive pelvic surgery, 3rd ed, Mosby-Elsevier, 2007. Copyright &copy;2007 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_3_12336=[""].join("\n");
var outline_f12_3_12336=null;
var title_f12_3_12337="Josamycin: International drug information";
var content_f12_3_12337=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"15\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Josamycin: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4303777\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Alplucine (FR);",
"     </li>",
"     <li>",
"      Iosalide (IT);",
"     </li>",
"     <li>",
"      Jomybel (BE);",
"     </li>",
"     <li>",
"      Josacin (DE);",
"     </li>",
"     <li>",
"      Josacine (FR);",
"     </li>",
"     <li>",
"      Josalid (AT);",
"     </li>",
"     <li>",
"      Josamina (ES);",
"     </li>",
"     <li>",
"      Josaxin (ES, IT, JP);",
"     </li>",
"     <li>",
"      Wilprafen (CZ, DE, HU, LU)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list synlist drugH1Div drugBrandNames\" id=\"F1979148\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Index Terms",
"    </span>",
"    <ul>",
"     <li>",
"      Josamycin Proprionate",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1979150\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Macrolide",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F1979153\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of infections caused by susceptible organisms including infections of the upper and lower respiratory system",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F1979149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: Oral: 1-2 g every 24 hours in 2-3 divided doses",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821089\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1979152\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Suspension, oral: 125 mg/5 mL, 250 mg/5 mL, 375 mg/5 mL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Tablet: 500 mg, 750 mg, 1000 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10400 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-2EE9D05621-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_3_12337=[""].join("\n");
var outline_f12_3_12337=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4303777\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979148\">",
"      Index Terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979150\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979153\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979149\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821089\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979152\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10400\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10400|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_3_12338="Trachelectomy cerclage PI";
var content_f12_3_12338=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F50693&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F50693&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 563px\">",
"   <div class=\"ttl\">",
"    Cerclage placed after trachelectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 543px; height: 314px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Radical trachelectomy is defined as partial or complete surgical removal of the cervix and parametria (connective tissue next to the uterus and cervix). Trachelectomy may be done through an incision in the vagina or abdomen, depending upon the surgeon's preference. The cervix and upper portion of the vagina may be completely or partially removed, depending upon the size and depth of the cancer. A permanent purse-string (cerclage) is placed at the lower end of the uterus or remaining cervix.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_3_12338=[""].join("\n");
var outline_f12_3_12338=null;
var title_f12_3_12339="MRI osteitis pubis";
var content_f12_3_12339=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F80072&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F80072&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 583px\">",
"   <div class=\"ttl\">",
"    MRI of osteitis pubis A",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 563px; height: 264px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEIAjMDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6M8W+JI/DcOns2n32ozX1z9khgs/K3l/KklJJkdFACxN39Kxl8dXjfd8E+JP+/th/8lUfEnjUvBX/AGGX/wDSC8p3m4GR25oAU+Nr8dfBHiT/AL+6f/8AJVMPjq8AyfBPiT/v7Yf/ACVUd7fYVCPWnx3kEikyfe9KAFXx1eN08E+JP+/th/8AJVJ/wnl3uI/4QrxJn/rrYf8AyVSG5iI46ms7zf378n86ANT/AITm9/6EnxJ/39sP/kqkPjq8HXwV4k/7+2H/AMlVkSasA4i9OM1UvtR2bmHUAkc0AbUnxHljYq/g3xICOv7yx/8AkmqkvxXhiOJPCfiQH/esv/kmuH1rVp2SRyMhQSa4q+1QwP56dTyKAPbB8Wrc5/4pTxHx/tWX/wAk1HJ8X7WMfP4V8RgfWy/+Sa8Fl124Vw+fv8U/XNZuPsMXtQB7e/xs01HCt4Z8SAk4A/0P/wCSKsS/F+1igE0nhXxIsZGc5sv/AJJr5wt764nuY+ed4/nXVeKNZLaLDbQcThcNQB6u/wAddHQ4bw54jz9LT/5IqCT4/wChRnD+HvEgP+5a/wDx+vnKSWZnUTfeJ4qOCGf7S+enU0AfRb/tEeHEYK2g+JAT/wBM7X/4/Vj/AIX5oe0N/wAI74k2nvttP/kivmi+hJYhevarumMHjKTH505/GgD6HX9oHQGYqPD/AIk3Dtstf/j9P/4X7of/AEL3iP8A75tP/kivm4yk3EmOppn788ZoA+mF+O+jOQF8OeIyScDi0/8Akipk+Numufk8M+JD+Fn/APJFfMkVxO0yJkfIwNaFvfTq0rN91QSaAPpWL4vWswzH4U8SH8bIf+3NSJ8V4nJC+EvEhI6/NZf/ACTXzrY6+UAb0rYtvFOSAeR04oA92HxRUkAeEfEhz/t2P/yTT5PiaYwC/g/xIAf9uxP/ALc15ZoniO3kaND1LAV1ttqEDMo9xQBvP8WYEuBA3hPxIJT0XdZf/JNXT8RJgiufBviQKen7yw/+Sa5y40+w1A75QPM6j61fjgZZ0ji+4sfNAGuvxBuGPHgvxIf+2lh/8lUn/Cwbjdt/4QvxLu9PMsP/AJJrPmkMixRr94EY4q9pa26O7Njzhy1AEg8fXRk2DwV4l3YzjzLD/wCSqkHjm9P/ADJPiX/v7Yf/ACVVlRFuEo6nmnuN7g++aAKj+Nr5ApbwT4kAY4H73T//AJKpw8Z6gRkeCPEmP+u2n/8AyVVl/wB84Xj5TmlWIkjHU0AUpfHcttJaf2j4T1+yt7i6gtPtEslkyI8sqxIWCXDNjc65wDUnj7x/Y+C7jT4LzTtSvpb2OaVBZCL5FjMYYsZJE7yrjGe9Z/jpJE0WwD8r/bOk/wDpwt65H9oVtviPwqP71lqA/wDIlpQBtJ8atOeEyp4Y8SGMdSPsfH/kxUI+OeknOPDXiQ/8BtP/AJIryqCEWsaGT/Uy/f8Aw/8A11ZlggEW+2+5zQB6Yvxz0ls48NeJTjr8tp/8kUh+OmkAHPhvxJx/s2n/AMkV5TYaHJczS3C42hcketUtPjQxSrH/AKyNuRQB7P8A8Lu0zyTL/wAIz4k2euLT/wCSKjT46aRIcJ4a8Sn/AIDaf/JFeM3T3bK3m58telP86CfT/K48ygD2NPjro7yMi+G/EhZeSNtp/wDJFTL8a9OaESjwv4l8s98Wn/yRXhomnhjWLy96evpUcj4XZE+7zPvj0oA9uk+PGixgmTw74jXHqLT/AOSKgk/aD8PxqGbQPEeD3CWp/lPXz9rFwkYWNeGXO6sOG7dpii/dbrmgD6eT9oHQXiMi+HvEpQdTstf/AI/USftE+G3zt0HxJx1zHaj/ANr1873F5GLTyEJz1P4VkiTzQsv4flQB9OD9ozw0SR/YPiXj1itv/j9Kf2ivDYZQdB8SZbp+7tuf/I9fM00pmVY+h9arypIZEjh/1i9KAPqF/wBorw2hw2geJc/9crb/AOP00ftG+Gj/AMwLxJ/36tv/AI/XzZsnWIbv9YQd1Z6+Z537ygD6iX9o7wyzBV0LxIWPQeVbf/H6dJ+0Z4aj+/oXiQf9s7b/AOP18yaWn+l3EnH7tf8AGoI1Nyof/aP40AfUMn7R3hmNFd9C8SBW6Hyrb/4/TW/aR8LhA50PxJtP/TK2/wDj9fMs1vtVc980+2hTDh/vcY4/OgD6Zi/aO8MykBNC8SHPT91bD/2vU4/aC0AhiPD/AIkIXr8lrx/5Hr5ak3wnc3TtU9rHIyStGP8AWDn2xmgD6fT9oDQX+74e8Sn/ALZ2v/x+hf2gdBZyq+H/ABJkdfktf/j9fLkV3OrvGf4cfrU8V3IziOTo/T8KAPqD/hfWi9vDviQ/RbT/AOSKkg+OukTuVi8N+JGYDONtp0/8CK+etPleJSi/dOM1pGVINsiE55zQB7evx70RoXlHh3xIEQ4JK2gwfp9op1v8eNFuFLQ+HfEbAe1p/wDJFeLxuLpSxHynrgVB9nsoGwv+tf8Ap/8AroA9tl+PeiROiSeHfEgZ87Rstef/ACPUi/HXSGcIvhrxKWIzgLaf/JFeF6lpU8cCzyjCDOw/zqtDI8MaMn+rfO4/Tp/OgD6BuPjfpdvAs0vhrxGIzkAj7Gen0uKhPx30dYPOPhvxII84zttP5faK8OLTrtI/1J6ZqwmyaI7Oo60AezH4+aIDg+HPEuf9y1/+P1reFvjDpHiLxLp+iw6PrdpcXzOkUtylv5YKxvIc7JWI+VG7da+eItkVw3mYy3TNdF8LnR/i94VEfQXU+f8AwDuKAPrCiiigDg/iqWF14MKdf7ab/wBILuubh1WY38sB7e9b/wAXZPJfwfIOdussf/JG7rzK7uQdXllIOCecelAHctJblSJfvEcfWsDUbiOJwtj/AK0nBrD17xALS/tkmH7gqAKuvrVlb2guIz85GQPegDfh1KWC2Xz/ALwqvNqeG3d34FcBrPiyfUN6AdAetcxBrtxNO0XpQB65Nq1rI/kzn5l4zWHc6i/2l4X+5J8kf1PArgLbWkhum+0de9X9Vlu7uyOoKf3CqVTmgDae+Q/aILnGQpH44rkdRBikHk8rIcH8aW81HdPbiX/WeXhcVjyyXE14T15z/WgCS6byFbPYfWq0Eocbn+6OT9KE/wBbJ5P+tx81NRUZwF+8TiT6UAadl5EUkci9WYfzo1W7Mzeaf4fkrJFw1s80b/cKkJ9e1S6ZL9oWdZP9ZGpYfUCgCSH5xu9OasL+4iZv+egxms3bO86IT94gZ9aW8eZH8tuidaAH3LEW8p9FJ5q3pe2OySV/usPm+lVYV868Y4/5ZH+VFgP9CeL+/IF/M4oAuTLFIwaD7oqrcZDAipHufJQwY+6MdKRyDHFI3RSGP4UAWfJEdssv96ovIMp3L1FNa6aVS0JOyoIwZZAw6jmgCMW87vMv95SPpxiltvtFkV9M5rTTz/MXPTPNSzrnI9aAKWl6hLCE3/cknVT9MivS5NQMVvLJB9xCjfh/nNecmygjH2d/9a/zL9e1dLoM9xPavZHlUU5oA9S0G48945/70ea1ZdQ8ogDr61xPhJsRyQ5+6prZuI/skMknQsp7e1AHV6Tch5GeUYYc9KnjQmAyDOWcVxl1q6s0SEcLHk/zrd8P6pBdR7F6L7UAdFb+chC+pxTbu8ltW2nGO9VNd1WLTbOOUfe6ismC/W8UTzHlvegDpra781CR1xU8NxKQPU1z8F/ChCr1PFa1pJtXef4qAM/xxdf8SvT4X++2taV+l/bmuZ/aFZE8TeEjJ0+x6hj677Sug8aeW2nacy/eGs6V/wCl9vXN/tFqr+JvB6N/FbX4H/fdpQBxmpIbjR4/s2cICT+lXPDojTSLnUrz+DaF/DNZGrRz2lwcSBAFXA9auQ6ybvSnsZ49jSDCH1/zmgCSDX4rhm+w8M4IP4VhwWaEiQf65mYuP5Vc0ywu7C5VIv8AVv1rdNrCpb7T/rGxjjvQBx1yu5pl7DHtUQ0uSSOJ4u2c11UmhvdArH909atXumLpmissR/eY5oAxbPT7hrWVR98AYrltauIZI5IWH7+H73HrWt4a1udL+WK5P7luP51zPi3zI9YkeD/VucjFAGJJ5zARD7rGkhsZzMo/u02WWfK/U0skshUeZx6UAJcfaIpiOeadbtOwfjpUdtNJuYR9+tWLqElF87q2dtADY5XQvHJ1k4FQO/luF9KrmJ7WZXk5iYnNaNwj/Zkkhz5cnSgCCV96qc9Peo333cLov3RjNXjbzx2Bm/u1Ws3kkjZ5O/SgA0sw7Ht2+9t5qRFgtrKNQfm3NVK6iSSaLd1XJX61qyWjpBHJLkwoDn8aAM4NI0gLdF6VpCXfGG7R1Uj5csvMZ+7V2Bttwg7FG7UAV0+Ys/du1V7zzcp5X3ed/wClPsVRZJS/Uk7aiad7eeYy/wCpOAaAGyTW0WzZ/rGzupk5f5GY8c4qWG18qOXb/q+GX9alkmf7JhScD71AFnRG+0SsjcxjG6tW3ljXUEim5tVNYlvfJBAdnLN1/Ctuz33SQFOi8tQB1a+IbWBGisvuIBnNV7cpdySXJ/1wwyf1qxHoKajpzqp+4VLfrWHqNumm6tElp95F+f8Az+dAGheXsl20ckv3zlTjtipLWHJDJ/rD93BrNvridri3LdJMj+X+NdHDJa6PZ+SY/Mu5V/dn+7nr/OgCrepttCP+Xk+lZEdi5Tzhjen+s/pUtxZXVnKWe4/eSfMq5qWDUrWO3mgkj23cm3B9cZz/ADoAjhhjOWj/ANYa6f4Z/ZY/in4RSP8A4+Wu5y/0Flcf41zcODGsI4nbpXR/DSDyfit4QVv9aLq4Df8AgFcUAfVFFFFAHB/FRQ1z4NU/xaw6/nYXleI+PFuNM1QkY/ece1e0/F5mWTwaU+8NaOP/AABu68x8boL7SZfO5kjYsKAOItpBOQZvvjpUF/dNnEf34xkfUc/0qlYN5V0wbp3rrL/w9bzaZHqnYjGKAORzK2ZLrq/XtR5UAyV6jkU2XypLxo4x86n5frUskXnxsIeZkBLUAZN9CJCWPQDJr0+zEFv4NhtB1lQn9K4G6hn+yj3Bqa91y4h0hLc9AuKAKWoacy6iTGPnDcfWq6WstvJJFP1YF67DSZLbWGtkh/1yoN1bEvhsvG0i9QpINAHnduhtB5i9W461reE7WW81B2k+5n5vpXa6f4YEoDXH3+wzXRaf4ZW0w5PDdaAPMdS0F5IHeD7ok6/jVGfSpbDVrfzceW4Ab6GvaJLAxtsh+7nFQaloQmWNsfdIoA88k0aCNreSD/Vu6gn2zUPj7QTBNaywj92yc16Zb6H9ogZB1RePrSa9p872EcBHAFAHilhDPJNHGmfKVhu+lJf2gttWtmT/AFLyru+mRmvVrLQ9kZK9QMivOvFthcx3srqAxXJA9e9AGp4t0aFRbT2/3DH1454rm47Au4j7McV1vhzXkvNJNpfWmJEUgH8K2obS3uYoRx8xAx+NAHnNxZfY8r7dqZPZmO3SRerDiuk1WzJ1QW0ONgYA1fudPMFoNvXGRigDmU0y5SxEi/ecYH1qLT7aXMouf+WYLH8K7u5tJ4NDEzdChJ744riLeW4/tBfLGY9w3fTPNAFfVEM9/H5P3SnP0p9lfCz1mGE/dZQv51Y1WExEyj7zDis200+41O6h+yjLo6s/0zQB6d8OL+G51C4t14PQe1bHxzeG3sLCODAncYNcl8H0jm8S3UFz1iP8jTvjVq0ep67Ha9oFKp/vf5xQBjWbeVZrdyf6zG1fqRU+jeKptI1JGflHcbh7ZqLV4xYeG7Qy/ffgYrE0i4+2au8Q7RHg/SgD1jXdYhbT47tOWk+73rj7DULm/urkDlo0J/KqeoX/ANptlt+MQ8jJqn4N1A6dfXbr951OM+poA09N8Uz6fqCRXPJLgfrXsfhjUTf2hlXqBkV8/wA1o+tzO9qM3LTD8817f4L0290jRIUl/wBY42/jQBo+M5VFhpKr999a0sN+F/BWH+0TK0PiTwmyx+Z/omoAj0G+05rV8VIgtNMJ/wBb/bWl7v8AwPgrN/aF2/8ACT+EvM+59k1Dd9N9pQB57dywarpyQpB5VwmWXHf1rnLm6um8jy5vKmiJU+44revLW0uIl+z9Bnbn3rn7m2e3zu+633aAO306287TYpzN5t23X2rftHt47ZPtWBKOvFcp4LfbdxfSrXjCacXbG0h82UdPUUAdJc6rBDbyS23VBzXD33iEaglzHqmBanjgU231a/jsnQw+VP396wJGhupnW7H78nn60ASLNAIJEsf+PYfcrm5f3t3t/DFaeowZhMI6Lk1zdrPO92zW0PmvkAe2KAJ7zTh54binC33KF9K34Iobqa1F1D5Uwzn3zirX9hx/apmb7vGBmgDm7e0w25/9UPv1dRIXlRbf7gB61vwWiRBli6NjNPezSPBkGN3TigDlZNOT+y5WfruOKg02xea2y3Kx9Pxrq5NORl2R87qdpVuLO4ckjai560Ac7Iu+3khrKlikFt5cP+sHSuxl+y3dsHjP7wM2f6VmppzyeaW6DoaAOTvLd7eKF5f9Yck9/Suh067jurERyfwdPxqvd2O7d6L61kNDIWeOMcnHagDZh063ivkkf/VFW3ZpsdxAY5FX/Vq3y1JpcM4WOJs+WB839Kmu9JknMoOPLONlAGUjwNISO3SrElwjQlY+MdasLp7iFIY+wqRNDNrFJJOfmbG38KAKrzSLBE8efl61HvLjzrr/AFdQiWYSsqj5R0461YlmzbMk33m+6KAKo2PIPJ/1T/drRhm+zyxL6A9azPsk0UCSdELD8K6vSNIudd1WGCy/1UYDXH07fyNAHonhyN4fCC3MfWTIPFc34bi265dfaf8AlmNw59c/4V0Wq3V1q9rFo+ifJaWwKmT+6Tgf0rlZ7PUdAhuQY/MY4zL1z1/xoA0NZto3t45rePfLubafTpV7w7ok7wPdTyb7gY2DPTrn/PtXA2U99f6naxSXWyKYkMPyrv7aX/hH52s3n821UBj7ZoA5rxXqrjVrK2T/AF5Zt3/jtWtehtZLxPM/4/FXt71Hr62lxcfa7b7652f1/lXO3VzIxEsp+deKALFs8w1cRwf61utdt8N7i3Hxd8KWyj/SvtU7yH2Fncj+tc/psL39piL5ZGxh/wC7W38L4FtPi34ShHzSm5uC8n97Fncf4mgD6uooooA8/wDi2SJvBpXqNaP/AKQ3dZk1pbXcLxzdXBXn6VpfF0Zl8Gj11sj/AMkbusm/vharGD03YJoA808T+ELjSrma5tMGBwd3070W1xjRXtz1WNhg/wC6a6y18TW17qsmjtnEhwc9weKzfF/g57ZBd2H3G5agDy2X7MLxjL98dKZLDFE4lsuJXOGq5Pptz9qk2ct2rMvI53kCQn98nLc0ALOqnib7x4FUJjuPlj+CtGaKUQIZ+o5qHTE8y62/3mxQB2ngXSGvIQ6Z38Y+td3B5tivl6kchuE+vasHwHbm3clMbgcj+ldBbwquoSXF3/ruq/XtQBsRwQokbjq5FakJ8vC1lQXXAz09KLjUNmVHPbpQBtjjmopZMnmuN1DxctoWjLY2DJPpXNa94ruWgWS2vBh/btQB6ob63t/mJ4HNZn9oRXs7eR0PrXl9jqExQy3F7y3HWtzTrzO0C9Hp+NAHbeRu+XnB46Vj6j4TW9mBbuaZbalfQnM10DFn5RjqfSr5uphbSzEZypJHr7UAcToHh/de3ls3PlS5rdJXTZURvuEjNT6fdeXcmX7HgMe1Lq2pBCSbUgDJJ9MUAPjawndcdzito6PDNbIIQNp9e9eda3qNvKsbD1GOarW+u6nbbSP9QOVoA7HxLoAu7f7N26fSuZPhW6sYJPspzhSR9cVraf4sivAI3H74ff4rSGqW8mE3bd3GfTNAHK2fhG5njae/P7tuXHt3rIuNVtdJNxZ6LjztpXt6V3l7dW88ckH2rOAfl9eOlc9p+hwjUFKnmRwo59xQBT0S0k0fw1LdQMFuLj55j6DvUGr6KbjTY71QZDIMhuePetLxMlveRyxwttmhUq5/CnWel3B0eJYr392ev0oA467E0UcasDiM7unbrVLQbLytXF4ejsK9B8Z6Ktpa2s32rcvl8jHUVyNxuxF5H3dwz9KAK14P7Nt7u7wW3sTj1qC5gvNau7a0tLXaWUMCOMe9bWtwm5urexs/vsmW9K7rwP4eFtfRmY/Ps4oAm8AeF49OhU3GPtQOWP0rttQu2g0oJH99pAF+tSGz8kHPTvVQSwSTxx91YcfjQBj62yrp+mbv9c+s6Xu/8D4Kq/tDyRx+JvCPnfca01BT/wB92lbXi9IlstNK9RrWl4/8D4K579pK3+1eJvBkY729/wD+h2tAHDXdlOLdZkx5H8FK1qf7NLz43OPl9q3NL1i3ha30m54znb+lVviLrFpPo/8AYVv/AK92yn4UAYFok+nSx3X8ANR61dS38iXdlMYpVzu96ZZw3WnpAL/hGXacUy60xV1CJXn8q2Jzn1zQBVWa+AM8k3muv3x6elJasb2UyN1XrxXS63pvh+00yI2l7iZwd+PbGP61zGnwot5E8GobNpOB/eoAp3Sb5ZU79PpWbFpM0N9HLbybGznHrXR6pZz3FxJLK+9/+WZ/nWNB5lveo6f8fCk5oA6+51ixh0YQi3xqBGN9UoIZjaxSXEu8tnAz0qpc/ZZnWWb/AI+O9NmvBEFAzg5xQBeEhl/0cD5n5/Ko57ic7ZLqby4EyPrWRd6tBEoeabyyMhawp9SGWQXO5RyB65oA6W+ubcbHtpvNRs8ntVN5fOKgdK5a21aSC9V4oOit82Kqpr17uYwjzxIx3D+7igD0TTdHnvZP9Hk2BfvDPWn/AGZIriSCaPaVI59a4yw8a3lmG8qLy5kx+NWv+Eylvv8Aj+/1jd6AOtu7O3ijQn/VORuxWXqtjs1IyWmDHgYqnp3jm10wyK8Pm5xjnp1/xq7F4qsbt/O8nyt360AQ6ppV2libpR8veqJubhdOjaH0O/8ASuhvNat7qBYoR+7/AOWn9KwInc3TLEf3KqcD60AWNO16C2tn+0jkkVeuLu0uraIw9Zc/0rm/3fkgnlAW8z9MVUklSSYfZP8AVrnNAHQrbAllm4C/dpiW0KJKy5LDGOaoC7gCDdJsK9R60JrcEV1CfL2Jzk+tAGbfXl/JdxrKf3Shh9OlewfDPRIW0Tz4pjH5ysJB1z6f1rgrx57uMygn7M3SrGl+Lr/QbWRbVA8ZwufTrQB6L4T0W+tb2/gWfzYEIdeenWtXSdmrwTQ3MIkRW2t7V5FY+LNas7xpxKWjkU7l9K6Hw58RJtLtplWASyMdx5xigDU1PwvBaXs08UHlJCQ6jPWsPU7i6v7CeZMbMBT+FZ2teOtS1mSW3nhEdvP94djism71S4h0/wCzQn9zGfm59aAJI/tEUcQi/iJ3VqQJsVXb7x61nWk0Oo6eqxffX7+fU9K0YcLCsZ6L15oA3NJ1r7Hb3UXaZAv8/wDGp/hCuz4p+EUPUXdyenrZz1g+VpslvMc/6SuPL/rXR/CQuPij4RV+11P/AOkdxQB9ZUUUUAeY/Hef7Np/haYdV1hsfX7FdgV51petyy6ZMuqjO5sIPU9q9D+PZiXTfCpn/wBUNa+b6fY7quEtv7PvMNEP3UPzMfYc0AQ+C7O5k1afUL+02ODtjPoK7i61KCG3l8z/AFmw4+uDXCal48s9N321qMsowOO9edap4nuNTvWagDs9Y1SG3vJJ7b/j6OSSfXmvP7jU5rvUppJ/vcmqlzJPLMrHpnJNRzHDbvxz60AdVY6tpKxQR6lnczAHj1NaYvNCyDbD3+lcOpLxO69VBb8avab88ReX/WAbgPegDtodah0pfNt+nWuyh1e0vNLiurlguRkt6V87ajqU8d+y9ecUonv7hgJrzZEeFTPX2oA961XxhpFhApF1uI5wO9cJqXxIiluJUgHytkcivP5LGeVxGejHafxq3DomxdnrxmgBt1qtxPbOYh8kj7T+NUvJvj/rTiL+E+lbdtYAMsR6KaszyiyOG6DqaAOa+wTxfvftW7PbPWnR6jcs626ttbOA3pV+8uir74c7H4qjqMpCR+oNAF+LVdXWVI/tn3GB/WtnS/EmrxyyJ9tPIx+lYWmIZkBX73b61PcssQO3/Wfx/wBaAN23+IOradcupTzx3NWJfiPNcxOJrMbmUiuElja4cCL7pIH4VuTeGv8AQIm/56fL+dAG5N49hhsNtvZ7Z9vzN6GsVvFIvAWmPzdsetZ76Atqhjf7pGDVuPRLLy4vLPzZGKAK9vrd0blvIztPBq8fEV/eYN392MbE4q9pOj2t1cOlxwU5pr+H4lvC0H3Qc0ASx+IBBFH5S7pQRvHr7VuR+OHhhiEdptcEYPofWsr+zic7evas28t5beRd33QeaANO41Ca+uZJ48ea+d/41JPfTwQJjpmsSxmtxO/XFX75TLbqz/6rHy0ATSeIp7hDAx+UDHNVhdbjjsfWsqWEk96jLiLO7p3oA27HUrqyuGu7Y52/JXp2heO4luLNNQbY7Kqlh2ryNQyW8b2/RyBSsAwKzHaxGAT2oA+p7TWIr2KP7OBICfvelZUkC6fqUtzN1Y5rwLwz4kn8NXG5LrdFkbh6jNeuDxXbeIhaqvXYKANbxLLHLZ6YyHltZ0v/ANL4KrfHW5gtfHHgd7n/AFZt9QX8d1r/AIVlX2pwu2mWan5/7Z0zj/t+grU+PQtj4v8AB5vP9WLTUSPrutaAPM9UZZtR+0qf9Gt2LIff/IrLRWvbxtX1KYRSD5I/cVQvL1mvfnk2WUbMQOm6s3WNWTULeeWxj2sMKDjrQBs6jqkcMuwz+Yw+dM9q57VtZ+1NHcxZ8/lWNZsPny26b/8AWDO+h0RSAnVs5oAnieF1e4fm4P3qrSHdcRvLP5e7O33qfyY45IzJ3JpphtZpmL5yvT8f/wBVADo/tX2nKXnyjirthrf9m3EzlvOJXBP93/P9KgLARmJMb2+7+FZZtHuLpLQS+W75D+/p/WgC1baqkEbXrSbmmYkDHTH/AOuqt7q11d4dPuDrXUah8MNT07wzY+ILXN9pc4bzJIgSYGVipDDsMjr0+lZ1pYxrA3m9DjpQByzB7qRVTr3rRh0GRVV5O/vXW2ltYqkf2f75yTUNx+6eUTc7sbP60AYracn2ciYfu9wzTNSsYFuFVJvKjYDb710sEM7RxqIfNDfpVCXy3mkiu7TlPufj1oA5+80mO0tjPHN5vr7Vkw/6VtI7V1M9pNcIyQQ+Wh+971l2FpJHe+SvLZ5oAQaYiIGfqelVb23fCyP0jzitrUr6e1TyvSiwu5Lyzkik9sUAcsryZIjz8/8ASnB7iRhbDqeldhapHbhUki80np7VoXKQJaMwi8on9aAOOttP1SJGX+A44NMl0e7dGKde4rda7nUI/wDAuasRzGdd8HU43UAYUGhXbQoZf9WOtTJpkoOzsf8AV1vRPIqssnGcYqhdxzLeWzQcAFmb9MUAZtw+oWyiK84tx0qG1uTBKfIOI3xmuou5YbuH7RdD5QNua5u5091ZruD/AFKn5aAL837yNWt8CYZzVWJ5GuFE3+sB5q4kLm1iuZf9Uc5qKeHeQV/1b/doAWV/LkZ/7tPS5kWCWRDw2M1WL/8ALP8AuUyTfxs/GgCx9kJt/tNq+2fOQPWtTTPEV0sYivk2lQQCT1rEWUxRv5//AAGrPnWtxbJE0e5m6H0oA9d8G2ukx6Gmp3R7kdfWp/AdskXxj8Kyxf6mS6uDHn0+x3Gf6V5hbX80FlHbQXRWKNgWX2r1HwJcW138VfAVxFN5krS3SsPTFnN/jQB9P0UUUAeTftGzi28PeHJG6DVyv52d0P614Fe63PcRPAv+qCkN9O9e5ftQLu8JeHl3bc6yvP8A263NfOUtwLZvLbo3B+lAA0rlf9H+7To4PNjJi/1w5aoHmKg+TjaKgS7+ZfrQBYDLH8txnJpGYqpMvMQ+7VS8GyTef4jirdms7Ltm/wBSRhaALFpcRSRFE4dhgfWqwvvLeV5P9YFKD61UmU28spU7SBkGsx9OnupFcXW7eQAPqaANfQFtyry3H/Hw0oCf72eK2bSyCXW+U/OxwOavaBpAtbFWl/1i/MPqOa27e1a4OF6ngZNAFW309UKmT7inn6VLqsUSwqbboO9Xl00RkJOcO3Aq3FD8ht/7oxxQBz9jbzrqixHoyb8/hmr2u6GbqzLjrtJ5+lbVnpu11brjFaupERWoUdxjigDwvVbKdCYx/AM1XtosQsYf9cASwrtvEmDK27OOa5a5jgtdU3r/ABIQPSgBLMraxl5+rcZrntbuWa4VYAdpIH61vWshuLVlHVJM/rWe9qkF75tzzkgmgA0c3CuhHXIIrvfCqvNdob37gYFvpXFLLCZ4xAfl3AcfWu08O3dtI8bsflJEZ+h4oAn1yFvtzhf9R/DVW1bySortdc0mK7sYZLfgdawYo7fS45p72eK3iUHLyuFHTjrQBVsoRFM8jdGHPNSSlvMHlfdzzn0qlo2q2fiDUJo9IaScW+C020hNxPAGep/CujNlMcm460AVoLcSqWP3RkmmzwWxfHYnFaCQbYWj4BYbfzrNmuDuEGPu+1AHO6jZGwuZJo/9Xgk/SpNPzewMYuEx0PpWxrVu02mSFevltj8q56whmWa1jPCtIoOOOMigCByPPkgOCACKhFnb25DdQ/FaHiGEaXP5rD5e9Z8U+9S83+pcYWgCVSzkJD92M5NI+d6gdScCovPMXEf3DwfpTkuII3Vz/Cc0AWVsPtBHmf6w9PrUdrd3Gn3ZuV6xEAfUU178yyKYeVzzUjR5VoP7/wA1AHTeEtT+3atpT3H+vk1nTcf+BsJ/lXeftVXSWmr+EHl+6be/X/x61P8ASvJvCw/4rDwyv9zWrD/0qir1D9rhnXUvB2yPzCYb8Y/4FbUAeFTO98rJz5W9dn9aTU1+yTxkYyi1Qmad1YeT5f8AWpV8wRwvJ0XOKAJxcfaQP3mzPb1qKa4fKxLFtCfePrU97MVsmCcSy/d/Dr/Om27vHpwW8++OlACCVdoC/e7/ANKlhhmKsYeR/FUEb7kX7P26043E9ujMfoaAOo+GWq6LoHjrT7/xST/Z0Sybx5XmgsVKrlfT5s/gK+g4PDnwl8bky6YNMFxMOlrKbZz7+Vxn8VNfJEKSXUpeTuciuv8ABh0261+0stav1sLBAXmmKMzbRjKqFBO49Bx70AfY/g/wxaeFtAXR7OWa4s1ZiouApIDdV+UAY69u9eUfE74LCdn1PwaqRyAmSTTmPysT3jP8P+709MdK25fjZ4K0myit9OW9nhhURxpFCEAAGAPnYGsS/wDj8QB/Z/h0sr52STXYA49Qqn+dAHjFtFcw3jw3kLwyxna0bKQykdQQehqS/wD9aMpv9/StjxZ42PizWUub/TNMtbkYBmtY2Ejr2V2LENjtxxWZO6Bv3fRutABpVz9mkkfzN3y9PSqiwx3kDSv97ccVbgVFJLjr0xTLpE3I8fATOf0oApabqn9j3hNz/qZPlrK1iaOz1T7RD9yXJX/P40anCkk0gk+9IePwqWymjmiS2uukGdn4/wD6hQBhXs6TXC27Q+Yeo9s1OVmtrVsW20DHPpU83mRagv2c/vT93/P40up/bmTzLn76c0AGkQz7ftRk3AEcelbVxNa3dqTJnevSsPT7spGDN/H938K1YN9xIiPjDdKAKzxukStFynQ/jUVvYpEXiT7x+c1PqVj5QcjolR2to5iWVeVPWgCGVnnjLx/wsAalv7yeGZQ/+qKjfU9whLReT95c7v6VBbP++uGuOiLxQBAl9G6OI/uVbMtstkEUcSg7+PTpVWPyP7M+0DruOKZbX0YVTef6t+lAGdHv8+SI58okbP61Yn2LbmNvvL0FVp7gJqCun+q/hq/ndHNKn+sbG2gCG2ieSNS3QdKZcHBTPG0mhkkMaFT+8XO+m4kl/dyZHpQBNBc+ZIkXr608zPaXO2OLzfX2qo2x2Ef/AC1T7lTSedHZyg8u2M0ALBO93fMrw+XhSw98V33wIl+0fFnwjJ/duLpf/JSf/CvO7lbpdKjZem75q9A+Bc/mfGfwip6h7g/+Sk9AH2lRRRQB4p+1e23wRoJ9NaT/ANJrivm0S5Pqfzr6S/atj83wToEY/i1pB/5LXFfPENlBAB5X+uHLc0AZ0EPmXDt6c4zTrmLg9AcdK0L+O3iSOV/9YxyPrSRKFlVj0dgD+dADLaP7Jbxyf3qt74J/9Znf2+tUm8hLdkHUyAVWuLmGDP2HHmfxZoAbqBEc6q2MEgGug0G0gYI4HKEEfhXDo4urwvN94EYzXW+FwCzbuhGD2oA6u0nE0ss7fdUFTWnZAySpJAPkVgT9BWMPJUiOP77HC/XtW7ppEUBEI/f4O6gCa8mBmUNyMgGp0Nt9nc84xWF5MzXLyP8AdXlqvaXNB/ZsvJ3F+KAN6DP2RBD9ym6mW+xHb97HFZ0dxtjZuBgE4q7ZXI1CMq2MIOc0AcLqwDFln++QRXD3k268aA9uK9j1XToWiklUYZVLflXlurnOonGM7uKAM6waeLzreX/VKpkXj2zVG+HmEt3HJrobDz/327pg5/Kubf8A1Fz/ALxoAksDi4hP+2P512fhlXjtJ54reS4eJ9ywx/ekI5Cgep6VxUX3IeRncDXf/DqT7FdSS3f3T9z69qAOY8T/ABc8SZksLa1XSxH8u2aPdMv/AH0MD8vxrzPUNQu9SuGnv7ma5mPV5XLH9a+o/EeiWPiGAQavp3mgKXRxwVz6EdK8p8R/CZ4I/O0W9WUsci3kHIH+8P6igDC8GfEA+F9KFnb6TBM3mGV5mkIZmPTt2AFdFB8ZpBBJHcaGkhc7gRdFcf8Ajhrd+FGipDZT6frugRHULeX5JZ4FYPG3TDEYbBz36EVvXOjaKUn+0aRpxdZDtzbIcfpQBY0TUINT07T7/wAryWuESTy927bntnjP5VZkh8maWc9wTWVDFHG0KwRpFFGRtRBtUAdgO1Wb24xG57hT3oAZqSoiRvIQUcgN9K5m48sXLm17A4qv4k1kxwAA844rn7a9nuCoGOeKAO21K5Gp6Yhm++i7RxXNXCmCF/ZTXQOiR+U1z0WPNZ195Ny22A8Nx+dAFKJfOtFPtinwnyxs9eKspH8jQ+nFReUY8KPvdKAKrRFZFJ7H1q2t6InAbpnn6Ux4hbIWm++4wPrSSQh9QhY9AnNAGj4UZz418OM3+rfWdP2f+BURr1T9rcuNT8HGPqIb/wD9Ctq8q8HeT/wlXhvZnd/bthj/AMCY69R/a9kMeo+DdvUxX4H521AHgrNJdSJLJ/FkD8KijuHknliX7sWM/jSBZnIM33f4f61PsxJGh/jzn8KAGK6LKmz73emyzIZmEh4PSrNq0CX5SDqFO6qMDyPc/J03HNAFq1RFcmPp3/pWXqVwskkkb5z0HFassWwSeTL5ZbG73rEnt3Xe0kvmZ6e1AF/TFSYRQXf+rU7hWzbxxu8sgH7vgR/h1rDsG3+XHWqlxhZx/wA8cfrn/CgC5ZvM1ztf/UBTu+laFlc2sFkwfkOfkqhpzxs8M0nvireqRRxulxH1bOaAF0ua3N2/2jHlEjt0rQuwEkGyby4X4T3rFtpoI2L3H3H/AKVo+VHqFnIh/wBUrKU/XP8ASgC7pYWxuxD5xkmKkpnnBNQzo7WU7SffDjNXVjjLpcIPuoAaz3kSSWdpOhxj9aAMV7hI9Tbd1CcVPa2xSza6m7sdv+fyqHUYIXieVfvRkY/H/wDVU66j5ejL5o4Y4X+v9KAMyGXGoxzTds7asTJ9ruZPNP3wNnNV5j9p1EyXP+qQCoSqXeoLHD/q41Zh+lAGlb23lSbJ4fMUfd46etbAt42tHaGLy5Vxt5qto08c+nyM3+sU4X+ta9rdoyRwx/8AHw2c0AYW77SiwMf3g+9ShPsKOvqKsX8EkwnjX/WKAX/pWZFK7oUlxmTgfh1oAjF2/wBqULjH8RpNReBNznr9aeLTycjmiK3LW87dcY/rQBUt0jURSo+3fnI9aJbiBrkiePaR90+vrVe4uyBEBncucCo7q4ur62aJ/ujpQBRupQt7uXhQeOK17e3eSAyx8ZAJ5rEjtZ4U8vyvMyfyrchuJI4YInh8vGce9AFCb7rC6+4GGauNLHNdrHD/AKvaMcVCyb53Y8jg1JDM+GVOnG7FADZpYYZXSb7w+7U1rMJd/oMcetU5okLqydec1NFcQoMTdeNtAEt27Iq7D8p612HwAaN/jR4XK/fEtwD/AOAk9ccrzTxt9m+4ByPauy+AMZX4z+GC33jLcf8ApJPQB9s0UUUAeL/tVKG8F6ArfdOsqD/4C3NfNwZnIS3xhK+j/wBq7P8AwhOg7ev9tJ/6TXFfM1qSryMOoBx9aALzy/aUKxf61Bls1W+0/Zz+8P7wdPrULefGDJ/eHUU6LzpAXf7oyTQA/wCyiUC4mGHPIoa3+1q0Y/hBqeKSJ1Kx/fPA+tbUQttJtFTrcSDcfrQBx+oaNsjjb0wePStHS1+zrn05ravtVge3RIP9e3BrN+zzzDJzigDVsdSt55ohN96Ng3Hsa6Hw7rFuLubPoa83jkNre7B1JxW5Y2U9vJHcHO2VgKAO/umeRTJbfdkGKgjcW8RE338ZA98VXjKiCItnYDz34rq9f+G2uPBbXuhxxX9nIqzJJA/LqRkfKcHkemaAOUku4GicPnzSCFPvioba/mgIDn5f4sfrVOW3uIla1urForpZQHDgggZ9Kp3dmTIMdc8UAdLq2tW39kyk9PLbP5V5HdTxvemS3/j6ZrvUsLm90aSIA5DYFczqPhrULJWlxyRmgCHR5rhHdO5BWsnWJQs8yR/6xgQ9W9PtZw8hh/12PmrGu4ZftjfaetAF+zs/NuoyOmzNei+FIfO1FIuypmuK0OKDaMj611fhaYpfSLKf3TcJQB6jKnkWPuozWRKpjiaTI+cEVa0658m1YcfdrOvUN1IsnTHNAE9hKFQRMOGG0j6//rqpq1oyRyNB90KSRnt1qxdnF4h9Iyf0rPvZ/lcex7+1AGbcXGy2Q+nIrB1G7MquwxkA4rcv5v8AR129a564WaadGcfKGBI9s0AZotJ74jceCe9d54U8ICWzZ2zgLk/lXNrcQuwRMbk5Hauh8IeJpbO/it5j+6d1VvoSAf0oAqajYGxa4gkwI2Rgv5HmudlXETTf3QVr0Dx/aRTw+fB91gRXn99H5VuE9aAImmNtHE/djirHnZPmcfLz+VVpIcwxj3qKWPyYnm5+YGP86ALwb7YwbI/GkltcOD71T8lvITy/vdvrU13PK1oFT/WIMv8ATvQBoeFY8eNfDh7f21Yf+lUVeoftfeZ9v8HCHqYb/P0zbV5p4fuPM8aeElHfVtP/APSmKvS/2vd39o+DdnXyr/P521AHhr26rbRNJ945xzUDo83D/dUcUyFJGVvP/wBXjkVC8T7wI/8AVHpQBLNF5UTcYzTFG6FE/velTpewlDbPjavDVD9qHm+Xa/dHC/jQAqRPOfsi9DyanisIGVmPUcGrkNw+nBbe25uH/wBZ369P61Jd3hsLbyX/ANc/L0AY80WWVLaLzepPfGKuWck95FJuh8uPADe+M0iy7rZs4O+myXcjQxRr/q487/xx/hQA6BjmVJY96R48s+mev9KltpXkZg7l1XGF9KrxXbxI4l5tTiq8dxa3AlEI4GMUAa/XAHXtT4YbqJ8noemKqQJNBAjDkNnFXbFp3LD2FAGolzI1uyv0xxWXE/2e5Zz3NS6ncTwrECOHbn8MVXkxNqhNv/rMDpQBG8NxdXwS3GfN6/h0qHVoZ7aMwXH8DDb/AFq82oQ6PcCdv9f1asy81GfWNRjn6jntQA1fspnmS7zlkBT9c/zqvZpEbeOOIcK7Vd1JAjxm56HOKs6NLp0V2Gj+/tOaAFFuWizjpW1ZYS2V26J1rNh3s3mRfddjnit2yTfCwn+9xtoAzbq5heJmh4c/eqiIzPGpXqmcVqz2M6B2Q/N/BWLceZ5oE/8ArB1FABdTTxQss33T901VikEMBnk/1I4b8amvmgW1In+8fu/1qjZK6qTF0NAEXlWUU3nD7g+YfjWmksEsTS2n+sXoBUJinlBLdF65qo8skD7rT/WL96gCzazJDcGeT/W96i1OW5nJdf8AVd6bJKbjZv8A9c33uKkRHMiIhHyZzmgBkc9nb2wZuZTwcc1DbO1uZVji8xDgn26069tpGLGTPHSnK3k26S/3AR+dADY5YZ5Qhh8tj196r3PkDzY1+8rLj9acZPJk2j/WPytOuLIOEZpvLkPLDPWgCTyfKkcy/wASrsrt/gG2PjT4WR/vGW5KfQWk+f5iuAt7d4LyLZN5gbOfavQvgaU/4Xn4X2jJ33OT6f6JNQB9q0UUUAeN/tRME8IaAzDcBrAOPX/RLmvmNbtjaPstdrGQAH8a+mP2qFVvBvh8Sfd/tpM/+A1xXzIsLlOfu+cNmPXPFADo5QXUS/fJGPrTolmaeRX+6eDRDArXDrMfnPStSx00GVAfUZ596AK0ccMcZC/fPT69q159OEUkEs/3mj71tXWl29jarN6+9ZGqTQeUmOtAGfb2Rli3Wv3/ADhv+ma2YLbUdTU2kP8Aq06/Sp9C0/7WgY9BzXT3F7b6ZbIlmNznhx6igDjdW8Ni1hUx8SrguM0yOFraOK1j5eQgj65rV1K4N4HZW8s4JC+vFc1dXIglXzj84PH1oA6zyp4reNZuGPQe9e5/AzULm48N3FjcBillLtikPo2SV/A5P/AhXzrFf7ooR6kCvcfDnjXRPCPhW1tbVTealP8Av5kiICK7AcM/sABxnp2oA9V1TStP1SHy9StILlF5HmoDtPqD1B9xXhHxG0TwpYXJk0XUblr8sv8Ao6PvhUf730z3bpjiqGqePdW8R6hJBf3Sw2gPy21v8qHnjd3b8Tj2FYQtftF456ZPOKAOp0w232BTMPmxnHvWLrs1t5cg4Pyn+VUpLtY5VlI+VW2HFcvrNy9xczfZc4IOKAIn0yE2M0q9WfAriNctvKuVXpziuxtpJrfQ5DL98MSPeuP1aQCcTzfeJyKAI4MKNvHPFbGnS/Z2Vs/dIP5VgWMe+4L8/NxWjaEySSRgHKA4oA9d0G9Op2aRehHNb12gFl5+OEBU1574DNwtwCOxzXpIVRA7XH3pFI/OgDk457i1mkaf/UuCq/jVXW90Vp5qffYHH5Vb1hoHdox95Bmqmp/8eUH4UAclN57sGl++OR9ak0qI3c7I3+ufhfqeP8KuQY898njvV2e5gg1W32ttIAwfSgCpqtlcWUCiXIcdPrWCV+yzLcw/60MGb8K6vULoSks11uGOh71z1+hnbER+Q8HntQB1dhrM+pab5d5/q1T5OnpXLax5/m4Q/u8/N9O9GkzJZeYJs+UAd30Fad5Yxmy+2pzA4JTn2oA51/IKt1HFW4ZbdUhQn7zAVWkXdIF9TiommEMqQk/fO080AXVkNvdt5mfLB+WhLopJK/8AfBFMM9xdfPN/qYvlXilSFpHDj7wOQKANvw58/irwq2OmtWH/AKVR16X+1tH5mq+Cx6RX5/W2ry/wpd+b4x8PRS/6xda0/H/gVFXqP7WjvHqng54+ohv/AP0K2oA8Cuk/fB/+ef8AWop3DeXKfujripri4kMJWSPd53Q46Y//AF0W7/Y4Nvmbw3b+7igBtzaWrW4kTq55ptrFHDGrQ/6ztUtuk93OIrf77VZW4S0E9rP/AK1cZoAnt5odPjeaYZupsBP1/wAazbqSZ5As0PmuMsPbNWbnyIrMSrHvkJ+U46V0GlPYw6WJppN95J9wHtjrQBzttYTXpH2uHy7RPvcdc1ozaX9nhB03/j3IqLUr65uYZYU9t1P0tFS1VHfZIOg9TQBkyQmWXB6qcGnTWPmRBfWn3U1zFcS/abbch/1bHv61UjuN84Ah8sbTQBrxYt7AqvMiYC1CEQRLLJ/rWzmqmmRSCBpI88Ek1Z8mczRy465oAHleXCuOF6VZ02ExysRnccYqte3cjElvvR/d/GrNmJriAGYAq33aAJb+G6mLrJ9zHFZWlzI15JGvWJTn8at6rva3wvSHOfx//VWZpqQofP8A4zQBZ1W5nfS0S3zv3n+lMtoktryJp/8AWuvzVXu9++S4foMYzV7TZVuAit99s7fw60AbNxc2ihA2NzdKn05wnmSDkDGP1rNghuYb1kvP9UVPl/WnWjy2UQe+5dmO3nt2oA15Z5Tte3DGZ+FA/lVuz8FeKdSXzbHRr6Sab+P7OwT/AL6OAOtVdI16TRL6HUdMuZbW8/5ZzLjaMdQ2eCD6HivoD4c/GfS9enh0rxCY9N1hsKjk7YLhv9kk/KT6Hr2JPFAHkemfAjxtqEqS3sen2gOQ32ufcQD6CPf/AErI8deAbfwTJZ6XLrUd9qsv72W3hj2rCnYlic5J6DA4GfSvs1iFUliABySe1eUeIPhP4Q8cXVzrNlqt59oum3vc2V6Jkdu3XcMdOARwAOlAHzPqcMktlHMkmwBsMPWqDXcIvyhj2ME6+tek/Fn4ZL4HsrWRNX+2x3TsiI8Ox1wMkk7iD1Hp1ryCWVE82No9zJjBHagDXsGaKLzpJNqqT8vrT9Z1G1uoUkjTY6ZyfXOKx4/3ltmW45X7i+vrV2GaNrdYLuMJE33T60AQ+bM1rv8A4HqS1lhtER/4yKglt5oDtg/49G+9UckSR4L/AHW+7QBHIr3N/wCa3TsKfKm6QgnpxQpgVGkjP71fu1Xt7tC8jXZ/eHpigC1bQ7pVjaby43+9716B8CoRbfGrwvEsoljaW4Kn0xaT/wCNedlvPBI6LXdfs+uG+NHhcdxLcY/8BJ6APtyiiigDxf8AaoVH8GaAsn3TrK/n9lucfrXzbKrwv+7++DlT79q+kv2qAD4M0DP/AEGVP/krc186QcgDvQBpaXYxmPzX/wBa33qkiRrCaQwD5XBFU0nEThW6Gorx2aTbB0JxQBdkvpbl1t5P9XkKee1Ma2a61yO2b/V7cJ9ab4Q0i41PUWjA6H+ta6Wv9n6rIZP9Yp8sfWgBNVubfTIltoT++XhsVitqjSTKkY+djtH40kss51SUHvxRJZ28kgaT/WAgj60APuFmf5bjqRisHUYy8ojXqhzXTQ/vV8v+7WfqOmrKGbtjJoAfohV0CTffTkfWuzt/+PNN3Q43Vxfhy2geVkXqnIrty6w2qBuR3oAgmJuHCwfcj5/AVrabyBt6k4qK0UzQt5OAmOfpTWZoFYLwcYFAFeG3mZpVf7pmwfpmq+p2VsiNG2NrAqfpileee2mRmzhyM/TNZ3iG6DoitwpwpoAz9UtYnsbFIPuruzXD67+8uFj/ALprtzOZNGjjk/1SSjZ+dcRq7/ab8ydwdlAEMEJbAHU9K0tN05tk4OPO2nb/AL3am2Fk11hI+HU8H3rvtL0NVs0a8B80DK/WgCT4dW6Qbs/68DLe9dXfTkOMZ68U3RIBpkPmNwCOarSWZnvzPB9xjz9KAIbpLa43eT/rv4u1czqVztk8v+4c/hXTXtpsk3ehyMVy+okW08rsMq4OfyoAy/NMbTP/AHlOPyps6+dAhPX+dKgMjq0X+rzzmtfU7KxnsYTbZ+0Z5NAGFcN5KwA9mFNm3Rt5sf3m6Y9akuLYQZ87qMkflTEvTFGQPvYoAs2dw9pqAkux8pj+b6d67zw/byXtszjm3lUhe/XivMkSZnWW7/1bfc+tdFoviC40K6gKH9y0i7vTGRQBp+JPD7WKSyqRuKnH1xXIRxDzF8v/AFmRur2tBDrliJ0+84OBmvJddsp4tbkRukbZP4UAZUkJ2XG0c7GwPwp2lt5d2Vl+8YTj8jVpmt1kUyffByPrUMK7YSx/jlAP50AX/DMcJ8d+FZD/AK0a1YY/8CY69V/a9D/2h4NaPqsV8f8Ax62rzXwx8ni7wymeus2H/pVFXpP7X2TqXgsL3jvs/nbUAeFOn2i933GMCPj2pttMEspIYYwwkb5m9MdKfKkMVoyH70v9Kq2Fu5YLa/dXl/x6f1oAt29uUtJBbSbp+w9KrXsF79kD3X3gwB/Gp1ikivhtPJ+9V9rWS8u4opDk7gwoAu6ra+XokEEQ5YAtWVdJJHIiW3YfPWpr586+2dRGoFZUtvuiYjtQBZs7iW3J8v8A1pU4rP8AtE89lIWJ8xJBu/E1Ztkj8lXk48vp/n8KfKySxMI/4uvFAFPW7iRreIN1GAKx7hrptRjLdAPlNblxs+weS2N2OKzI0mwB/BGetAF+B5pi2RwmP1qXzYMFB/rei1VF3DIoRP8AXrwtPQCJszj9+33aAEKbFLR/f3L5n58Vrj/SrxPK5EcZD/jVeFILhlz/AKwfe/pRDFBDczsDzt4oAtxRQyWDnyfMdGOfxrBtbh2vJFeHygpGOOtXJvPttIWRfuyOf0//AF1n29xM2qHPQKM0AR6xcfOI+PnNT2LpCkLN1TO2s/UmR9QIXr0NbOnWOV87+7j9aAOhtrx5ngZ/unOM1PqX+kOkY6nOOais4cYl9ulZ98ZIjPcR+2aAJLmKRY9lyeF+57etZX2eSTzUeON4iM5b+HHpTxcSXcYE03lxtkHHepLeWCGUJcTeZb/w47UAemfCn40ap4agtdN15ZtT0dPkErHM8CjptJ+8B6H8CMYrz+SN9O1G8bRpHS0guJBazR5QvGWO0jgEcYPrzWNqMMEjtLazeXGnT3zRbuAkX77zPMz+GP8A9dAGjrXiHWdWtIzrOo3d5Ha5EAnlZ/L3Y3Yz9F/KsaK5kjRZk/i4PFR3V15F15Tf6vvVpUSeMN/Av3OPWgB8hkhQCSLzO4z2zVdLlLljE0JjPbHelhimkLAD5FxTpLRAoK/eHWgCwsXlkW86bg/Q+mKlmsYLeEjzN2e3pVC0m8nzB64pVee4l2wQ+YB972oAZY2ST3ErQ/6xBkU7SIYJLedZv+PpD8v9auT2MqpGyxeWSDk+tVnM2QGk2gdR60AVjMkbOHz5hru/2fXb/hc3hhHX70twyn0xaT5H6iuIcJxsj2t3bHWu7+Aaj/hc/hVj1ElyB9Psk/8AhQB9sUUUUAeNftR7f+EQ8P7/ALv9srn/AMBbmvm+GVjMwg5U19H/ALUqq/g7w+r9DrK/+ktzXzfPEQTtxu60AEvn7hjmtvwvo81/dDd90kZ+lZ9jBNdgXD8qmFau/wDBEv2YyMn+qUZb6CgBtrLD4XklRB88gKr9cYH61yk2oApPPLyzOSPrml1jW2vL24jc/Isv7v654rmp764url7f8OaANC4uBzC33X+Y064lZbdY4futxz71lTPtieOX/WKpx9algl/0VBI22TsfQ0AaMEYS3kY9FUn9M03VL2BLGF7T768v9B1qg7bY2aS53yAEhP7x7Csu5eWYNvPlLj5l9vSgDb0TVBNKxc/L35rsLC7uYAM/8esp2j6GvNPDLSQXUv2ZdxxwPWu/0+RJrKYlvLn2EsvrwaANa3vbePzo84DKQPyNXNPkhuwEQfOv3fr2rlb4kT/L97yjj8qvWkwWzUodso++fT3oAl1TMc8yyf6wggH3rC1mZZLUxz9UB5/CrNxbrFcIGu9wkIcj1Gap+IJjLaGOE/Iq80AZ5vYYtBCjrvH865W1kMupuRgnPFaN5FjRFP8A00FZEXEq/wC9QB6PpOPssfnff4xXSf2mTeRQDqI8DPrXENJueIeseK0lj2QRso5U5FAHSXE9x0NTWl9OjKh6MQPzrDhW4Ubh/wAtDimX7blhSHmZGBagDc1GfklugHNc5fCBSW/v8Vq2k6KhM/Ue1YlxNC8LOvaUHr70AOgSC7/dKcEcCo55jbfux1TmrWhX6Wd8st+f3DMMVL4hu7G/n/df6tjgmgDnLiee5G27+6wwn1NNmSGK2QN/rT9369qkkljjdUP3UIMY9x0p1jciWZjN96gB1kNyhZMGQ9PY0RkPNJHN99AcfWojN/pDf41JFL86gdcjv70AbPhzxKbKQy8/J8uK2ILf+3tfZcfejL1ykEtvc2Miwj98j5atm2vv7CFzcHo4Xj8qAKeu6RcafeP54/dD7tZQl9q9h1OCx1vwjHcP/rWQhfrivJ9VsvsTlW6DrQBZ8KybvGXhcf8AUasP/SqOvWf2sWRNT8IGTp9nv/8A0K1rx/whz428L7Puf21YZ/8AAmOvWP2vW26h4N94r8frbUAfPMssZkIT8asZdLWRVwRIVJ/CpLf92HJ/1bY3VJbLPPcg25Pkqe9AENm0basIAegG6un1C+tbKFIIcee4IX61jPcyWd9FKc+WmfM/TH9agnuEvNQkeP7kimgASFy1xJN1K/NVLSHUhfsf+uVjmpdOmEMTRE/KWOame3RZY3tM7jndj9P60ATXVy8gaOfO8ld1O1HZK/kWmMhRvrPuGnefZStBJYgTvJtzzj1oAhEslnFOH7YwfzqpE7PH56fd71rwyx3VpctJHtxtw2OvWscBY5VVf9Wx+egDdhiS4igK/eYHNMiLx3bxp0jwWqawEkJS4hz5Q4X8adPHI13tkkK7lLY9aAK88sNxdCdurcH8Ku3Sbo4vs83l4zn36Vm2cCXVnK5j2urYU+tOjtpniEd50P8Aq/60AWRd+XE6XE3mZ+77VkrdxxXgePv1qxdRNb7fM+4nT3rP1AWv2cTx/fyKAKd2/m30sndiK6nS7s2enl2/1XG78K5eW4me73jpgYrUtrt5AN/8HSgDoP7Ume2Ett/qqybiUl/Ok+4T89JcTPcQb0l2iLtnrn/9VPs0e6iAnj2Qn7x9aAHWU32vfGp/djG3NTzKkKFHHzDgcetN2QW4MFtN5aH9apyvJykc3mbOvtQBXYSJcpantkr+NSP54mMU0ZZRwp9KjSbyXLTx72GNp64q5HM8aGdpNyt0HpQAht0SBppJN2MED0qKX99FG0HTndU1skcjtK+MHpmqdwyNPKE6AjNAFi2hQq8adW64oX9xvj9BWar7UceuKv20v2W2D/3qAIZ3R0kDdewpEWaCFHHKlgaSaXe4f+/Tm/dhS+fLb7woA29YvJNRjjtpP4VBFUFZHgRZPubgD+FUVuNrqq/6tuFq+Y3iRZFHB5NAEt3NNLNcW648lQu3HXvXYfAUovxj8JRoORLdZ/8AASauORVeKTUVPL4Vs/5967z4GQBPi14Sc/eM9x+tnP8A4UAfZdFFFAHi/wC1UxXwToZX7/8Aa4C/732S5x+uK+bbTadRAb/X+Wd35V9JftUkjwZoBH3hrKkfX7Lc4r590+DZPE8H+udgG/MUAaEawWXh2eZs+aSdvHfHFU7vVzYaUscP+ulXLVW8QXot7Bo4R++aTDVgC6+0wMkn+sVTt/KgCWVFVw6ffY73+lS/uXheQfeCkj61Smm2QoseTKeG+lLCJsHP0NAFydfNsSR12mqjNNFdoLv7nl/LT2s9uXz98Y+lVjCFmSNvuswB/GgC0krblKffByPrU0lnMI2nj5lwS+P1qW3i+xkSTKphT5lDDIOOxFfSdn8NPCvj3wjaaroLyaTLcxciL96kcnRlKsc4DA9xxQB8waQwtLnzJAN5PB967CWe4Nnk/wDLUbfzFdNrXwJ8VaJcyT2jJq1uOVa3bDD3KHp9F3Vz0tjcxT/YbpGtbmE/vInBB/I0AQWizzoYG+7jBrWazuHtBHEPkQZPbitfT9NxeRHsI89qvX/7uGRB/EpAoA4x7QiVSvUMCKxTDP5Vxu6F+a9Ce3DWQDdMc+tc/r1nD5ICfe7UAcXqwK24tVHONwrn7WLF3+8+/nj611F889zDJKx4hUr+Qri3lzeEZ6t1oA7SynSJcXX41pW9y10RGP8Aj2XpWPYWvk3sMw7pXV2lv50TE+lABBcSNxbZHl/MOtSWTyTTv9p79amt4Au1H6NxVCXT2W8Yw/cBz+FAFyG8Jne3g+4ODXNanOIraVSOr1s3UgtgSx4HPWuXub1prmQQ/c70AEv2h4UeYHygcrT55/Otl6Hy/m/Kr2nsbaExqOcbx+VZEcirb3Lznl3IoAEl8yJm9ATVhZcwRgVDbXZjiZIfukEGk85f4/u9/pQAtsB9rbPTPNWbeaNbkpDnzGOF+vaqhlh/5Y/c759KXzjkeT93+lAGjok8jb0/iSUGT6ZGf0q5KkG3UCDzJIqj8ay452WNjZf6zb8w9qvQypIkLt/rwwLfnQBq6TrU+kARr/qcgN9K7CGDT/EVoj2eN5/1gPpXmfnfuT7Sj+dXNC1e50zVopYfuGVc49MigDW0Ow+x+NvDyR/cTXbDJ/7eo69I/a3O3U/BrekN+f8Ax62rmbK+trzxDoZiH71ta052/wDAyKum/a1Vn1fwUi/xR34P0zbUAeASxPclQkvlB+p9a0tKsUtGZkl8wr1qG5QwMIbbiRiN30qLWr1rW7Asv9Wqjd9aAHahtmFwz/e4xWNArpDJvk2jjA9amN2XBdvvS/5/rUcNsiMZHzntQBbs8eUA0e0HqfWnywwxyxNDJtJzuGevpVe5u3dUVjwucVHG8b5D/hQBOzi4mePYFx39aguZtqrGf4DxU8SpAGKfxU1YEuywfjZyO1AE1958mjqYOikbsfpVGKWTzXROuwZq2JPNRvIxt6N+FUCDbzDyfvPw1AFzTXe000zydmyKs/I0cd233nzg0jr9ktdtx/ByPx60sMtq8Khzgv0oAtR/Mvmy5wfuU57mMwutz1X/AFf9f6VBHceWwjHQdKqwKj3srP1C8UAOmeCWJI5Ty2dtUHh8g/uf9YD8lTwXMyRhR03EelVLCV49TcyfxdKAEkieMCe7++3SpbJJnmWUfdPSi98z7W5h/wBYelTQPIiES8SnrQAXazzzrvP7tPvVP5fnmO3n/wCPc8j8KqGK93E/wGpYcxHnqaALepxo9j5cP+rPCj6VVtiIbeFPTNTXDM0QAxsH3qfL9i8u28j/AFmDu/SgDLgZ21XK9ADmpd6TwsE+8rHNDpM1y/8AdFTSJDFAZF/1642igB6wlbdJOm3P61CsruzKnSTrx6U5LrfCizj95JnH4UyR3RdjdOcUATw7IdypF5p7+1Nu3kkjCRQ+WxPBqC0fyTJtTdI+Np9MVLbpA82biTdL6elABcMkemeWv/HyGGaljuEE6xyj946c/hVZkRLh93fG2lut/kZxh/4KAI4t6wBX6CTIqS8u/wDTyrf6vaA1Nt/9UM/63vTppZ44WEv8X3OKAJymHhuOlvFn9cV6B8Cv33xm8MXCD9yZrgD/AMBLivOoDcpb+ZIPk+7Xd/s9LEnxj8Nqv+sE85/A2lxQB9t0UUUAeL/tVDPgrQV9dYUfna3NfMNrd+VebeT5Zz+Rr6g/ambb4O0BvTWV/wDSW5r5cH7q6aXH3qAGysHuijYwf3hNKwZkKw/dIxVlExIGH/LQgdfWlmnbmFfvDgUAVYLW2HzR/wCsHL1OwhIwOuKLpVaONVO1zgSH271GLZlO6C63KDnHrQA2SH92wB7Yp/Mtssa9V6UyVhat5k33mPFWbbT3uCJo2w7Hg+hoAZMZkgjVhuB4I9RX1F+zBZXVv4Cubq4LLBd3jtBF2CrhS31JBH/ARXzO9ikEg+13W6QHgeprsfFXxN1SPwzY+HdDuTpVjbwLGUtWKySYHJaTryckgYHNAH0v4u+I/h3wxI9vc3f2rUBx9jtcSSA/7XZfxIrxPxn8QtR8XSm3lsba000HKrszN68uf/ZcA98147oUWzbKxyWYHk811k5Frbq3HzcUAT22pyfazBbHjOK2reYXY2TffXkfWuV0pblL5Xh+67AH6ZrpbC5BuHWY/vI8lfqKAHXFx5TbT071ieJdTt44dq9cf0pdf1CeG5HYyHGPSvPdbvJxeSZ96AL1tcCfTbfd90yMG+lcxq1qYL5ooj8jHca6Oxe3mtk8773asbXIm+0jf/q8/KaANnw9eEqsI5I6ZrrYDOOT93vXnmiXnkTtF03fLXV2hwv3cn07mgDoUlJcbc5JGKlmE/kOCf4SD+VQadeeXEV+yYJGM46VYvpc26hOWPTFAFHWbPzniPbyj/KsKKxMYndeqoWA/Cuiuji0zN9/GRWSNQIIj4G/5fzoAxJTPFE8p/iU/wAqqwPb48qX7zfPXS2K2r25W46mQDH41X1iyisd00HTGaAMht20+R0xSaeEZ3Fz0Iwas2krRxl0yzOOB6ntTmkkZdtza4JHJ9KAMwWsQuWMHQelTxgTusp6AhDUlo/kSSGP/VgZOfSiS38lwI/9U53H6UAJGYklkSPljkDFOjhmMigjgkA8+9NhSJGmZPvqpI+o6VLZOJpotp+fcN/0zQBp6TEZLgovVDxVMRqsrtP94Sg/rVoQ25klHbBqvfR4vYzNgxCP5aALfhKWWP4h+GYx/qpdZsM/hcxmvZv2sCq6x4LZu0V8R9d1tXkfg6OI+MPDEifeGs2H/pVHXqn7X0y2994Olb+GK+x/31bUAeI3KTzMw87y0k/pWS8aKzQpL5jdT7VYvZnnvI7pvubfl9KrSnAmmXHmHAX9aAKjvIri6jHK/KcVOpkjKmQdfmFFqTCyRnmbqR9atWt3NHfETdGU7aAEW489R6J/WgSvKNq8KOuaprLG0cySdXbg4qYQ4011g6Bl3YoAfJbwIoY9ahhl2uzR/wCrTh8e/Sp7m33Ohi7KN9SJKkaGJOr9fwoAgvZnKI1pxG+d1UEhJky3JJ5q9JKjxujdU6VQsN/23LZxnigDTkSFLbdP97I2064xc3GV5WJRj8f/ANVTXWoeV8vk+YTUFtcb5SWh8sZGfegCUTCUCLtUcz+Wqx+jCp9X/eWsRsP9Yp+aqdxKn2grP/rto3UAM1W4C3bA/wCrKjdiqlom8yEfcONv9an1BEWFWj71HZJGUBk7dKAEvN8EZkTtTI/PmtvM77hUmq+XKsKR5/iz+lVbe4kVvs0fTNAGubmZL5QT8uznmlhuEa0wv3txzUEuVhBk/wBan+r/AB61ZMTzJbySff5z+lAFlLYPbox+73x3qszpHlrPPmrUbtIsz+TnzOFH406Ozns5BuH7xvmagCDzZHmDTfffOarDfHfr8haF/vn0qeW4zct533lPy06a4e4t/LbpuGMUAW7mSG1YSK+7dwo9Kru7swjfkA5H41Fcukd6iP1CjFOeV8S7hxxtoAmMLxsmz7r9aih8m1vjI3U+tRk+bCnXjNPhiwWK/wCsH3cUAW2lgkuRP/dqG4eOeffH2pk1xGsbLN/rO9LC8CRq9AD2R5gu3/VJ9/8ApSLH5pEcGPL6nikuUBkgeH7smd34Yx/OoUjSC68xQckYNAE13Gj+W6/eOQfwxXffAJCvxm8KnHBlufm/7dJ68/Y+QZlbmNcFvxr0D4AIf+Fw+EpU/wBU8lzt/wDASagD7YooooA8a/akVm8H+Hwn3jrK4/8AAW5r5ffEl4YpuoNfTX7VxYeCNBKfe/tlMf8AgNcV8xP9pMg2/ez2oAiUl7pkHJQ5FIjTJLIzHhRzVl4JoEYz/ekBX9KR4PLijf8AunOKAGzv50Cmp5IiLlSvXy+PyqnJd+Q4OPvnFW5LseVHnp3oAaQCMTH5jTob252mGH7o4NIy26Auej8VH5UP8H3h0oAsXkgaKMS8yEgD61ganNPK/ln+GthLOaWQMegOT+dZs9j9sv8AyueGxQBt+GIrjyhiug8kHib71Jo0JtrFYx/AP6VooLeSNnhz5oBLUAVFdoImCff2nH1xUatNbxNPcZ3EHn3qe4h8yGRv7qk/pWNqE/l2wUYyRigCDX9Q8y8V/SMn9K5i6H2iQSenNWrgzX06wnpuAP06VKbL7KpTuRigB4iWKBJW+6eT9KpXaGeQeV90mtGSNVuEZ8bRGTWfAvnTsZf9VjigDMMbRXLKn3ucfWun0BpZGS4n+9GwXH41kLbbHlaEfKATTrSXMiDpyKAPRY3WdDvxtPXHpVjSPKRpI7flSpHNc1pxCupPTIzW1GpWRHj/ANW7AEexoAff2nrXM6jbbJQ/905/Ku1uri3dIkA+4axNWltoCS2MPwfxoAw9JQz3BA5JPH1qx5M09w8N7/qxwoqnC0cc7Na5yvIp9vdyM0r3XYEmgCMCCK5ZTkeWc/lSTXBnceV9w9c0rXBmUmH7uOeO1V15YY/SgCeRlhRwcbcH8qitnE5BXmIn5vpUcw3NjsabHlJERRyxAFAFm8ijKP8AZvQ4/Kqdsk6OrN2OTVwwjzV87724fzqBYv8ASmoA0Im+zp5/tmomnaSRHGd0hAoGbk7F+8vStvRtERClzc9MhjQA3wt8njfwskn3/wC2rD/0pjr1f9rlmXUPB5T/AJ43+fputq4HTrKK28Z+GRByv9tWDZ/7eoxXd/teyCPUfBu7oYr4frbUAfOkqrPJuXqnX8amhmee6ghBOznPpViKK1ikVx9w8v8A0qEy28k0q/8ALutAD7pbW3uXS1Pzfxf0qMGOVgZO3SiOXyvM+yn92cUW8ySz4uuv8P8AWgBbp43hCp1HWltLb9ztx9+mXNu6SlovunpTUu5o8ofutx9KAJF/c7ox9OtVpIgrebn7vNOvIozblufmYbqtzxWzNAkeSzLzQBQZt8Tt64qeweONkeTtnFUrlXjugj9AeK1I4fNEftQAX7RtIJ4+3Y0WkvmLJL/dxWpDEluonl/1aferHknjju5LmL/UykKP1oAk2PJMJI/xFUbmV2naKTHzdK0jPBbRbIerctWW6/aJw3pQBXmIhkjQ4285rTS3tmjUxffHJrMSHy7w/WlvFkMytF1WgCfU0cxANwozg1UCusamP8avR6TdTlHuuj/c5/OtJbf9wYT/AAUAY1rcK7FLqby2GNh9auhdksUizeYvP4VnXkTxMSmcd8Vq6dcWrWbCT74xj9aAHs6GRi+N0mMUiyzLMgH3E/rVOKVBcneOO1aFkySSTpCP3jFcfrQBTvo4Vm+1nr0/OhYLUMu77x5FWZ/lxG/+sX71Z7tscHvQBd1G3jNshfoD8tRSNaxXgZuqqMU+3kS7dY5P4OahedJL8GPvwfwoAmSUNJK6/dbGKpXlxIjIE75zWjOux/N9KrTRnUANuMjkUAQxbx88nb1qw2whZJO/SmLHetG5UcZwBU0huoreMSfxZxQBWuH86I/Zv9YnTmtDSoHuUVp4fM8nmT29KzVQoSZup+7UsNw9vOhf7pPFAE+oSpNP5vk+WhO1Pw61237Pob/hdnhUv/fucf8AgJNXFyWiTy+dJ0bpXoHwIjRPjL4T2dpLnP8A4CTUAfadFFFAHiX7WJkHgbQjD/rP7ZTb/wCA1xXzVHAkqbofuj/Wf71fTH7Vv/Ik6D/2GUx9fstzXzMfPA6HP0oAQ3AZSjfwcmrDywSRRt2BB+tNS2URsbjrIMfnUEisqGKDGFBoAdCpkuGaL7g5P0qveglsDqematW23yG8v/WY+ammXzf3XPy0AK8NwbQcdq3NI0eeW8hY9AmTWRFCNtaNlf8AlgSEHC/IeKANjVLC30fRZJJsh5m2jPvWDocKvrm64x5CpkCm67rTXGyCfscR49e1bXh9RpthKsefMkQsw9qALtpu+ytj/j38wEYHOM064JgJaH7r8H6GktpTFAzr1YHAqAzBhvm5dRkfWgBlxemCCQL12nH5Vxuq3QRmeX779K0tav8AMoB+lctsxfBj0dh+pFAGvppMMfmj7xHFSSSBWDzfefgUs5uIoFWPiM8H6VBpmfsx2ruPmAgfjQBYWEykMT6U6IiMTrecIVIT64NFxfXBBUWu1o+Q1Vb1pZIFef7z8UAbkNlDLprFfvbT+eK5TUbf7PKPrmtlG8qzC9yKz9Vg8yAMeKAJdJ1LdtQdVOfyruNKubeW1fzP9ZtO3615PZyG3lcj7y5IrqtFvoxGWuuknDfQ0AdwhIiYr1wcVS1W3CwK833n4FXJZo8xFD+5ER2/lT5LTz4oom6OQ3NAHH3CeVkexpqfuI2b/noCK19Vsre3zcdj8n9KyI13uqTNtiJAU+lAEMmAjZ6YqCAwAAntzXVS6Ez2Je3ug2ATtHfisTVNK+yxK78yN9360AZVstusW8n78oH60piMtnKJP9XG+5fwqe6Nw9qI/wC4M9ajihFvbSGX7zoQMfSgB6nyIEi9SHqxDtdd7Hgcmq4gdrdBD/rTwv1qN1khQh/9cB89AD4S0N+JofulgT9M16D4e1H7RCYD/wAtRs/Pj+tecw4cb26Dn8KvaPctaXPmwHapIOfT3oA9b/s/ZqXh2TvDrWndevN5CP61pfteJv1LwYf7sV+f1tv8a5/w94i+3TaJZy/vJP7Z00B/TF7Ca2P2yW23ngwH+KO+X9bagD5/Nohmlkb7xxii0eZZtvk+Yv8AKqyS+T8nrUglniieSD7p60AWJok8/KQmM9/ercipFb+a33lHy1Rjuy8Ifq7VHEs7zqZjx2oAtySvNFG0mdnOKjIgb5YuvJb8KhaF/PfZjG05qxpNtatpUrSffDUAAj+0RPJxwQKZMj/Z0eM/6vOTUcDsjqI/u96pXssBu1B7nmgCxpnmT3m549+TwfStm+2QFHkfcvOR6VDpi7QDB361HNaT3LXDNL5YTGffOf8ACgB0UuJlnn/49v4aSe78qR5bWLzY26e1Lb7FgxFN5kqqfwqoNRSLTwsn+uLHNAEF48kkZmmh8tD196jtrXd5Uq/6pzxUsSTXtnJ02Liug0q0stMtobmYfvBnbQA+202O6jSGWby1bmtey03RRFK1xefdwPyrmtUmmvrgMv3Hzg1Wi0+cSrGwGO9AHfSxeH7mxENhqJSVASQe/pWDbabLdSzyXlxsjGBG2evXNYT6VaxPI0k3lOcY9/WtEI8dgDHN5qL19qAI9X0h2QSWkvmLFnf7Z/ya5+32RvM0uNzYxW8NRSW0aJPvdGrM1LT/AC7VJgPvZoAht981wEfoelX42+zXPl8c1k2l6ka/McMvTP61btj58okmP3uVoAtzvteQ+uKpWyefKx4+U1cRJ0klx0OKjSKeSUkH7qmgCumz7WVfj0xSSrHDIxj6N1qrbKWdftPChm61fX7TDK7wn9wMYoALb98HQ9TQE8jee8f9abLmWWOY/eGap3KOJw6dG60AWvtE7RySwdFxux/n607mS188H98On41NaTJDGzAfL/Hx+VQzQ+dOkq/6sk7aAI3ffHE3/LwcipPNjjhIf/j4bAFRbGMzbPur1qw0yLGWXqo55oAf5QlgjaA/v+d1d78AoY4vjJ4VI/13m3G//wABJ684s7krcNNnrXovwGnE3xu8LsV+ZpLkg/S0m/xoA+2aKKKAPFv2q/8AkS/D49daQf8AktcV80yz7yEIHyc19LftVAN4L8Pg9P7aQ/8AktcV813XAYnsKAGMpVS69X6VDFFNbyJEehIc1JLIGhjVvung/SpI5i6GSL7gGzn0oAakG2SV+7gj86arAsFI4TkmmucRt6gGnCVfs6eZwvf6d6AGy5c74fujk1uW9itzYeYwGFXdWZZrFFInkdJCF/M1bvZzBDJEDyyleD6igDK0PTvtmrzGP/VxncT7Cu2sonVdlv0bj8+Kp+F7J1i32ORK4w3Pr/8ArrXkSe2lQzA7wQR9aAFEQibbMAGJ4FYl7dG2tpWHUPn9a2J50hJnue/JrhvFN9DM7GD7v1oAydYvJ7y8jPcuK0bGzCKHmxuY1n6XAY5I5JeLl2Hl/StRJ5o7ZlmGH8zGfxoAWQ+Y4j5+Q9qVY/srB8feIoEs+fmHHepli3OHz90g80AU4t0krumdygkUphmkG6fqKuzW+DuH/LTj86YEEJO7oOtAFERHIwfmqZF+1uEf74+79adJmJxLD91jQ96Z1YJ99BkfUc0AY+tW3kylYv8AW/xcVFoEyJdhLroSAa0pjLdROJ/vEEVzT5s5ZNvUA4oA9V0uUq8cZx9mLAD860p71/tMcMHADAZ/GuM8Nar9ptoUTiVSN3511U6ef5O3GSwx+dAEogjktJGuugkyfzrldQhc3EgHEBHy13NtCslvJHcdUUn8axr54IDxjPagDHuXuIGhEf8Aq/L+b8qrySNIjMn3lGV+tb8MhmtnyMnaePXisa5mWWZIpLXaqkbj6DPNAGRcCZ7eVpvvBSeO/FWUm/1WP+ef9Kb5MPnuIR8uORSmOFBuA5HIoAuSnfFHJ3Ug/rSbGnBxy3as9rtgpxwccU1ZfNv90n3xGSPrQBNNMpPkT9RxUZUhTFD91/lJ9qcrq7BLj7x4oMZjlW2i+4p3k+gFAGz4JkWDxf4Yt4f4tZsN/wD4FRmvUP2y/wDj58G/9c77+dtXmXhKPPjTwvJ6azYf+lMden/tjMFvvBe77uy+B/O2oA+e/OKWPl5/1lNtthiMLcyH7v8AWi+hzFHs+5ztqzBChtkDj73AoAqM1qhMcv8ArhUtvE5kHlfdNBs4LEmJevX86jneZUx/AaALqCSwkld4fML4HPao2YQKT5Xl7WU/XNLs228RgxuOdwoHntFJH1dsYoAcH36jNN22DFUbSI3CH/bY0+/22lqif8tmz5n9KfpW9YjJF98YxQBOYZLbaY8/J1qRpZ7hQrf6t/vf0/rUd3LDGgl8nzbpvUdKtLLLFarcyRCJTnzPegCpKj2qndzGPuVnR6fPfXieRGWL98dKXULlb11MQ+TnFdT4fnj0i189xy4AFAFiO0h0W3hSGTfdy53j0x0/nUeoolzCvnf6znNULu/cXbuT945X8av6Z4f1HXJQ6DMWRu/GgCEXELRQ2o6jNU4VkF1LC3ViNorv28NadpdkE/5bMPm+orlruJ7KZpovurmgCD7NPCu6cjan3eaqSXE2cxfcf71Wm1qe9GHP7pThvxrodP06LUrQJH1A+X60AcbLD5rp9hk2zfxj19K17SI3tlPbyJsmjwHPrnP+FVLjSbqz1gRXcohgJ4NXdZtJ7W3D2l1vV87T/eoA4u4t1srx0/5ak/JV+H94qtP/AKxaivmkltS/l7Zowd59c9P5Vn2kkzncehOfyoA6a0uJ5nKr0VT+Z/8A1VTg837PJvkKMSdo9adbhHT7Qv3pPlP4UTRJJgyYCr6UAZa206ys8ybVOCp9a0LNfPfBx8qnOaUedtYLxCPu1Vt2UXQReC3WgCWG0xCT0wxqrO+11X6jpV24/eSmH0qBoMkRMB5a8tQBLD8tvKv/AD0x+mf8aRbhI40jk4x0qVB9pUv53l268fWqlwEzt83zF/g4/OgB0rosTeX/ABU2NZFjQxnr15qtCwR2abp/DVyRYPs5kH3nYYoAkKSHaZO1eh/AQhvjJ4Uz95Zbgf8AkpPXALM8V4f7xT5P612v7PEok+MfhXd/rhNdZ+n2SagD7fooooA5X4jeB9P8e6Pa6dql1fWsdtdC7SSzZFfeEdMHerDGJG7elefSfs6eGpAQ+veJSDx/rbb/AOMUUUAIP2cvDIUKNd8S4HT97bf/ABilf9nPw04AbXvEmB/01th/7QoooAQfs5eGgc/294l/7+23/wAYpW/Z08NspB17xLg/9Nbb/wCMUUUASj9nrw8GRh4g8SZT7p8y14/8gUyT9nfw5Jjfr/iQ4YN/rLXr/wB+KKKANC3+B+l25zD4l8SIcY4Np0/8B6J/gfpc+3zfE3iVscj5rT/5HoooAik+A+jyAh/EniUgjB+e1H/tCs2T9mvwrI+59c8Slv8Artbf/GKKKAJz+zt4cKKn9v8AiXapyB5tt/8AGKan7OfhpCSuveJAT/00tv8A4xRRQBNH+z5oEYwniHxKB/10tf8A4xQ37PmgMMN4h8Sn/tpa/wDxiiigBi/s8eHVII8QeJQR0/e23/xikP7O3hwsWOv+JST1zLbf/GKKKAHv+z14eeLy28QeJSmMY8y1/wDjFVo/2bfC0RJTXPEgJ6/vbb/4xRRQBIf2c/DRBzr3iTn/AKa23/xioZ/2avCk4Al1rxIw/wCutsP5QUUUAOs/2bvC9mc22ueJEP8A11tj/OCr6fATREOU8ReJAR/t2v8A8j0UUAW1+CunKpUeJ/EmCMHmz6f+A9U5/gHok5zL4i8SE/79qP5QUUUAJH8AdDjlEieIvEocDAO+1/8AjFI3wA0Jndj4i8SlnBDfPa8/+QKKKAIk/Z48OoSV1/xIM9f3lr/8YqN/2cvDLnLa74kJ/wCutt/8YoooAWX9nPwzKytJrviQlRgfvLYf+0KP+Gc/DW0r/bviTBGP9bbf/GKKKAGxfs4+GYp1mj13xKJB0Pm23/xinn9nXw2XZ/7e8Sbm4J8y25/8gUUUAWdH/Z/8OaXrOnajFrPiCWWxuoruOOWWDYzxuHUNiEHGVGcEV0/xN+GWkfER9MbWL3UrVrASrH9jeNdwk2bt29G/55rjGO9FFAHFL+zd4XUALrniUAf9Nbb/AOMUH9m3wuWBOueJSR0/fW3/AMYoooAH/Zs8LPndrniQ5/6bW3/xikX9mvwquMa34k44/wBdbf8AxiiigBqfs0eFEIK634lHOf8AX2//AMZqQfs3eFxIJBrviUOOQfOtv/jFFFACXH7Nvha5lMk+t+JHc8EmW2/+MUn/AAzX4Wwg/tzxL8n3f31vx/5AoooAUfs2+Fg+7+3PEm71822/+MUk37NnhaYYk1zxKf8Attbf/GKKKAI0/Zm8JJjbrPiT/v8AW5/9o1Y/4Zy8M8f8T3xLxwP3tt/8YoooAZB+zb4XgcNFrniUEHP+utj/AO0K2LH4I6ZYsWtfE3iSNjjJzZnp9beiigCa7+Dlnd4+0eKvEr46Z+xj/wBt6zbz4AaDeQtFc+IfEjo3Ub7UfygoooAjs/2efDtnH5dtr/iRE9N9qf5wVdtvgbpVs++DxL4kVvXNof529FFAEepfAfRdTQrfeIvEcqnqM2g/lb1St/2dPDVuFEOveJFC9B5tsQP/ACBRRQA2b9nDwxMXMmueJDv+9iW2Gfygqsv7MXhBTldZ8Sg/9d7f/wCM0UUAWY/2cPDEa4TXfEoHp5tsf/aFI/7N/hhwQ2u+JSD2822/+MUUUAMb9mrwoybG1vxJt9POtv8A4xSQfs0eE4CTFrXiRT/12tj/AO0KKKAHyfs3eF5M79c8SnP/AE1tv/jFLH+zf4YjjZE1zxIFbr+9tv8A4xRRQAxf2a/CqjA1zxLj/rtb/wDximj9mfwkJFf+2fEm9eh822/+MUUUAOl/Zq8Ky58zW/EjZ9Zbb/4xSf8ADNHhPZs/trxJt9POt/8A4xRRQAo/Zq8KAADW/EuB0/fW/wD8Yrc8GfBDw/4S8T2GuWOqa3cXNkztHHcyQmMlo2jOQsSno579cUUUAeq0UUUAf//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Coronal T1 and matching fat-suppressed coronal PD-weighted MR images demonstrate subarticular marrow changes of symphyseal degeneration and athletic osteitis pubis. Note areas of subchondral sclerosis (black arrow), fatty change (Modic Type 2 signal abnormality identified by white arrowheads), and signal hyperintensity indicating 'osteitis' (Modic Type 1 signal abnormality identified by white arrows). These changes are bilateral but asymmetric.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Read JW. Groin disruption injury. Sports Medicine Imaging. For more information, visit",
"     <a href=\"file://www.sportsmedicineimaging.com/Home.html\" target=\"_blank\">",
"      file://www.sportsmedicineimaging.com/Home.html",
"     </a>",
"     . Copyright &copy; 2009 SportsMedicineImaging.com. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_3_12339=[""].join("\n");
var outline_f12_3_12339=null;
var title_f12_3_12340="Anterior column and hemitransverse acetabular fracture";
var content_f12_3_12340=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F62299&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F62299&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Anterior column and hemitransverse acetabular fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 444px; height: 516px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) The anteroposterior pelvis radiograph demonstrates medial subluxation of the femoral head with segmental displacement of the iliopectineal line. Ilioischial line displacement is present and, unlike the anterior wall fracture, the relationship of the ischium to the ilioischial line is preserved.",
"    <br>",
"     (B) The obturator oblique radiograph appears similar to that seen in the isolated anterior wall fracture but the fracture is seen to be multifragmentary with impaction.",
"     <br>",
"      (C) The iliac oblique view shows disruption of the posterior border of the innominate and displacement through the greater sciatic notch.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"       Reproduced with permission from: Moed BR, Reilly MC. Lower extremity: Acetabulum fractures. In: Rockwood and Green's Fractures in Adults,&nbsp;7th ed, Bucholz RW, Court-Brown CM, Heckman JD, Tornetta P (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2010. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins.",
"      </div>",
"      <div class=\"contractual\">",
"       <br/>",
"       <a href=\"file://www.lww.com\">",
"        file://www.lww.com",
"       </a>",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_3_12340=[""].join("\n");
var outline_f12_3_12340=null;
var title_f12_3_12341="Rounded atelectasis PA";
var content_f12_3_12341=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F82006&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F82006&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Rounded atelectasis in the right lung",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 393px; height: 320px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Chest frontal radiograph shows a nodular mass in the right mid-lung (long arrow). A tail-like connection is seen between the mass and the hilum (short arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_3_12341=[""].join("\n");
var outline_f12_3_12341=null;
var title_f12_3_12342="Placement of laparoscopic monitors at head of table";
var content_f12_3_12342=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F83867&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F83867&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 522px\">",
"   <div class=\"ttl\">",
"    Placement of laparoscopic monitors at head of table",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 502px; height: 655px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure depicts the location of the ports and monitors in preparation for performing an intra-abdominal procedure.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_3_12342=[""].join("\n");
var outline_f12_3_12342=null;
var title_f12_3_12343="Lobectomy specimen";
var content_f12_3_12343=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F59835&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F59835&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intralobar sequestration with recurrent left lower lobe pneumonia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 390px; height: 480px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A left lower lobe lobectomy specimen shows multiple cysts permeating the left lower lobe, basilar segments.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_3_12343=[""].join("\n");
var outline_f12_3_12343=null;
var title_f12_3_12344="Staphylococcus lugdunensis";
var content_f12_3_12344=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Staphylococcus lugdunensis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/3/12344/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/3/12344/contributors\">",
"     Vivian H Chu, MD, MHS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/3/12344/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/3/12344/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/3/12344/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/3/12344/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/3/12344/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 21, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Staphylococcus lugdunensis is a coagulase-negative staphylococcus (CNS). Like other CNS, S. lugdunensis in humans ranges from a harmless skin commensal to a life-threatening pathogen (as with infective endocarditis). Unlike other CNS, however, S. lugdunensis can cause severe disease reminiscent of the virulent infections frequently attributable to S. aureus [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12344/abstract/1\">",
"     1",
"    </a>",
"    ]. In addition, most S. lugdunensis isolates remain susceptible to a large number of antimicrobial agents.",
"   </p>",
"   <p>",
"    S. lugdunensis was first described in 1988 and was distinguished from other coagulase-negative staphylococcal species via DNA relatedness studies based on 11 clinical strains. The new species was named after Lyon, the French city where the organism was first isolated (Lugdunum, the Latin name of Lyon) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12344/abstract/2\">",
"     2",
"    </a>",
"    ]. S. lugdunensis is unique among CNS because of its propensity for causing aggressive native valve infective endocarditis (IE) and its susceptibility to a vast array of antimicrobial agents.",
"   </p>",
"   <p>",
"    The microbiology, clinical features, and treatment of S. lugdunensis infections will be reviewed here. Other issues related to coagulase-negative staphylococci are discussed in detail separately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;S. lugdunensis infections in humans range from harmless skin colonization to invasive infection. The majority of infections are related to skin and soft tissue, the bloodstream, and prosthetic devices.",
"   </p>",
"   <p>",
"    The frequency of S. lugdunensis infection is probably underappreciated, since many clinical laboratories do not routinely speciate coagulase-negative staphylococci [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12344/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Among 494 coagulase-negative staphylococcal isolates from a clinical setting, S. lugdunensis accounted for 3 percent of isolates [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12344/abstract/3\">",
"     3",
"    </a>",
"    ]. Unlike S. epidermidis, in general S. lugdunensis should be presumed to be a true pathogen. Among 229 S. lugdunensis clinical isolates in one series, only 15 percent were considered contaminants or colonizing organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12344/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;S. lugdunensis is a gram-positive, catalase-positive, coagulase-negative coccus. It is a non-motile, facultative anaerobe that may demonstrate hemolysis on blood agar [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12344/abstract/6\">",
"     6",
"    </a>",
"    ]. Colonies of S. lugdunensis can appear unpigmented, cream-colored, or pale yellow to golden after 5 days of incubation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12344/abstract/2,6\">",
"     2,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Slide and rapid latex agglutination tests are used by many laboratories to distinguish coagulase-negative from coagulase-positive staphylococci (S. aureus). However, the performance characteristics of these tests for S. lugdunensis are variable, and the presence of clumping factor can lead to false identification of S. aureus [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12344/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. For this reason, the tube coagulase test should be used to distinguish S. lugdunensis from S. aureus. Identification of S. lugdunensis can also be accomplished through commercially available phenotypic identification systems (commercial kits and automated systems) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12344/abstract/8,10\">",
"     8,10",
"    </a>",
"    ]. In addition, S. lugdunensis can be identified by molecular methods using gene targets [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12344/abstract/11-14\">",
"     11-14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Antibiotic susceptibility",
"    </span>",
"    &nbsp;&mdash;&nbsp;S. lugdunensis isolates are unique among the coagulase-negative staphylococci (CNS) by virtue of their susceptibility to a wide range of antimicrobials. In vitro testing of clinical S. lugdunensis isolates has demonstrated antimicrobial susceptibility to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/2/4136?source=see_link\">",
"     cefazolin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/10/20646?source=see_link\">",
"     daptomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     moxifloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/36/1608?source=see_link\">",
"     nafcillin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/17/34068?source=see_link\">",
"     quinupristin-dalfopristin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12344/abstract/9\">",
"     9",
"    </a>",
"    ]. S. lugdunensis resistance to beta-lactams, macrolides, and aminoglycosides is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12344/abstract/6,15,16\">",
"     6,15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The rate of penicillin-resistance was reported to be as low as &lt;4 percent in the 1990s [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12344/abstract/17\">",
"     17",
"    </a>",
"    ], although a decade later estimates of 12 to 27 percent were described [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12344/abstract/7,8,18\">",
"     7,8,18",
"    </a>",
"    ]. Among 59 clinical S. lugdunensis isolates in one series, 76 percent were beta-lactamase negative with penicillin MICs of &le;0.13",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12344/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Methicillin resistance in S. lugdunensis has been noted in only a few case reports, and presence of mecA (the gene encoding methicillin resistance in S. aureus) in S. lugdunensis is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12344/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. The",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/15/8437?source=see_link\">",
"     oxacillin",
"    </a>",
"    breakpoint for S. lugdunensis was modified in 2005 to more precisely reflect the presence of mecA. S. lugdunensis isolates with an oxacillin MIC &le;2",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    are defined as susceptible; those with oxacillin MICs of &ge;4",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    are defined as resistant [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12344/abstract/22\">",
"     22",
"    </a>",
"    ]. This is in contrast to other coagulase-negative staphylococci for which the breakpoint for oxacillin susceptible is &le;0.25",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    and for oxacillin resistant is &ge;0.5",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12344/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     Vancomycin",
"    </a>",
"    tolerance has been described in S. lugdunensis, meaning that the bacteria are able to survive in the presence of an antibiotic to which it is considered susceptible by MIC. This was demonstrated in 93 percent of S. lugdunensis isolates tested using an",
"    <span class=\"nowrap\">",
"     MBC/MIC",
"    </span>",
"    ratio of &ge;32 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12344/abstract/9\">",
"     9",
"    </a>",
"    ] and 46 percent (6 of 13) of isolates tested by the killing curve method [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12344/abstract/24\">",
"     24",
"    </a>",
"    ]. The clinical significance of vancomycin tolerance is uncertain, although these findings raise important concerns regarding selection of antimicrobial therapy.",
"   </p>",
"   <p>",
"    The presence of biofilm appears to influence the efficacy of antimicrobial agents in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12344/abstract/25-27\">",
"     25-27",
"    </a>",
"    ]. A study of S. lugdunensis antimicrobial susceptibility demonstrated that planktonic S. lugdunensis isolates were susceptible to all 10 anti-staphylococcal agents tested, while those in biofilms were highly resistant. Biofilm formation was increased in the presence of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/36/1608?source=see_link\">",
"     nafcillin",
"    </a>",
"    by 93 percent of organisms, while biofilm formation was decreased in the presence of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    .",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/51/33584?source=see_link\">",
"     Moxifloxacin",
"    </a>",
"    was the only antibiotic with activity against the S. lugdunensis organisms in biofilm; 73 percent of the biofilm isolates were susceptible [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12344/abstract/9\">",
"     9",
"    </a>",
"    ]. The clinical significance of biofilm and antimicrobial susceptibility is uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adherence factors allowing S. lugdunensis to bind to host tissues and implantable materials are thought to play a major role in the pathogenesis of S. lugdunensis infections. Von Willebrand factor binding protein allows interaction between the organism and clotting during vascular injury, and fibrinogen binding protein allows S. lugdunensis to bind host matrix proteins.",
"   </p>",
"   <p>",
"    Biofilm formation plays a major role in the pathogenesis of S. lugdunensis infections: it permits attachment of the organism on implantable devices and provides protection from antibiotics and host immunity [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12344/abstract/28\">",
"     28",
"    </a>",
"    ]. The biofilm of S. lugdunensis is composed of proteins rather than polysaccharide (which is a major component of biofilm produced by other organisms) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12344/abstract/29\">",
"     29",
"    </a>",
"    ]. The clinical significance of a protein based biofilm matrix is uncertain, although the presence of biofilm appears to modify the efficacy of antimicrobial agents in vitro. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Antibiotic susceptibility'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The role of biofilms in the pathogenesis of infection due to coagulase-negative staphylococci is discussed in further detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/28/9672?source=see_link&amp;anchor=H6#H6\">",
"     \"Microbiology, pathogenesis, and epidemiology of coagulase-negative staphylococci\", section on 'Attachment, adherence, and slime production'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pathogenesis of S. lugdunensis has not been associated with toxin production.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequency of S. lugdunensis infection is probably underappreciated, since many clinical laboratories do not routinely speciate coagulase-negative staphylococci (CNS). Virulent infection due to CNS should prompt speciation; unlike S. epidermidis, S. lugdunensis should generally be presumed to be a true pathogen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Skin and soft tissue",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most clinical infections due to S. lugdunensis are soft tissue infections. Among 50 S. lugdunensis infections observed in a single institution over a five year period, about 80 percent were soft tissue infections [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12344/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several studies suggest that S. lugdunensis tends to colonize and cause infection below the waist [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12344/abstract/18,30,31\">",
"     18,30,31",
"    </a>",
"    ]. There are reports of S. lugdunensis IE occurring in the setting of prostate cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12344/abstract/6\">",
"     6",
"    </a>",
"    ], vasectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12344/abstract/32\">",
"     32",
"    </a>",
"    ], and perineal lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12344/abstract/33-35\">",
"     33-35",
"    </a>",
"    ], all suggesting that S. lugdunensis has a predilection for colonization and infection of the perineal area. Among 38 patients with S. lugdunensis infection in one series, 73 percent of infections (mostly soft tissue abscesses) occurred below the waist [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12344/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a series of 140 patients, the prevalence of inguinal colonization with S. lugdunensis was about 20 percent (among both men and women) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12344/abstract/36\">",
"     36",
"    </a>",
"    ]. Inguinal colonization of the inguinal area appears to predispose to infection after invasive procedures, and shaving this area prior to surgery has been associated with an increased rate of S. lugdunensis infections [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12344/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The breast is another important site of S. lugdunensis infection. Breast abscesses (both spontaneous and postoperative infections) have been reported in non-lactating women [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12344/abstract/37\">",
"     37",
"    </a>",
"    ]. In one review, breast abscesses accounted for five of seven S. lugdunensis infections that occurred above the waist [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12344/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Endocarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;S. lugdunensis endocarditis is an aggressive infection that affects native valves with greater frequency than prosthetic valves in contrast to other coagulase-negative staphylococci (CNS). In a review of 48 cases of S. lugdunensis endocarditis, 81 percent involved native valves [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12344/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    S. lugdunensis native valve endocarditis is typically community-acquired and associated with a high rate of complications and death. In a review of 53 patients with native valve S. lugdunensis endocarditis, the rate of heart failure was 45 percent, periannular abscess 19 percent, embolization 30 percent, and death 42 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12344/abstract/39\">",
"     39",
"    </a>",
"    ]. While high rates of heart failure and valvular complications are also seen in the setting of endocarditis due to other coagulase-negative staphylococci (mostly S. epidermidis), the mortality rate of S. lugdunensis endocarditis rivals that of S. aureus [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12344/abstract/40-43\">",
"     40-43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/31/14840?source=see_link\">",
"     \"Epidemiology, risk factors and microbiology of infective endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    S. lugdunensis also causes prosthetic valve endocarditis. In a review of nine cases of S. lugdunensis prosthetic valve endocarditis, the rate of heart failure was 22 percent, periannular abscess 66 percent, embolization 11 percent, and death 78 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12344/abstract/39\">",
"     39",
"    </a>",
"    ]. The majority of these infections are late onset. Among six cases of S. lugdunensis prosthetic valve endocarditis, one infection occurred within 6 months of valve implantation; the rest occurred between 2 to 13 years after the original valve implantation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12344/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    S. lugdunensis",
"    <span class=\"nowrap\">",
"     pacemaker/ICD",
"    </span>",
"    lead endocarditis has also been described. Among seven patients managed with both hardware removal and antibiotic therapy, one patient died [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12344/abstract/39\">",
"     39",
"    </a>",
"    ]. Small colony variants of S. lugdunensis (pathogenic forms that facilitate persistent and recurrent infection) have been reported in the setting of pacemaker retention and persistent infection [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12344/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Reasons for the high mortality observed in cases of S. lugdunensis endocarditis are unclear. Nevertheless, evidence suggests that the prognosis for S. lugdunensis endocarditis has improved. Among 20 cases of S. lugdunensis endocarditis reported up to 1993, the mortality was 70 percent; among 28 cases reported after 1993, mortality was 18 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12344/abstract/15,38\">",
"     15,38",
"    </a>",
"    ]. The mortality observed for the later cases is more consistent with the mortality associated with coagulase-negative staphylococcal (mostly S. epidermidis) native valve endocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12344/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is unclear why the late cases were associated with an improved prognosis. Possible explanations include a higher rate of surgery for cases after 1993 than cases before (64 versus 35 percent), earlier diagnosis of S. lugdunensis endocarditis due to more frequent speciation of coagulase-negative staphylococci, and a higher proportion of native valve cases after 1993 than before (89 versus 70 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12344/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Bacteremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;S. lugdunensis non-endocarditis (non-IE) bacteremia is a less aggressive infection than S. lugdunensis endocarditis. Among 21 episodes of S. lugdunensis bacteremia in one series, six appeared to be clinically significant cases of non-IE bacteremia. Five of these patients had a hemodialysis or tunneled intravenous catheter; none experienced suppurative complications or death [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12344/abstract/45\">",
"     45",
"    </a>",
"    ]. Similar outcomes were observed in another series of 15 cases of non-IE S. lugdunensis bacteremia; a catheter or foreign device was identified in 73 percent of patients, and there were no complications related to the bacteremia [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12344/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, the data suggest that there is a dichotomy for S. lugdunensis bacteremia. Non-IE bacteremia tends to be health-care associated (ie, nosocomial or associated with foreign devices) and has a relatively good prognosis; bacteremia with endocarditis is often community-acquired and associated with an aggressive course [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12344/abstract/47\">",
"     47",
"    </a>",
"    ]. However, the data are subject to selection bias, since coagulase-negative staphylococci is not speciated in many institutions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Prosthetic devices",
"    </span>",
"    &nbsp;&mdash;&nbsp;S. lugdunensis infections of prosthetic joints have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12344/abstract/48-50\">",
"     48-50",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      S. lugdunensis infection was reported two years after a total hip arthroplasty in an otherwise healthy patient [",
"      <a class=\"abstract\" href=\"UTD.htm?12/3/12344/abstract/48\">",
"       48",
"      </a>",
"      ]. This was treated with abscess drainage, intra-articular teicoplanin injections, and oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/21/33104?source=see_link\">",
"       clindamycin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      for 3 months [",
"      <a class=\"abstract\" href=\"UTD.htm?12/3/12344/abstract/48\">",
"       48",
"      </a>",
"      ]. The patient remained asymptomatic up to 6 years of follow-up.",
"     </li>",
"     <li>",
"      S. lugdunensis infection of knee arthroplasty was reported in a patient on",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      four years after total knee arthroplasty. This patient was treated with resection arthroplasty, 6 weeks of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      , and delayed reimplantation with no relapse after 10 months follow-up [",
"      <a class=\"abstract\" href=\"UTD.htm?12/3/12344/abstract/49\">",
"       49",
"      </a>",
"      ]. Other cases of S. lugdunensis knee arthroplasty infections with clinical cure have been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?12/3/12344/abstract/49,50\">",
"       49,50",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    S. lugdunensis has also been reported in association with ventriculoperitoneal shunts and external ventriculostomy drains [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12344/abstract/51,52\">",
"     51,52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Other infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of other infections due to S. lugdunensis have been described:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Septic arthritis after arthroscopic anterior cruciate ligament revision has been described [",
"      <a class=\"abstract\" href=\"UTD.htm?12/3/12344/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Osteomyelitis of the thoracic and lumbar spine has been reported in the setting of advanced age and immunosuppression [",
"      <a class=\"abstract\" href=\"UTD.htm?12/3/12344/abstract/50,54-56\">",
"       50,54-56",
"      </a>",
"      ]. Osteomyelitis of the ear canal has been noted in a patient with non insulin dependent diabetes [",
"      <a class=\"abstract\" href=\"UTD.htm?12/3/12344/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Acute postoperative endophthalmitis (mean of 7.6 days after cataract surgery) was observed among five patients in one series. Treatment included intravenous, intravitreal, topical antibiotics, and pars plana vitrectomy (four patients). Despite aggressive treatment, outcomes were poor for three out of the five patients [",
"      <a class=\"abstract\" href=\"UTD.htm?12/3/12344/abstract/58\">",
"       58",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/18/24873?source=see_link\">",
"       \"Bacterial endophthalmitis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Cases of endometritis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12344/abstract/59\">",
"     59",
"    </a>",
"    ], acute suppurative lymphadenitis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12344/abstract/60\">",
"     60",
"    </a>",
"    ], psoas abscess [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12344/abstract/61\">",
"     61",
"    </a>",
"    ], urinary tract infection [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12344/abstract/62,63\">",
"     62,63",
"    </a>",
"    ] and peritonitis with exit site infection [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12344/abstract/64\">",
"     64",
"    </a>",
"    ] have also been described.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of infection due to S. lugdunensis should be guided by the results of antibiotic susceptibility testing. Most isolates are susceptible to penicillin, and this is the drug of choice for treatment of infection if susceptibility permits. Isolates possessing beta-lactamase (fewer than one-quarter) are resistant to penicillin [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12344/abstract/19\">",
"     19",
"    </a>",
"    ]. Almost all of S. lugdunensis isolates are susceptible to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/15/8437?source=see_link\">",
"     oxacillin",
"    </a>",
"    ; and the presence of mecA is rare [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12344/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     Vancomycin",
"    </a>",
"    is an appropriate alternative agent if resistance or sensitivity precludes use of beta-lactam agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Skin and soft tissue",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to antibiotic selection for treatment of S. lugdunensis skin and soft tissue infections is as outlined in the preceding section. Abscesses should be drained if possible. The duration of therapy depends on individual circumstances but in general consists of one to two weeks of therapy; the clinical response to therapy should guide antibiotic duration. Deep seated infections may warrant parenteral therapy initially, though therapy may be completed with oral agents depending on individual circumstances.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Endocarditis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of native valve infectious endocarditis (IE) should consist of 6 weeks of parenteral beta-lactam therapy or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    (depending on susceptibility testing and beta lactam hypersensitivity). Limited data suggest comparable mortality outcomes with monotherapy and combination therapy for native valve IE [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12344/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment of prosthetic valve IE should consist of combination therapy including a beta-lactam (or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    ) with an aminoglycoside and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    . The",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    should be administered for the first two weeks of therapy; the beta-lactam (or vancomycin) and rifampin should be continued for 6 weeks. This approach is extrapolated from the S. aureus literature. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/57/34712?source=see_link\">",
"     \"Antimicrobial therapy of prosthetic valve endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Surgery must be considered given the frequency of valvular compromise in the setting of S. lugdunensis IE. In a review of 10 patients with S. lugdunensis IE, all patients with left sided IE had serious complications; surgery was required in more than half of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12344/abstract/39\">",
"     39",
"    </a>",
"    ]. Predictors of surgery included age &lt;50, absence of significant comorbidity, aortic valve involvement, and periannular abscess. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/49/22297?source=see_link\">",
"     \"Surgery for native valve endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The treatment of S. lugdunensis pacemaker endocarditis includes antibiotic therapy as well as removal of the pacer system. The mortality with this infection is low if the pacemaker and leads are removed [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12344/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/19/44345?source=see_link\">",
"     \"Infections involving cardiac implantable electronic devices\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Bacteremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacteremia without endocarditis (often related to an intravascular catheter) has a good prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12344/abstract/46\">",
"     46",
"    </a>",
"    ]. For intravascular catheter-related S. lugdunensis bacteremia, the catheter should be removed, followed by 5 to 7 days of antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12344/abstract/65\">",
"     65",
"    </a>",
"    ]. The approach to antibiotic selection is as outlined above. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Treatment'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The outcome of retaining the intravascular catheter is uncertain, but would likely require a longer course of antibiotics [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12344/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Prosthetic devices",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of prosthetic joint infections generally consists of two-stage arthroplasty and at least 6 weeks of antibiotics. Antibiotic selection for treatment of infection due to S. lugdunensis is as outlined in the preceding section (see",
"    <a class=\"local\" href=\"#H12\">",
"     'Treatment'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    The long-term outcome of S. lugdunensis prosthetic joint infection is unknown. Although some case reports describe definitive treatment of S. lugdunensis prosthetic joint infections without prosthesis removal, these data must be interpreted with caution since coagulase-negative staphylococcal infections can be indolent with delayed presentation.",
"   </p>",
"   <p>",
"    Additional considerations for treatment of prosthetic joint infections are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/19/6457?source=see_link\">",
"     \"Treatment of prosthetic joint infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Other infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotic selection for treatment of infection due to S. lugdunensis is as outlined in the preceding section (see",
"    <a class=\"local\" href=\"#H12\">",
"     'Treatment'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    General approaches to septic arthritis, vertebral osteomyelitis, and other types of infection that can be caused by S. lugdunensis are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/28/22985?source=see_link\">",
"     \"Vertebral osteomyelitis and discitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11049?source=see_link\">",
"     \"Septic arthritis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In humans, the significance of S. lugdunensis ranges from a harmless skin commensal to a life-threatening pathogen (such as in the case of infective endocarditis). Unlike other coagulase-negative staphylococci, however, S. lugdunensis can cause severe disease reminiscent of the virulent infections frequently attributable to S. aureus. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The frequency of S. lugdunensis infection is probably underappreciated, since many clinical laboratories do not routinely speciate coagulase-negative staphylococci. Virulent infection due to CNS should prompt speciation; unlike S. epidermidis, S. lugdunensis should generally be presumed to be a true pathogen. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      S. lugdunensis is a gram-positive, catalase-positive, coagulase-negative coccus. The tube coagulase test should be used to distinguish S. lugdunensis from S. aureus. S. lugdunensis isolates are unique among the coagulase-negative staphylococci by virtue of their susceptibility to a wide range of antimicrobials. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Microbiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Biofilm formation plays a major role in the pathogenesis of S. lugdunensis infection; it provides protection from antibiotics and host immunity and permits attachment of the organism on implantable devices. The presence of biofilm appears to modify the efficacy of antimicrobial agents in vitro. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical infections due to S. lugdunensis include soft tissue infections, endocarditis, bacteremia, prosthetic device infections, osteomyelitis, and others. Several studies suggest that S. lugdunensis tends to colonize and cause infection below the waist. S. lugdunensis endocarditis is an aggressive infection that affects native valves with greater frequency than prosthetic valves. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of infection due to S. lugdunensis should be guided by the results of antibiotic susceptibility testing. We recommend treatment of S. lugdunensis with penicillin (if susceptibility and individual circumstances permit) (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Appropriate alternative agents include other beta-lactam drugs and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      . The duration of therapy depends on the site of infection. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12344/abstract/1\">",
"      Frank KL, Del Pozo JL, Patel R. From clinical microbiology to infection pathogenesis: how daring to be different works for Staphylococcus lugdunensis. Clin Microbiol Rev 2008; 21:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12344/abstract/2\">",
"      Freney J, Brun Y, Bes M, et al. Staphylococcus lugdunensis sp nov and Staphylococcus schleiferi sp nov, two species from human clinical specimens. Int J Syst Bacteriol 1988; :168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12344/abstract/3\">",
"      Gatermann SG, Koschinski T, Friedrich S. Distribution and expression of macrolide resistance genes in coagulase-negative staphylococci. Clin Microbiol Infect 2007; 13:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12344/abstract/4\">",
"      Kleiner E, Monk AB, Archer GL, Forbes BA. Clinical significance of Staphylococcus lugdunensis isolated from routine cultures. Clin Infect Dis 2010; 51:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12344/abstract/5\">",
"      Herchline TE, Ayers LW. Occurrence of Staphylococcus lugdunensis in consecutive clinical cultures and relationship of isolation to infection. J Clin Microbiol 1991; 29:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12344/abstract/6\">",
"      Fleurette J, B&egrave;s M, Brun Y, et al. Clinical isolates of Staphylococcus lugdunensis and S. schleiferi: bacteriological characteristics and susceptibility to antimicrobial agents. Res Microbiol 1989; 140:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12344/abstract/7\">",
"      Tan TY, Ng SY, He J. Microbiological characteristics, presumptive identification, and antibiotic susceptibilities of Staphylococcus lugdunensis. J Clin Microbiol 2008; 46:2393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12344/abstract/8\">",
"      Mateo M, Maestre JR, Aguilar L, et al. Genotypic versus phenotypic characterization, with respect to susceptibility and identification, of 17 clinical isolates of Staphylococcus lugdunensis. J Antimicrob Chemother 2005; 56:287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12344/abstract/9\">",
"      Frank KL, Reichert EJ, Piper KE, Patel R. In vitro effects of antimicrobial agents on planktonic and biofilm forms of Staphylococcus lugdunensis clinical isolates. Antimicrob Agents Chemother 2007; 51:888.",
"     </a>",
"    </li>",
"    <li>",
"     Carroll K, Weinstein M. 2007. Manual and automated systems for detection and identification of microorganisms. In: Manual of clinical microbiology, 9th ed, Murray PR, Baron EJ, Jorgensen JH, et al (Eds), ASM Press, Washington, DC 2009. Vol 1, p.192.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12344/abstract/11\">",
"      Petti CA, Simmon KE, Miro JM, et al. Genotypic diversity of coagulase-negative staphylococci causing endocarditis: a global perspective. J Clin Microbiol 2008; 46:1780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12344/abstract/12\">",
"      Martineau F, Picard FJ, Ke D, et al. Development of a PCR assay for identification of staphylococci at genus and species levels. J Clin Microbiol 2001; 39:2541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12344/abstract/13\">",
"      Poyart C, Quesne G, Boumaila C, Trieu-Cuot P. Rapid and accurate species-level identification of coagulase-negative staphylococci by using the sodA gene as a target. J Clin Microbiol 2001; 39:4296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12344/abstract/14\">",
"      Goh SH, Potter S, Wood JO, et al. HSP60 gene sequences as universal targets for microbial species identification: studies with coagulase-negative staphylococci. J Clin Microbiol 1996; 34:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12344/abstract/15\">",
"      Vandenesch F, Etienne J, Reverdy ME, Eykyn SJ. Endocarditis due to Staphylococcus lugdunensis: report of 11 cases and review. Clin Infect Dis 1993; 17:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12344/abstract/16\">",
"      Higaki S, Kitagawa T, Morohashi M, Yamagishi T. Distribution and antimicrobial susceptibility of coagulase-negative staphylococci from skin lesions. J Int Med Res 1999; 27:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12344/abstract/17\">",
"      Paterson DL, Nuttall N. Serious infections due to Staphylococcus lugdunensis. Aust N Z J Med 1997; 27:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12344/abstract/18\">",
"      Hellbacher C, T&ouml;rnqvist E, S&ouml;derquist B. Staphylococcus lugdunensis: clinical spectrum, antibiotic susceptibility, and phenotypic and genotypic patterns of 39 isolates. Clin Microbiol Infect 2006; 12:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12344/abstract/19\">",
"      Herchline TE, Barnishan J, Ayers LW, Fass RJ. Penicillinase production and in vitro susceptibilities of Staphylococcus lugdunensis. Antimicrob Agents Chemother 1990; 34:2434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12344/abstract/20\">",
"      Becker K, Pagnier I, Schuhen B, et al. Does nasal cocolonization by methicillin-resistant coagulase-negative staphylococci and methicillin-susceptible Staphylococcus aureus strains occur frequently enough to represent a risk of false-positive methicillin-resistant S. aureus determinations by molecular methods? J Clin Microbiol 2006; 44:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12344/abstract/21\">",
"      Tee WS, Soh SY, Lin R, Loo LH. Staphylococcus lugdunensis carrying the mecA gene causes catheter-associated bloodstream infection in premature neonate. J Clin Microbiol 2003; 41:519.",
"     </a>",
"    </li>",
"    <li>",
"     CLSI. 2005. Performance standards for antimicrobial susceptibility testing: Fifteenth informational supplement. CLSI/NCCLS document M100-S15. Clinical and Laboratory Standards Institute, Wayne, PA. 2005.",
"    </li>",
"    <li>",
"     NCCLS. 1999. Performance standards for antimicrobial susceptibility testing. Ninth informational supplement M100-S9. NCCLS, Wayne, PA. 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12344/abstract/24\">",
"      Bourgeois I, Pestel-Caron M, Lemeland JF, et al. Tolerance to the glycopeptides vancomycin and teicoplanin in coagulase-negative staphylococci. Antimicrob Agents Chemother 2007; 51:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12344/abstract/25\">",
"      G&ouml;tz F. Staphylococcus and biofilms. Mol Microbiol 2002; 43:1367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12344/abstract/26\">",
"      O'Gara JP. ica and beyond: biofilm mechanisms and regulation in Staphylococcus epidermidis and Staphylococcus aureus. FEMS Microbiol Lett 2007; 270:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12344/abstract/27\">",
"      Pareja J, Gupta K, Koziel H. The toxic shock syndrome and Staphylococcus lugdunensis bacteremia. Ann Intern Med 1998; 128:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12344/abstract/28\">",
"      Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science 1999; 284:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12344/abstract/29\">",
"      Frank KL, Patel R. Poly-N-acetylglucosamine is not a major component of the extracellular matrix in biofilms formed by icaADBC-positive Staphylococcus lugdunensis isolates. Infect Immun 2007; 75:4728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12344/abstract/30\">",
"      Tan TY, Ng SY, Ng WX. Clinical significance of coagulase-negative staphylococci recovered from nonsterile sites. J Clin Microbiol 2006; 44:3413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12344/abstract/31\">",
"      Bellamy R, Barkham T. Staphylococcus lugdunensis infection sites: predominance of abscesses in the pelvic girdle region. Clin Infect Dis 2002; 35:E32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12344/abstract/32\">",
"      Fervenza FC, Contreras GE, Garratt KN, Steckelberg JM. Staphylococcus lugdunensis endocarditis: a complication of vasectomy? Mayo Clin Proc 1999; 74:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12344/abstract/33\">",
"      Lessing MP, Crook DW, Bowler IC, Gribbin B. Native-valve endocarditis caused by Staphylococcus lugdunensis. QJM 1996; 89:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12344/abstract/34\">",
"      Patel R, Piper KE, Rouse MS, et al. Frequency of isolation of Staphylococcus lugdunensis among staphylococcal isolates causing endocarditis: a 20-year experience. J Clin Microbiol 2000; 38:4262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12344/abstract/35\">",
"      Polenakovik H, Herchline T, Bacheller C, Bernstein J. Staphylococcus lugdunensis endocarditis after angiography. Mayo Clin Proc 2000; 75:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12344/abstract/36\">",
"      van der Mee-Marquet N, Achard A, Mereghetti L, et al. Staphylococcus lugdunensis infections: high frequency of inguinal area carriage. J Clin Microbiol 2003; 41:1404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12344/abstract/37\">",
"      Lina B, Vandenesch F, Reverdy ME, et al. Non-puerperal breast infections due to Staphylococcus lugdunensis. Eur J Clin Microbiol Infect Dis 1994; 13:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12344/abstract/38\">",
"      Seenivasan MH, Yu VL. Staphylococcus lugdunensis endocarditis--the hidden peril of coagulase-negative staphylococcus in blood cultures. Eur J Clin Microbiol Infect Dis 2003; 22:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12344/abstract/39\">",
"      Anguera I, Del R&iacute;o A, Mir&oacute; JM, et al. Staphylococcus lugdunensis infective endocarditis: description of 10 cases and analysis of native valve, prosthetic valve, and pacemaker lead endocarditis clinical profiles. Heart 2005; 91:e10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12344/abstract/40\">",
"      Chu VH, Woods CW, Miro JM, et al. Emergence of coagulase-negative staphylococci as a cause of native valve endocarditis. Clin Infect Dis 2008; 46:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12344/abstract/41\">",
"      Fowler VG Jr, Miro JM, Hoen B, et al. Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA 2005; 293:3012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12344/abstract/42\">",
"      R&oslash;der BL, Wandall DA, Frimodt-M&oslash;ller N, et al. Clinical features of Staphylococcus aureus endocarditis: a 10-year experience in Denmark. Arch Intern Med 1999; 159:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12344/abstract/43\">",
"      Watanakunakorn C. Staphylococcus aureus endocarditis at a community teaching hospital, 1980 to 1991. An analysis of 106 cases. Arch Intern Med 1994; 154:2330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12344/abstract/44\">",
"      Seifert H, Oltmanns D, Becker K, et al. Staphylococcus lugdunensis pacemaker-related infection. Emerg Infect Dis 2005; 11:1283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12344/abstract/45\">",
"      Ebright JR, Penugonda N, Brown W. Clinical experience with Staphylococcus lugdunensis bacteremia: a retrospective analysis. Diagn Microbiol Infect Dis 2004; 48:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12344/abstract/46\">",
"      Zinkernagel AS, Zinkernagel MS, Elzi MV, et al. Significance of Staphylococcus lugdunensis bacteremia: report of 28 cases and review of the literature. Infection 2008; 36:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12344/abstract/47\">",
"      Friedman ND, Kaye KS, Stout JE, et al. Health care--associated bloodstream infections in adults: a reason to change the accepted definition of community-acquired infections. Ann Intern Med 2002; 137:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12344/abstract/48\">",
"      Sanz&eacute;ni L, Ringberg H. Fistulating periprosthetic Staphylococcus lugdunensis hip infection cured by intra-articular teicoplanin injections--a case report. Acta Orthop Scand 2003; 74:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12344/abstract/49\">",
"      Sampathkumar P, Osmon DR, Cockerill FR 3rd. Prosthetic joint infection due to Staphylococcus lugdunensis. Mayo Clin Proc 2000; 75:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12344/abstract/50\">",
"      Weightman NC, Allerton KE, France J. Bone and prosthetic joint infection with Staphylococcus lugdunensis. J Infect 2000; 40:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12344/abstract/51\">",
"      Elliott SP, Yogev R, Shulman ST. Staphylococcus lugdunensis: an emerging cause of ventriculoperitoneal shunt infections. Pediatr Neurosurg 2001; 35:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12344/abstract/52\">",
"      Spanu T, Rigante D, Tamburrini G, et al. Ventriculitis due to Staphylococcus lugdunensis: two case reports. J Med Case Rep 2008; 2:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12344/abstract/53\">",
"      Mei-Dan O, Mann G, Steinbacher G, et al. Septic arthritis with Staphylococcus lugdunensis following arthroscopic ACL revision with BPTB allograft. Knee Surg Sports Traumatol Arthrosc 2008; 16:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12344/abstract/54\">",
"      Murdoch DR, Everts RJ, Chambers ST, Cowan IA. Vertebral osteomyelitis due to Staphylococcus lugdunensis. J Clin Microbiol 1996; 34:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12344/abstract/55\">",
"      Camacho M, Guis S, Mattei JP, et al. Three-year outcome in a patient with Staphylococcus lugdunensis discitis. Joint Bone Spine 2002; 69:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12344/abstract/56\">",
"      Greig JM, Wood MJ. Staphylococcus lugdunensis vertebral osteomyelitis. Clin Microbiol Infect 2003; 9:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12344/abstract/57\">",
"      Thomas S, Hoy C, Capper R. Osteomyelitis of the ear canal caused by Staphylococcus lugdunensis. J Infect 2006; 53:e227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12344/abstract/58\">",
"      Chiquet C, Pechinot A, Creuzot-Garcher C, et al. Acute postoperative endophthalmitis caused by Staphylococcus lugdunensis. J Clin Microbiol 2007; 45:1673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12344/abstract/59\">",
"      Bello C, Eskandar M, El GR, et al. Staphylococcus lugdunensis endometritis: a case report. West Afr J Med 2007; 26:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12344/abstract/60\">",
"      Kim JH, Lee JY, Kim HR, et al. Acute lymphadenitis with cellulitis caused by Staphylococcus lugdunensis. Korean J Lab Med 2008; 28:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12344/abstract/61\">",
"      Hammami BK, Ghorbel H, Abid F, et al. [Psoas abscess of the adult: study of 38 cases]. Tunis Med 2007; 85:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12344/abstract/62\">",
"      Casanova-Roman M, Sanchez-Porto A, Casanova-Bellido M. Urinary tract infection due to Staphylococcus lugdunensis in a healthy child. Scand J Infect Dis 2004; 36:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12344/abstract/63\">",
"      Haile DT, Hughes J, Vetter E, et al. Frequency of isolation of Staphylococcus lugdunensis in consecutive urine cultures and relationship to urinary tract infection. J Clin Microbiol 2002; 40:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12344/abstract/64\">",
"      Schnitzler N, Meilicke R, Conrads G, et al. Staphylococcus lugdunensis: report of a case of peritonitis and an easy-to-perform screening strategy. J Clin Microbiol 1998; 36:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12344/abstract/65\">",
"      Mermel LA, Farr BM, Sherertz RJ, et al. Guidelines for the management of intravascular catheter-related infections. Clin Infect Dis 2001; 32:1249.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3155 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-190.111.122.2-6B4A64F196-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_3_12344=[""].join("\n");
var outline_f12_3_12344=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Antibiotic susceptibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Skin and soft tissue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Endocarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Bacteremia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Prosthetic devices",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Other infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Skin and soft tissue",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Endocarditis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Bacteremia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Prosthetic devices",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Other infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/57/34712?source=related_link\">",
"      Antimicrobial therapy of prosthetic valve endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/18/24873?source=related_link\">",
"      Bacterial endophthalmitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/31/14840?source=related_link\">",
"      Epidemiology, risk factors and microbiology of infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/19/44345?source=related_link\">",
"      Infections involving cardiac implantable electronic devices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/28/9672?source=related_link\">",
"      Microbiology, pathogenesis, and epidemiology of coagulase-negative staphylococci",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11049?source=related_link\">",
"      Septic arthritis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/49/22297?source=related_link\">",
"      Surgery for native valve endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/19/6457?source=related_link\">",
"      Treatment of prosthetic joint infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/28/22985?source=related_link\">",
"      Vertebral osteomyelitis and discitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_3_12345="Therapy of resistant or relapsing diffuse or focal proliferative lupus nephritis";
var content_f12_3_12345=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Therapy of resistant or relapsing diffuse or focal proliferative lupus nephritis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/3/12345/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/3/12345/contributors\">",
"     Ronald J Falk, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/3/12345/contributors\">",
"     Peter H Schur, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/3/12345/contributors\">",
"     Gerald B Appel, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/3/12345/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/3/12345/contributors\">",
"     Richard J Glassock, MD, MACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/3/12345/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/3/12345/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/3/12345/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal treatment of lupus nephritis (LN) varies with the type of disease (morphologic class) that is present. Immunosuppressive therapy is indicated in patients with diffuse and severe focal proliferative LN, and in membranous LN associated with the nephrotic syndrome, an elevated serum creatinine,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    associated proliferative disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/3/27706?source=see_link\">",
"     \"Diagnosis and classification of renal disease in systemic lupus erythematosus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A significant number of patients are resistant to standard induction treatments. The percentage of patients who fail to achieve remission in response to immunosuppressive therapy is variable, depending in part upon the criteria that are used to define remission. In addition, as many as one-half of patients with proliferative LN who initially achieve remission on immunosuppressive therapy relapse (also called renal flare) following reduction in or cessation of immunosuppression.",
"   </p>",
"   <p>",
"    The treatment of resistant and relapsing lupus nephritis will be reviewed here. The treatment of proliferative or membranous LN and issues related to end-stage LN are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/37/37466?source=see_link\">",
"     \"Therapy of diffuse or focal proliferative lupus nephritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/12/44233?source=see_link\">",
"     \"Clinical features and therapy of membranous lupus nephritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39352?source=see_link\">",
"     \"End-stage renal disease due to lupus nephritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DISEASE RESISTANT TO INDUCTION THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are two major issues involved in proliferative lupus nephritis (LN) that is resistant to induction therapy: the definition of remission and the treatment of resistant disease. In addition, one must consider the risks of overly aggressive therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Definition of remission",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no consensus on the optimal definition of remission with immunosuppressive therapy in patients with proliferative lupus nephritis (LN). As a result, the reported incidence of \"resistant\" LN is variable.",
"   </p>",
"   <p>",
"    Resistance to induction therapy is most often defined as the failure to achieve either complete or partial remission and is associated with a worse long-term prognosis compared to patients who attain remission. Assessment for the development of remission requires a minimum of three months and, in some patients, as long as 12 months after the initiation of induction therapy.",
"   </p>",
"   <p>",
"    The definition of clinical remission in patients with proliferative LN is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/37/37466?source=see_link&amp;anchor=H11#H11\">",
"     \"Therapy of diffuse or focal proliferative lupus nephritis\", section on 'Criteria for clinical remission'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Summarized briefly, the following points deserve emphasis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The goal of immunosuppressive therapy is to abolish active immunologic disease. Among patients with proliferative LN (as opposed to membranous lupus alone in which proteinuria may be the sole urinary manifestation), cessation of inflammation is characterized by resolution of hematuria (less than &le;5 red cells per high power field), pyuria, and cellular casts. Attainment of immunologic remission is often associated with significant improvements in biomarkers of immunologic activity such as low serum complement and high anti-dsDNA antibody titers [",
"      <a class=\"abstract\" href=\"UTD.htm?12/3/12345/abstract/1-3\">",
"       1-3",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      A potential problem is that persistent hematuria may be due to some other factor, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      -induced bladder irritation. This distinction is difficult in some patients, since the percentage of red cells that need to be dysmorphic to diagnosis glomerular bleeding is not well defined. The disappearance of dysmorphic red cells and of red cell and other cellular casts is compatible with but not diagnostic of a nonglomerular cause. Another problem is that the identification of dysmorphic red cells and cellular casts requires considerable experience. If cyclophosphamide-induced bladder toxicity is considered likely, cystoscopy may be warranted. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/59/34746?source=see_link&amp;anchor=H1824471562#H1824471562\">",
"       \"Etiology and evaluation of hematuria in adults\", section on 'Red cell morphology'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25098?source=see_link&amp;anchor=H15#H15\">",
"       \"General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases\", section on 'Bladder toxicity with CYC'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Remission of proliferative LN is also associated with a reduction in urinary protein excretion, and a reduction in or stabilization of the serum creatinine concentration. The time course of the reduction in proteinuria after the inciting stimulus has been removed may be quite prolonged. A number of studies have found that proteinuria ranged from 1 to 1.6",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      after six months of induction therapy among patients with eventually satisfactory renal outcomes [",
"      <a class=\"abstract\" href=\"UTD.htm?12/3/12345/abstract/1-3\">",
"       1-3",
"      </a>",
"      ]. Despite these observations, some clinical trials have used complete resolution of proteinuria as a criterion for remission and, not surprisingly, reported lower rates of clinical remission.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Prolonged recovery after removal of the immunologic stimulus has been noted in other glomerular diseases. As an example, studies in patients with drug-induced membranous nephropathy have shown that the average time to resolution of proteinuria is one year after discontinuation of the offending drug, with some patients requiring three years [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12345/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Even more prolonged gradual recovery after removal of the causative antigen has been described in poststreptococcal glomerulonephritis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12345/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/54/19306?source=see_link&amp;anchor=H12#H12\">",
"     \"Causes and diagnosis of membranous nephropathy\", section on 'Drugs, particularly penicillamine and gold'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/30/35304?source=see_link\">",
"     \"Poststreptococcal glomerulonephritis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Over time, another problem that can occur in most forms of proteinuric chronic kidney disease is progressive glomerulosclerosis with increasing nonnephrotic proteinuria in the absence of inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12345/abstract/7\">",
"     7",
"    </a>",
"    ]. In patients with LN, this can reflect healing of severe structural damage during the active phase (due to factors such as necrosis and crescent formation) or, when a significant portion of the glomeruli have been irreversibly damaged, to nonimmunologic factors that can lead to increased protein excretion and glomerulosclerosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/19/26938?source=see_link\">",
"     \"Secondary factors and progression of chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A clear understanding of the extent of immunologic remission is essential when deciding whether or not the patient is likely to benefit from further immunosuppressive therapy. A repeat renal biopsy is indicated in selected patients with resistant LN. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/42/41638?source=see_link&amp;anchor=H14#H14\">",
"     \"Indications for renal biopsy in patients with lupus nephritis\", section on 'Repeat biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Treatment of resistant disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to patients who are considered resistant to initial therapy (ie, who have ongoing evidence of active nephritis) varies with the agent used for induction therapy (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil [MMF] or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ) and the severity of disease. In general, we treat cyclophosphamide-resistant patients with MMF, and MMF-resistant patients with cyclophosphamide. The induction and maintenance regimens used in resistant LN are the same as those used for primary therapy. Patients who fail treatment with both cyclophosphamide and MMF may be treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , although one must keep in mind that long-term efficacy and toxicity of rituximab have not been fully defined. Our approach is consistent with recommendations made by both the Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guidelines for glomerulonephritis and the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association",
"    <span class=\"nowrap\">",
"     (EULAR/ERA-EDTA)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12345/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Rituximab for cyclophosphamide and MMF resistance'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Cyclophosphamide resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited data from small case series suggest that MMF may be effective in inducing remission in the infrequent patients who are resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12345/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. As an example, one series evaluated 12 patients who were resistant to or relapsed following cyclophosphamide [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12345/abstract/11\">",
"     11",
"    </a>",
"    ]. The following findings were noted at a mean follow-up of 13 months:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Proteinuria decreased in ten patients, with a mean reduction in the urine protein-to-creatinine ratio of 2.5. The urine protein-to-creatinine ratio fell below 3.5",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      in seven patients who had nephrotic range proteinuria at baseline.",
"     </li>",
"     <li>",
"      All patients had hematuria",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      cellular casts at baseline; the urine sediment returned to normal in six patients.",
"     </li>",
"     <li>",
"      The serum creatinine was stable or decreased in ten patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The preferred regimen for MMF is that used in the largest clinical trial (ALMS) in patients with LN [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12345/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/37/37466?source=see_link&amp;anchor=H18#H18\">",
"     \"Therapy of diffuse or focal proliferative lupus nephritis\", section on 'Mycophenolate mofetil'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     MMF resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few studies have examined the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    among MMF-resistant patients. However, cyclophosphamide and MMF are the only agents that have demonstrated efficacy in patients with severe LN. As a result, cyclophosphamide is the preferred agent in MMF-resistant patients. We suggest a short course cyclophosphamide regimen to minimize toxicity. The regimens are described elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/37/37466?source=see_link&amp;anchor=H17#H17\">",
"     \"Therapy of diffuse or focal proliferative lupus nephritis\", section on 'Dosing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Rituximab for cyclophosphamide and MMF resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Favorable results with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    have been noted in small observational studies and case reports of lupus nephritis (LN) that is resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    or MMF [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12345/abstract/14-18\">",
"     14-18",
"    </a>",
"    ]. Data are more limited for patients who are resistant to or cannot tolerate both drugs.",
"   </p>",
"   <p>",
"    When considering the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , one must keep in mind that long-term efficacy and toxicity have not been fully defined. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/40/21130?source=see_link&amp;anchor=H2#H2\">",
"     \"Rituximab and other B cell targeted therapies for rheumatoid arthritis\", section on 'Rituximab'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The largest reported experience included 22 patients with focal or diffuse proliferative LN who had persistent disease activity despite a variety of immunosuppressive drugs; most had been treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    (11 patients) or MMF (12 patients) as well as other drugs (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12345/abstract/14\">",
"     14",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     Rituximab",
"    </a>",
"    (0.5 to 1 g on days 1 and 15) was added to the existing immunosuppressive regimen.",
"   </p>",
"   <p>",
"    Three months after the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , five had a complete response (normal serum creatinine, inactive urine sediment, and protein excretion &lt;500",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    and seven had a partial response (&gt;40 percent improvement in renal parameters). The effect of rituximab in those patients initially treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    was not specifically noted.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     Rituximab",
"    </a>",
"    was also assessed in a series of 20 patients with diffuse proliferative (15 patients) or membranous (5 patients) LN, all but two of whom had resistant or relapsing disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12345/abstract/15\">",
"     15",
"    </a>",
"    ]. Fifteen patients had been previously treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    . Rituximab was given at a dose of 375",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    weekly for four weeks. Ten patients received additional doses of rituximab as maintenance therapy because of an increase in B cell count.",
"   </p>",
"   <p>",
"    At a mean follow-up of 22 months, 5 of the 15 patients with diffuse proliferative LN achieved complete remission, defined as protein excretion &lt;500",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    absence of hematuria, and an increase in estimated glomerular filtration rate (eGFR) by at least 50 percent. In addition, five patients had a partial remission, defined as decrease in protein excretion by at least 50 percent and stabilization of the eGFR.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8086226\">",
"    <span class=\"h3\">",
"     MMF plus tacrolimus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combination therapy with MMF and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    may be effective for MMF-resistant patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12345/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. In one observation study, tacrolimus (.075",
"    <span class=\"nowrap\">",
"     mg/kg/day)",
"    </span>",
"    was added to MMF in 17 patients with MMF-resistant type IV (n = 15) or type V (n = 2) lupus nephritis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12345/abstract/19\">",
"     19",
"    </a>",
"    ]. After a mean follow-up time of 24 months, six patients (35 percent) had a complete response (defined as urinary protein excretion &lt;0.3",
"    <span class=\"nowrap\">",
"     g/day,",
"    </span>",
"    normal sediment, and normal or stable renal function) and six had a partial response (defined as protein excretion &lt;2.9",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    with stable or improved renal function). Tacrolimus was well tolerated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4958184\">",
"    <span class=\"h3\">",
"     Belimumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/31/37365?source=see_link\">",
"     Belimumab",
"    </a>",
"    (Benlysta, formerly termed Lymphostat-B) is a human monoclonal antibody that inhibits the soluble form of a B-cell survival factor. Belimumab has received FDA approval for the treatment of patients with active autoantibody-positive SLE who are receiving standard therapy. Belimumab has not been studied among patients with active renal disease as such patients were excluded from the phase I and III trials. We recommend NOT using belimumab for the treatment of patients with resistant or relapsing lupus nephritis until data are available that address its efficacy in this population, unless all other potential therapies have failed and no contra-indications to its use exist. The results of phase III randomized trials of benlysta are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41578?source=see_link\">",
"     \"Overview of the therapy and prognosis of systemic lupus erythematosus in adults\"",
"    </a>",
"    .) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12345/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     RELAPSING DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients with proliferative LN relapse (also called a renal flare), particularly following reduction in or cessation of immunosuppression [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12345/abstract/23-32\">",
"     23-32",
"    </a>",
"    ]. Two reviews noted the followed range of findings in different studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reported renal relapse rates after reduction in or cessation of immunosuppression range in different series from 5 to 15 per 100 patient years, with an average of 8 per 100 patient years for the first five years after attaining remission [",
"      <a class=\"abstract\" href=\"UTD.htm?12/3/12345/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In terms of overall relapse rates, the most relevant data come from trials that used the current recommended approach of induction followed by maintenance immunosuppression. Three trials of intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil (MMF) induction followed by",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      or MMF maintenance for one to three years reported relapse rates of 28 percent at 41 months [",
"      <a class=\"abstract\" href=\"UTD.htm?12/3/12345/abstract/25\">",
"       25",
"      </a>",
"      ], 23 percent at six years [",
"      <a class=\"abstract\" href=\"UTD.htm?12/3/12345/abstract/1\">",
"       1",
"      </a>",
"      ], and 32 percent at four years to five years [",
"      <a class=\"abstract\" href=\"UTD.htm?12/3/12345/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A variety of risk factors for relapse have been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12345/abstract/23,24,32\">",
"     23,24,32",
"    </a>",
"    ]. These include more severe disease at baseline, a delay in reaching remission, and attainment of partial compared to complete remission. In a National Institutes of Health study (performed prior to the use of maintenance immunosuppression), complete and partial remission occurred in 73 and 19 patients, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12345/abstract/32\">",
"     32",
"    </a>",
"    ]. Partial remission was associated with a higher rate of relapse (63 versus 40 percent), a shorter median time to relapse (18 versus 36 months), and a greater likelihood of severe nephritic relapse.",
"   </p>",
"   <p>",
"    In addition to requiring additional immunosuppressive therapy, relapses, particularly those with a nephritic sediment, also predict a worse renal prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12345/abstract/24,32,33\">",
"     24,32,33",
"    </a>",
"    ]. In one report, for example, nephritic relapses (active urine sediment, increase in serum creatinine at least 30 percent above previous baseline, and usually increased proteinuria) were associated with a marked increase in the rate of a persistent doubling of the serum creatinine at a median follow-up of 10 to 11 years (relative risk 6.8) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12345/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Definition and clinical recognition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relapse of proliferative lupus nephritis (LN) following initial remission is primarily defined as recurrent immunologic activity, as usually manifested by an active urine sediment (a \"nephritic\" relapse), often accompanied by increases in protein excretion and the serum creatinine [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12345/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. The new finding of red cell",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    white cell casts is a particularly strong predictor of relapse; in one report, casts were noted before or at the onset of 35 of 43 relapses; the positive predictive value was even greater (24 of 25) when protein excretion &gt;1",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    was also present [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12345/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A small proportion of patients with proliferative LN in remission have only a \"proteinuric\" relapse (&ge;2",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    increase in protein excretion over baseline) with an inactive urine sediment and a stable serum creatinine [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12345/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. In a report of 41 relapses in patients with severe proliferative LN, 33 were nephritic and eight were proteinuric [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12345/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Measurement of the glomerular filtration rate (GFR) alone, either directly or by estimation from the serum creatinine (eGFR) or the creatinine clearance (Ccr), may be misleading when monitoring the course of LN that seems to be inactive. As in other renal diseases, nephron loss in LN is associated with compensatory hypertrophy and intraglomerular hypertension in the remaining normal or less affected glomeruli [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12345/abstract/7\">",
"     7",
"    </a>",
"    ]. As a result, the GFR and the serum creatinine may initially remain stable and the degree of proteinuria may fall after the resolution of active inflammation following immunosuppressive therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12345/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, over time, there is often increasing glomerulosclerosis on repeat renal biopsy, often in the absence of clinical or serologic evidence of active lupus [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12345/abstract/7,35\">",
"     7,35",
"    </a>",
"    ]. In one study, for example, the number of sclerotic glomeruli increased from 15 up to 60 percent over a three-year period despite a relatively stable GFR [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12345/abstract/7\">",
"     7",
"    </a>",
"    ]. Both healing of previous inflammatory injury and nonimmunologic mechanisms of progression can account for these findings without requiring relapse and active disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12345/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=see_link\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Slowly progressive inactive LN should NOT be treated with immunosuppressive agents. Therapy should be directed toward aggressive antihypertensive and antiproteinuric therapy with blockade of the renin-angiotensin system (eg, angiotensin converting enzyme inhibitor or angiotensin II receptor blocker). The goal blood pressure is less than",
"    <span class=\"nowrap\">",
"     130/80",
"    </span>",
"    mmHg and goal protein excretion is less than 500 to 1000 mg per day. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/37/37466?source=see_link&amp;anchor=H7#H7\">",
"     \"Therapy of diffuse or focal proliferative lupus nephritis\", section on 'Nonimmunosuppressive therapies'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=see_link&amp;anchor=H24#H24\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\", section on 'Blood pressure goal'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=see_link&amp;anchor=H149378842#H149378842\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\", section on 'Proteinuria goal'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend serial monitoring of the urinalysis, urine protein-to-creatinine ratio, serum creatinine, and serologic factors (complement C3 and C4 levels and anti-dsDNA titers) be performed every three to four months in stable patients with proliferative LN in remission to detect renal relapses. In some patients, a renal biopsy may be required to verify recurrent active LN rather than nonimmunologic progression of renal disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/42/41638?source=see_link&amp;anchor=H14#H14\">",
"     \"Indications for renal biopsy in patients with lupus nephritis\", section on 'Repeat biopsy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Urinary protein excretion is monitored in most patients with chronic kidney disease by measuring the urine protein-to-creatinine",
"    <span class=\"nowrap\">",
"     (P/C)",
"    </span>",
"    ratio on a spot urine specimen. However, when monitoring for relapse in patients with proliferative LN, one study found that spot urine",
"    <span class=\"nowrap\">",
"     P/C",
"    </span>",
"    ratio measurements were associated with false-positive and false-negative results compared to ratios obtained on 24-hour urine collections, primarily in patients with subnephrotic proteinuria (24-hour PC ratio less than 3) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12345/abstract/36\">",
"     36",
"    </a>",
"    ]. As an example, a 24-hour urine",
"    <span class=\"nowrap\">",
"     P/C",
"    </span>",
"    ratio of 1 was associated with spot urine",
"    <span class=\"nowrap\">",
"     P/C",
"    </span>",
"    ratios ranging from 0 to 2.5. The correlation was much better at 24-hour urine",
"    <span class=\"nowrap\">",
"     P/C",
"    </span>",
"    ratios above 3. Thus, if the urine",
"    <span class=\"nowrap\">",
"     P/C",
"    </span>",
"    ratio increases, a 24-hour urine collection should be obtained on the same day as a spot sample to determine the correlation between the urine",
"    <span class=\"nowrap\">",
"     P/C",
"    </span>",
"    ratio and total protein excretion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13914?source=see_link\">",
"     \"Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who have an increase in anti-dsDNA titers or new hypocomplementemia following a clinical remission should be monitored more carefully (particularly over the ensuing three months) but are generally not treated SOLELY for changes in serologic activity.",
"   </p>",
"   <p>",
"    The suggestion for serologic monitoring following clinical remission is based in part upon the observation that an elevation in the titer of anti-dsDNA antibodies and, to a lesser degree, a fall in circulating complement levels are associated with a high likelihood (over 75 percent in one report) of subsequent clinical relapse, which typically occurs within the ensuing 8 to 10 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12345/abstract/37\">",
"     37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/10/1192?source=see_link&amp;anchor=H26100791#H26100791\">",
"     \"Antibodies to double-stranded (ds)DNA, Sm, and U1 RNP\", section on 'Titer, pathogenicity, and disease activity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, many relapses do not involve the kidney. As an example, only 40 percent of the relapses were renal or predominantly renal in the preceding study [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12345/abstract/37\">",
"     37",
"    </a>",
"    ]. In addition, most physicians do not routinely monitor antibody and complement titers at monthly intervals as was performed in this study and, although plasma C3 and C4 levels tend to vary inversely with disease activity, there may be a prolonged reduction in C4 levels long after clinical remission has been induced [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12345/abstract/38\">",
"     38",
"    </a>",
"    ]. As a result, it has been suggested that a fall in complement levels is a more valuable predictor of subsequent relapse than is the absolute plasma concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12345/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Treatment of relapsing disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of relapsing proliferative lupus nephritis (LN) depends upon the initial immunosuppressive regimen and the severity and timing of relapse. Given the increased drug exposure, greater attention must be paid to potential toxicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Mild relapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mild relapse is defined as increased activity of urine sediment and possibly a modest (eg, less than 50 percent) increase in protein excretion but with a stable serum creatinine. Data are limited on the optimal approach to such patients. We suggest the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients who are no longer on maintenance therapy, a trial of oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (60",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      for one week, tapered to 30 mg every other day for three months) can be considered.",
"     </li>",
"     <li>",
"      For those initially treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      who are now on",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      maintenance therapy, one can increase the dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      as well as azathioprine, particularly if the azathioprine dose has been tapered.",
"     </li>",
"     <li>",
"      For those who were initially treated with MMF for induction and who are now off maintenance therapy, MMF may be restarted. For patients who are still on maintenance therapy with lower doses of MMF, the MMF dose can be increased to 2 to 3",
"      <span class=\"nowrap\">",
"       g/day.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Moderate to severe relapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;By comparison, reinstitution of more aggressive immunosuppressive therapy is usually warranted in patients with moderate to severe relapse, which is generally defined as an active urine sediment plus a rise in serum creatinine with or without increased proteinuria. These manifestations are often accompanied by a flare in extrarenal manifestations of lupus.",
"   </p>",
"   <p>",
"    As mentioned above, a minority of patients with proliferative LN have a proteinuric relapse, characterized by increased proteinuria (&ge;2",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    increase in protein excretion over baseline) with an inactive urine sediment and a stable serum creatinine [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12345/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Repeat biopsy may be helpful since such patients may have transformed from proliferative to membranous LN or have combined proliferative and membranous LN, which, as described in the next section, might be treated differently from pure proliferative LN.",
"   </p>",
"   <p>",
"    The choice of immunosuppressive therapy for moderate to severe relapse depends upon the initial induction regimen. All of the regimens include glucocorticoid therapy. In each of the following settings, there are no randomized trials to provide guidance. The preferred regimens are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/37/37466?source=see_link&amp;anchor=H13#H13\">",
"     \"Therapy of diffuse or focal proliferative lupus nephritis\", section on 'Induction therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      was used for induction and the patient is taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      for maintenance, many experts try to avoid a second course of cyclophosphamide, although others base this decision upon the total amount of cyclophosphamide that has been administered and upon the time that has elapsed since the last exposure to cyclophosphamide. A suggested cumulative dose limit is 240",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      or approximately 16 grams, although there are no data that suggest that staying within this arbitrary limit prevents side effects.",
"      <br/>",
"      <br/>",
"      Although studies of efficacy of MMF in this setting are lacking, MMF is preferred for the initial treatment of relapse using the same regimen recommended for induction therapy.",
"     </li>",
"     <li>",
"      If MMF was used for induction and the patient is no longer taking maintenance therapy, either MMF or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      may be used for the treatment of relapse. Cyclophosphamide is preferred if relapse occurs while the patient is still taking MMF for maintenance therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients who continue to relapse, like those with resistant LN, may benefit from a trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12345/abstract/15\">",
"     15",
"    </a>",
"    ]. However, randomized trials of rituximab for relapsing disease have not been performed. The long-term efficacy and toxicity of rituximab has not been defined. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/40/21130?source=see_link&amp;anchor=H2#H2\">",
"     \"Rituximab and other B cell targeted therapies for rheumatoid arthritis\", section on 'Rituximab'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     DIFFUSE PROLIFERATIVE PLUS MEMBRANOUS LN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with concurrent diffuse proliferative and membranous lesions are more likely to be resistant to standard induction regimens with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    and to have a worse long-term renal outcome. This was illustrated in a report of 85 patients with severe LN participating in a randomized trial [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12345/abstract/39\">",
"     39",
"    </a>",
"    ]. Patients with combined diffuse proliferative and membranous lesions compared to those with diffuse proliferative lesions alone had a significantly lower rate of both attaining remission (27 versus 60 percent) and, at ten years, of renal survival (50 versus 75 percent).",
"   </p>",
"   <p>",
"    Patients with both diffuse proliferative and membranous lesions may respond better to combined induction therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil (MMF) plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    . This was suggested in a small, short-term prospective trial in which 40 patients with diffuse proliferative plus membranous LN were randomly assigned to induction therapy with MMF (0.75 to 1",
"    <span class=\"nowrap\">",
"     g/day)",
"    </span>",
"    and tacrolimus (3 to 4",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    or to intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    alone [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12345/abstract/40\">",
"     40",
"    </a>",
"    ]. MMF was titrated to area under the time concentration curve from 0 to 12 hours at 20 to 45 mg per",
"    <span class=\"nowrap\">",
"     h/L",
"    </span>",
"    and tacrolimus was titrated to maintain a blood trough concentration between 5 and 7",
"    <span class=\"nowrap\">",
"     ng/mL.",
"    </span>",
"    All patients received glucocorticoids (three doses of intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    500",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    followed by oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    at 0.6 to 0.8",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for four weeks and then slowly tapered until a maintenance dose of 10",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    was reached).",
"   </p>",
"   <p>",
"    At nine months, there was a significantly higher rate of complete remission (defined as protein excretion &lt;400",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    normal urinary sediment, and normal serum creatinine) in patients treated with combined therapy (65 versus 15 percent, respectively). The long-term efficacy and safety of such a regimen are unknown, but this trial provides the best available information for the treatment of combined disease [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12345/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Almost half the patients with proliferative lupus nephritis (LN) are resistant to induction therapy, which is defined as failure to achieve complete or partial remission. Other patients attain remission and then relapse as maintenance immunosuppressive therapy is being tapered or has been discontinued.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Resistant LN",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with proliferative LN who are resistant to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil (MMF) plus glucocorticoids as first-line therapy, we recommend intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      plus glucocorticoids (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). The regimen is the same as that used for induction therapy. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'MMF resistance'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/37/37466?source=see_link&amp;anchor=H17#H17\">",
"       \"Therapy of diffuse or focal proliferative lupus nephritis\", section on 'Dosing'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with proliferative LN who are resistant to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      plus glucocorticoids as first-line therapy, we recommend treatment with MMF plus glucocorticoids (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). The regimen is the same as that used for induction therapy. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Cyclophosphamide resistance'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/37/37466?source=see_link&amp;anchor=H18#H18\">",
"       \"Therapy of diffuse or focal proliferative lupus nephritis\", section on 'Mycophenolate mofetil'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients who have failed treatment with or are unable to tolerate both",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      and MMF, we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      although randomized trials have not been performed and long-term follow-up is not available (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). The preferred regimen is 0.5 to 1 g given on days 1 and 15, or 375 mg weekly for four weeks. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Rituximab for cyclophosphamide and MMF resistance'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Relapsing LN",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with mild relapse defined as an increase in the activity of the urine sediment with less than 50 percent increase in proteinuria and a stable serum creatinine, we suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    therapy (",
"    <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"     Grade 2C",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Mild relapse'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    For patients with moderate to severe relapse, the choice of immunosuppressive agent varies with the drug used for initial induction therapy and whether or not the patient is still taking maintenance immunosuppression. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Moderate to severe relapse'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    All of the regimens include glucocorticoid therapy and are the same as those used for initial induction or maintenance immunosuppression. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/37/37466?source=see_link\">",
"     \"Therapy of diffuse or focal proliferative lupus nephritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      was used for induction and the patient is taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      for maintenance, we suggest a trial of MMF and cessation of azathioprine (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      If MMF was used for induction and maintenance and MMF has been discontinued, we suggest reinstitution of MMF (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      If MMF was used for induction and maintenance and relapse occurs while the patient is still taking MMF, we recommend",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Among patients who continue to relapse despite the above interventions, we suggest a trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Rituximab for cyclophosphamide and MMF resistance'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Diffuse proliferative and membranous LN",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with concurrent proliferative and membranous LN who are resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , we recommend combined treatment with MMF and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    &nbsp;(",
"    <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"     Grade 1B",
"    </a>",
"    ). The preferred regimen is that used in the randomized trial. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Diffuse proliferative plus membranous LN'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12345/abstract/1\">",
"      Contreras G, Pardo V, Leclercq B, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004; 350:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12345/abstract/2\">",
"      Chan TM, Li FK, Tang CS, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 2000; 343:1156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12345/abstract/3\">",
"      Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005; 353:2219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12345/abstract/4\">",
"      Hall CL, Fothergill NJ, Blackwell MM, et al. The natural course of gold nephropathy: long term study of 21 patients. Br Med J (Clin Res Ed) 1987; 295:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12345/abstract/5\">",
"      Hall CL, Jawad S, Harrison PR, et al. Natural course of penicillamine nephropathy: a long term study of 33 patients. Br Med J (Clin Res Ed) 1988; 296:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12345/abstract/6\">",
"      Potter EV, Lipschultz SA, Abidh S, et al. Twelve to seventeen-year follow-up of patients with poststreptococcal acute glomerulonephritis in Trinidad. N Engl J Med 1982; 307:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12345/abstract/7\">",
"      Chagnac A, Kiberd BA, Fari&ntilde;as MC, et al. Outcome of the acute glomerular injury in proliferative lupus nephritis. J Clin Invest 1989; 84:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12345/abstract/8\">",
"      KDIGO. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int Suppl 2012; 2:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12345/abstract/9\">",
"      Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 2012; 71:1771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12345/abstract/10\">",
"      Karim MY, Pisoni CN, Ferro L, et al. Reduction of proteinuria with mycophenolate mofetil in predominantly membranous lupus nephropathy. Rheumatology (Oxford) 2005; 44:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12345/abstract/11\">",
"      Dooley MA, Cosio FG, Nachman PH, et al. Mycophenolate mofetil therapy in lupus nephritis: clinical observations. J Am Soc Nephrol 1999; 10:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12345/abstract/12\">",
"      Glicklich D, Acharya A. Mycophenolate mofetil therapy for lupus nephritis refractory to intravenous cyclophosphamide. Am J Kidney Dis 1998; 32:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12345/abstract/13\">",
"      Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009; 20:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12345/abstract/14\">",
"      Vigna-Perez M, Hern&aacute;ndez-Castro B, Paredes-Saharopulos O, et al. Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther 2006; 8:R83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12345/abstract/15\">",
"      Melander C, Sall&eacute;e M, Trolliet P, et al. Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome. Clin J Am Soc Nephrol 2009; 4:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12345/abstract/16\">",
"      Fra GP, Avanzi GC, Bartoli E. Remission of refractory lupus nephritis with a protocol including rituximab. Lupus 2003; 12:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12345/abstract/17\">",
"      Thatayatikom A, White AJ. Rituximab: a promising therapy in systemic lupus erythematosus. Autoimmun Rev 2006; 5:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12345/abstract/18\">",
"      Camous L, Melander C, Vallet M, et al. Complete remission of lupus nephritis with rituximab and steroids for induction and rituximab alone for maintenance therapy. Am J Kidney Dis 2008; 52:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12345/abstract/19\">",
"      Cort&eacute;s-Hern&aacute;ndez J, Torres-Salido MT, Medrano AS, et al. Long-term outcomes--mycophenolate mofetil treatment for lupus nephritis with addition of tacrolimus for resistant cases. Nephrol Dial Transplant 2010; 25:3939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12345/abstract/20\">",
"      Lanata CM, Mahmood T, Fine DM, Petri M. Combination therapy of mycophenolate mofetil and tacrolimus in lupus nephritis. Lupus 2010; 19:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12345/abstract/21\">",
"      Navarra SV, Guzm&aacute;n RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12345/abstract/22\">",
"      Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011; 63:3918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12345/abstract/23\">",
"      Grootscholten C, Berden JH. Discontinuation of immunosuppression in proliferative lupus nephritis: is it possible? Nephrol Dial Transplant 2006; 21:1465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12345/abstract/24\">",
"      Sidiropoulos PI, Kritikos HD, Boumpas DT. Lupus nephritis flares. Lupus 2005; 14:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12345/abstract/25\">",
"      Houssiau FA, Vasconcelos C, D'Cruz D, et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002; 46:2121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12345/abstract/26\">",
"      Ioannidis JP, Boki KA, Katsorida ME, et al. Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int 2000; 57:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12345/abstract/27\">",
"      Mosca M, Bencivelli W, Neri R, et al. Renal flares in 91 SLE patients with diffuse proliferative glomerulonephritis. Kidney Int 2002; 61:1502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12345/abstract/28\">",
"      Chan TM, Tse KC, Tang CS, et al. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 2005; 16:1076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12345/abstract/29\">",
"      Moroni G, Gallelli B, Quaglini S, et al. Withdrawal of therapy in patients with proliferative lupus nephritis: long-term follow-up. Nephrol Dial Transplant 2006; 21:1541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12345/abstract/30\">",
"      Swaak AJ, van den Brink HG, Smeenk RJ, et al. Systemic lupus erythematosus. Disease outcome in patients with a disease duration of at least 10 years: second evaluation. Lupus 2001; 10:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12345/abstract/31\">",
"      Mok CC, Ying KY, Tang S, et al. Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis. Arthritis Rheum 2004; 50:2559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12345/abstract/32\">",
"      Illei GG, Takada K, Parkin D, et al. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum 2002; 46:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12345/abstract/33\">",
"      Moroni G, Quaglini S, Maccario M, et al. \"Nephritic flares\" are predictors of bad long-term renal outcome in lupus nephritis. Kidney Int 1996; 50:2047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12345/abstract/34\">",
"      Hebert LA, Dillon JJ, Middendorf DF, et al. Relationship between appearance of urinary red blood cell/white blood cell casts and the onset of renal relapse in systemic lupus erythematosus. Am J Kidney Dis 1995; 26:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12345/abstract/35\">",
"      Cheigh JS, Kim H, Stenzel KH, et al. Systemic lupus erythematosus in patients with end-stage renal disease: long-term follow-up on the prognosis of patients and the evolution of lupus activity. Am J Kidney Dis 1990; 16:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12345/abstract/36\">",
"      Birmingham DJ, Rovin BH, Shidham G, et al. Spot urine protein/creatinine ratios are unreliable estimates of 24 h proteinuria in most systemic lupus erythematosus nephritis flares. Kidney Int 2007; 72:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12345/abstract/37\">",
"      ter Borg EJ, Horst G, Hummel EJ, et al. Measurement of increases in anti-double-stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term, prospective study. Arthritis Rheum 1990; 33:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12345/abstract/38\">",
"      West CD. Relative value of serum C3 and C4 levels in predicting relapse in systemic lupus erythematosus. Am J Kidney Dis 1991; 18:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12345/abstract/39\">",
"      Najafi CC, Korbet SM, Lewis EJ, et al. Significance of histologic patterns of glomerular injury upon long-term prognosis in severe lupus glomerulonephritis. Kidney Int 2001; 59:2156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12345/abstract/40\">",
"      Bao H, Liu ZH, Xie HL, et al. Successful treatment of class V+IV lupus nephritis with multitarget therapy. J Am Soc Nephrol 2008; 19:2001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12345/abstract/41\">",
"      Glassock RJ. Multitarget therapy of lupus nephritis: base hit or home run? J Am Soc Nephrol 2008; 19:1842.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3092 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.244-820E8C5BBF-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_3_12345=[""].join("\n");
var outline_f12_3_12345=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DISEASE RESISTANT TO INDUCTION THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Definition of remission",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Treatment of resistant disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Cyclophosphamide resistance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - MMF resistance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Rituximab for cyclophosphamide and MMF resistance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8086226\">",
"      - MMF plus tacrolimus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4958184\">",
"      - Belimumab",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      RELAPSING DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Definition and clinical recognition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Treatment of relapsing disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Mild relapse",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Moderate to severe relapse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      DIFFUSE PROLIFERATIVE PLUS MEMBRANOUS LN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Resistant LN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Relapsing LN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Diffuse proliferative and membranous LN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/10/1192?source=related_link\">",
"      Antibodies to double-stranded (ds)DNA, Sm, and U1 RNP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/10/41130?source=related_link\">",
"      Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/37/13914?source=related_link\">",
"      Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/54/19306?source=related_link\">",
"      Causes and diagnosis of membranous nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/12/44233?source=related_link\">",
"      Clinical features and therapy of membranous lupus nephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/3/27706?source=related_link\">",
"      Diagnosis and classification of renal disease in systemic lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39352?source=related_link\">",
"      End-stage renal disease due to lupus nephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/59/34746?source=related_link\">",
"      Etiology and evaluation of hematuria in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/32/25098?source=related_link\">",
"      General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/42/41638?source=related_link\">",
"      Indications for renal biopsy in patients with lupus nephritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41578?source=related_link\">",
"      Overview of the therapy and prognosis of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/30/35304?source=related_link\">",
"      Poststreptococcal glomerulonephritis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/40/21130?source=related_link\">",
"      Rituximab and other B cell targeted therapies for rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/19/26938?source=related_link\">",
"      Secondary factors and progression of chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/37/37466?source=related_link\">",
"      Therapy of diffuse or focal proliferative lupus nephritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_3_12346="Abdominal myomectomy";
var content_f12_3_12346=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Abdominal myomectomy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/3/12346/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/3/12346/contributors\">",
"     William H Parker, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/3/12346/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/3/12346/contributors\">",
"     Howard T Sharp, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/3/12346/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/3/12346/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/3/12346/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 22, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H25049674\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uterine leiomyomas (fibroids or myomas) are the most common type of pelvic tumor in women, with an approximately 70 to 80 percent lifetime risk [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12346/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. There are many management options for fibroid-related symptoms, including expectant management, medical therapy, non-excisional procedures (endometrial ablation, uterine artery embolization, magnetic resonance guided focused ultrasound), and surgery (myomectomy, hysterectomy).",
"    <strong>",
"    </strong>",
"   </p>",
"   <p>",
"    Abdominal myomectomy (performed via laparotomy; also referred to as open myomectomy) was developed in the early 1900s as a conservative treatment for women with uterine myomas. Myomectomy is the surgical removal of leiomyomas from the uterus, leaving the uterus in place. This can be accomplished using an abdominal, laparoscopic, hysteroscopic, or vaginal approach.",
"   </p>",
"   <p>",
"    Abdominal myomectomy will be reviewed here. General principles of the treatment of uterine leiomyomas, as well as laparoscopic, hysteroscopic, and vaginal myomectomy and techniques to reduce blood loss during myomectomy, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/14/18666?source=see_link\">",
"     \"Overview of treatment of uterine leiomyomas (fibroids)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/48/8970?source=see_link\">",
"     \"Laparoscopic myomectomy and other laparoscopic treatments for uterine leiomyomas (fibroids)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/53/32601?source=see_link\">",
"     \"Hysteroscopic myomectomy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/24/16775?source=see_link\">",
"     \"Prolapsed uterine leiomyoma (fibroid)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/54/10088?source=see_link\">",
"     \"Techniques to reduce blood loss during abdominal or laparoscopic myomectomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25049681\">",
"    <span class=\"h1\">",
"     PATIENT SELECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abdominal myomectomy is performed mostly for women with intramural or subserosal leiomyomas (",
"    <a class=\"graphic graphic_figure graphicRef53241 \" href=\"UTD.htm?30/16/30978\">",
"     figure 1",
"    </a>",
"    ). Intracavitary myomas (submucosal and some intramural myomas that protrude into the endometrial cavity) (",
"    <a class=\"graphic graphic_figure graphicRef59668 \" href=\"UTD.htm?26/32/27143\">",
"     figure 2",
"    </a>",
"    ) may also be removed during abdominal myomectomy. However, hysteroscopic myomectomy is the procedure of choice when only intracavitary myomas are removed, since it offers the advantages of a faster recovery and less perioperative morbidity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/53/32601?source=see_link&amp;anchor=H2#H2\">",
"     \"Hysteroscopic myomectomy\", section on 'Patient selection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Appropriate candidates for abdominal myomectomy are women with the following characteristics:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Symptomatic uterine fibroid(s)",
"     </li>",
"     <li>",
"      Hysteroscopic or laparoscopic myomectomy is not feasible",
"     </li>",
"     <li>",
"      A laparotomy is required to treat intraabdominal pathology other than leiomyomas.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14328797\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common indications for abdominal myomectomy are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Abnormal uterine bleeding",
"     </li>",
"     <li>",
"      Bulk-related symptoms &ndash;",
"      <span class=\"nowrap\">",
"       pelvic/abdominal",
"      </span>",
"      pain or pressure; pressure on the urinary or gastrointestinal tract resulting in urinary (eg, urinary frequency, urinary incontinence, hydronephrosis) or bowel symptoms (eg, constipation)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Dysmenorrhea is an infrequent indication for myomectomy. Dysmenorrhea is more commonly associated with conditions (eg, endometriosis) other than with myomas. Myomectomy or other fibroid-specific treatment for the indication of dysmenorrhea should be performed only when other therapies for dysmenorrhea have failed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/36/28233?source=see_link\">",
"     \"Treatment of primary dysmenorrhea in adult women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Myomectomy is occasionally required for necrotic leiomyomas following uterine artery embolization. In such cases, myomectomy may be performed either through an abdominal or hysteroscopic route, depending upon the site of the myoma [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12346/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22473?source=see_link&amp;anchor=H15#H15\">",
"     \"Uterine leiomyoma (fibroid) embolization\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7945019\">",
"    <span class=\"h2\">",
"     Unproven indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myomectomy should be performed only for women in whom the procedure is likely to ameliorate a specific symptom. Indications for which the benefit of myomectomy remains unproven are discussed in this section.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7945374\">",
"    <span class=\"h3\">",
"     Evaluation of pelvic malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Leiomyomas may make it difficult or impossible to evaluate the adnexa in some women with a pelvic examination or pelvic ultrasound. However, improving the ability to evaluate the ovaries to exclude ovarian cancer is not an indication for myomectomy.",
"   </p>",
"   <p>",
"    There is no evidence that pelvic examination increases early detection or decreases the mortality related to ovarian cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12346/abstract/5\">",
"     5",
"    </a>",
"    ]. For women in whom a leiomyomatous uterus makes it difficult to evaluate the adnexa, pelvic imaging should be performed only if symptoms of adnexal disease develop (eg, lower quadrant pelvic pain) or for selected women who require screening for ovarian cancer. If sonographic visualization of the ovaries is occluded by myomas, magnetic resonance imaging should be performed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/14/10474?source=see_link&amp;anchor=H17#H17\">",
"     \"Screening for ovarian cancer\", section on 'High-risk women'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/43/42681?source=see_link&amp;anchor=H6245040#H6245040\">",
"     \"The gynecologic history and pelvic examination\", section on 'Timing issues'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24601?source=see_link&amp;anchor=H3883756#H3883756\">",
"     \"Approach to the patient with an adnexal mass\", section on 'Imaging studies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Likewise, exclusion of uterine sarcoma is not an indication for myomectomy. Uterine sarcoma is rare and the likelihood of finding sarcoma in women with a preoperative diagnosis of leiomyomas is much lower than the risk of severe complications associated with surgery for benign disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/38/22121?source=see_link&amp;anchor=H23337512#H23337512\">",
"     \"Differentiating uterine leiomyomas (fibroids) from uterine sarcomas\", section on 'Should hysterectomy be performed to exclude uterine sarcoma?'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7945234\">",
"    <span class=\"h3\">",
"     Infertility",
"    </span>",
"    &nbsp;&mdash;&nbsp;The location of a fibroid, and not its size, is the key factor regarding impact on fertility [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12346/abstract/6\">",
"     6",
"    </a>",
"    ]. Leiomyomas that distort the uterine cavity (submucosal or intramural with an intracavitary component) result in difficulty conceiving a pregnancy and an increased risk of miscarriage [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12346/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, a systematic review of mostly observational studies found that infertility is not associated with subserosal fibroids and that the role of intramural fibroids is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12346/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Since abdominal myomectomy is performed mainly to remove intramural or subserosal myomas, its role in women with infertility is uncertain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/60/30662?source=see_link&amp;anchor=H4#H4\">",
"     \"Reproductive issues in women with uterine leiomyomas (fibroids)\", section on 'Infertility and miscarriage'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7945277\">",
"    <span class=\"h3\">",
"     Prevention of obstetric complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Avoidance of obstetric complications is not an indication for myomectomy in most women. There are no high quality data regarding whether leiomyomas adversely affect pregnancy outcome. Myomectomy may be appropriate for selected patients with a history of obstetric complications that appear related to the presence of leiomyomas. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/60/30662?source=see_link&amp;anchor=H3#H3\">",
"     \"Reproductive issues in women with uterine leiomyomas (fibroids)\", section on 'Preconceptional planning'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/45/15065?source=see_link\">",
"     \"Pregnancy in women with uterine leiomyomas (fibroids)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14328804\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abdominal myomectomy is contraindicated in women in whom laparotomy or uterine conservation are contraindicated (eg, medical comorbidities, cervical or uterine cancer). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41735?source=see_link\">",
"     \"Overview of the principles of medical consultation and perioperative medicine\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7944123\">",
"    <span class=\"h1\">",
"     MYOMECTOMY VERSUS OTHER TREATMENT APPROACHES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice of treatment for women with uterine leiomyomas is guided by the type of symptoms in the individual patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7950745\">",
"    <span class=\"h2\">",
"     Abnormal uterine bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormal uterine bleeding in women with leiomyomas is treated initially with medical therapy (eg, estrogen-progestin contraceptives,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/58/14248?source=see_link\">",
"     tranexamic acid",
"    </a>",
"    ). If medical therapy is not sufficiently effective or tolerated, therapeutic options include interventional radiology procedures (uterine artery embolization, magnetic resonance guided focused ultrasound), endometrial ablation, myomectomy, and hysterectomy. There is no single treatment of choice. The decision depends upon patient characteristics and preferences.",
"   </p>",
"   <p>",
"    The choice of a therapy for chronic abnormal uterine bleeding is discussed separately. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/41/20122?source=see_link&amp;anchor=H30#H30\">",
"     \"Chronic menorrhagia or anovulatory uterine bleeding\", section on 'Choosing a long-term treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H748326\">",
"    <span class=\"h2\">",
"     Bulk-related symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment options for bulk-related symptoms (pelvic pain or pressure) include hysterectomy, myomectomy, or interventional radiology procedures (uterine artery embolization or magnetic resonance guided focused ultrasound). Some pharmacologic treatments (eg, gonadotropin releasing hormone agonists) reduce uterine size, but are generally",
"    <strong>",
"     not",
"    </strong>",
"    used because chronic treatment is required and results in menopausal symptoms and decreased bone density. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/41/20122?source=see_link&amp;anchor=H24#H24\">",
"     \"Chronic menorrhagia or anovulatory uterine bleeding\", section on 'Gonadotropin-releasing hormone agonists'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The choice of treatment for bulk-related symptoms depends upon the patient&rsquo;s desire for future fertility",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    uterine conservation and her preferences regarding definitive treatment and the invasiveness of treatment. Size and location of myomas and access to clinicians with expertise in minimally invasive procedures are also important factors in this decision.",
"   </p>",
"   <p>",
"    Choosing between myomectomy and other treatments is discussed in this section; comparisons among other treatments are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/14/18666?source=see_link\">",
"     \"Overview of treatment of uterine leiomyomas (fibroids)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3251085\">",
"    <span class=\"h3\">",
"     Women who desire future pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myomectomy is the procedure of choice for women who desire future fertility. Laparoscopic myomectomy is a minimally invasive approach that is appropriate for selected women. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/48/8970?source=see_link&amp;anchor=H3730094#H3730094\">",
"     \"Laparoscopic myomectomy and other laparoscopic treatments for uterine leiomyomas (fibroids)\", section on 'Candidates for laparoscopic myomectomy'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Women who are planning future pregnancy should be counseled about obstetric issues following myomectomy. (See",
"    <a class=\"local\" href=\"#H427523\">",
"     'Uterine rupture during pregnancy following myomectomy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Interventional radiology procedures may not be appropriate for women planning future pregnancy because of potential safety issues and detrimental effects on ovarian function. As examples, uterine artery embolization may have a negative effect on fertility and obstetric outcomes, and the safety of pregnancy following magnetic resonance guided focused ultrasound has not been established. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/14/18666?source=see_link&amp;anchor=H25#H25\">",
"     \"Overview of treatment of uterine leiomyomas (fibroids)\", section on 'Interventional radiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22473?source=see_link&amp;anchor=H17#H17\">",
"     \"Uterine leiomyoma (fibroid) embolization\", section on 'Ovarian dysfunction'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22473?source=see_link&amp;anchor=H25#H25\">",
"     \"Uterine leiomyoma (fibroid) embolization\", section on 'Pregnancy after UFE'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3251120\">",
"    <span class=\"h3\">",
"     Choosing the least invasive approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Traditionally, bulk-related symptoms of myomas were treated with abdominal myomectomy or hysterectomy. In current practice, however, there are a variety of alternatives to laparotomy. Less invasive approaches offer the advantages of smaller incisions and a shorter recovery period. The options include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Interventional radiology procedures",
"     </li>",
"     <li>",
"      Laparoscopic myomectomy",
"     </li>",
"     <li>",
"      Laparoscopic hysterectomy",
"     </li>",
"     <li>",
"      Vaginal hysterectomy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Eligibility for these procedures is limited by fibroid size and location. In addition, some women may not have easy access to physicians who have experience with these procedures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/48/8970?source=see_link&amp;anchor=H3730094#H3730094\">",
"     \"Laparoscopic myomectomy and other laparoscopic treatments for uterine leiomyomas (fibroids)\", section on 'Candidates for laparoscopic myomectomy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22473?source=see_link&amp;anchor=H2#H2\">",
"     \"Uterine leiomyoma (fibroid) embolization\", section on 'Indications and contraindications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/22/14698?source=see_link\">",
"     \"Laparoscopic approach to hysterectomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26149120\">",
"    <span class=\"h4\">",
"     Interventional radiology procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interventional radiology procedures have two important advantages compared with myomectomy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      General or regional anesthesia is not required.",
"     </li>",
"     <li>",
"      Abdominal incisions are not required, which reduces postoperative discomfort and improves cosmesis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, the recovery time from interventional radiology procedures is typically two weeks or less. This is similar to laparoscopic myomectomy, but much shorter than abdominal myomectomy, which generally requires four to six weeks for recuperation.",
"   </p>",
"   <p>",
"    Uterine artery embolization has been compared with open or laparoscopic myomectomy in only one randomized trial (n = 121) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12346/abstract/8\">",
"     8",
"    </a>",
"    ]. There was no difference between groups in the rate of symptomatic relief after six months (89 versus 88 percent). This overall outcome does not specifically address treatment of bulk-related symptoms, since the results for bleeding, pain, and pressure symptoms were combined. Women who underwent uterine artery embolization compared with myomectomy had higher rates of complications (21 versus 16 percent) and of prolonged hospital stay (16 versus 10 percent), but these differences did not reach statistical significance. The reintervention rate after an average of two years was significantly higher for uterine artery embolization (33 versus 3 percent); reintervention was myomectomy in this study. Of note, however, the indication for most reinterventions is this study was the size of fibroids, not recurrence of symptoms. A similar difference in the reintervention rate was reported in a retrospective cohort study that compared uterine artery embolization with myomectomy (29 versus 3 percent at four years; interventions were myomectomy or repeat embolization) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12346/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Over the long-term, however, myomectomy also has a high rate of intervention. Studies with up to 7 to 10 years of follow-up report subsequent surgery for fibroid-related symptoms in 21 to 34 percent of women following myomectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12346/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. For embolization, studies with five or more years of follow-up have reported that 20 percent of women undergo subsequent surgery. High quality and long-term data are needed to address the comparative risk of reintervention for these two procedures. (See",
"    <a class=\"local\" href=\"#H3250292\">",
"     'Subsequent treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Magnetic resonance guided focused ultrasound is not widely available and has not been evaluated in comparison with myomectomy.",
"   </p>",
"   <p>",
"    In summary, uterine artery embolization and laparoscopic myomectomy are both minimally invasive approaches. Based upon available data, the risk of reintervention appears to be higher for uterine artery embolization, at least in the first several years after the procedure. As a result, we suggest laparoscopic myomectomy rather than embolization. Women who place a high priority on avoiding any abdominal incisions may reasonably choose embolization. Some women are not candidates for laparoscopic myomectomy. For these women, the advantages of a minimally invasive procedure outweigh the risk of reintervention. The clinician should counsel the patient about all options and choose the procedure based upon patient preference.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26149127\">",
"    <span class=\"h4\">",
"     Myomectomy versus hysterectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who are not treated with interventional radiology procedures may choose between myomectomy and hysterectomy. This choice largely depends upon the availability of minimally invasive procedures and patient preference. There are no high quality data comparing myomectomy and hysterectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12346/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Traditionally, women with symptomatic fibroids who have completed childbearing have been counseled to undergo hysterectomy, but this approach is not supported by evidence or current practice. The rationale for counseling patients to undergo hysterectomy has been based upon two presumed benefits: hysterectomy eliminates the risk of future cervical or uterine pathology and hysterectomy has been thought to be associated with less blood loss and fewer complications than myomectomy.",
"   </p>",
"   <p>",
"    Prevention of future cervical or uterine pathology is not a relevant indication for hysterectomy in current practice. Advances in cervical cancer screening and diagnosis and treatment of abnormal uterine bleeding have provided less invasive options.",
"   </p>",
"   <p>",
"    In addition, myomectomy does",
"    <strong>",
"     not",
"    </strong>",
"    appear to have a higher risk of blood loss or complications than hysterectomy, according to observational data [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12346/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. The largest report was a retrospective study of 394 women with leiomyomatous uteri who underwent either abdominal myomectomy or hysterectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12346/abstract/13\">",
"     13",
"    </a>",
"    ]. Estimated blood loss (227 versus 484 mL) and the rate of hemorrhage (10 versus 14 percent) were significantly lower in the myomectomy group. The overall morbidity rate, adjusted for age, weight, and uterine size, was comparable in the two groups. &nbsp;",
"   </p>",
"   <p>",
"    The decision between myomectomy and hysterectomy must be individualized. The least invasive procedure should be chosen. Each patient should be counseled regarding the procedures for which she is eligible. This will depend primarily on the size, number, and location of fibroids. Based upon these factors, some women are candidates only for laparotomy.",
"   </p>",
"   <p>",
"    For women who are eligible for all procedures, no studies have directly compared outcomes for the various minimally invasive approaches (laparoscopic myomectomy, with either vaginal or laparoscopic hysterectomy). Some factors that may affect a patient&rsquo;s decision include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hysterectomy offers the advantage of definitive treatment.",
"     </li>",
"     <li>",
"      Some women prefer myomectomy because they wish to conserve their uterus.",
"     </li>",
"     <li>",
"      Hysterectomy is associated with a risk of subsequent pelvic organ prolapse surgery.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some women desire definitive therapy, and are willing to accept a more invasive or extensive procedure to avoid the risk of recurrent symptoms. Hysterectomy rather than myomectomy is the appropriate choice for these women, since some women require further surgery following myomectomy. (See",
"    <a class=\"local\" href=\"#H3250292\">",
"     'Subsequent treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    An increasing number of women wish to conserve their uterus as an important component of their body image. Women who are concerned about effects on sexual function should be counseled that most studies have found no impact of hysterectomy on sexual outcomes. Women who prefer to preserve their uterus, but do not plan future childbearing, are candidates for either myomectomy or interventional radiology procedures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/19/12602?source=see_link&amp;anchor=H17#H17\">",
"     \"Overview of hysterectomy\", section on 'Psychosexual issues'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In some women, hysterectomy may be associated with subsequent pelvic organ prolapse. Consistent results from large observational studies show women who undergo a hysterectomy are at risk of having subsequent prolapse repair surgery. However, this risk may be limited to women for whom prolapse was the indication for undergoing hysterectomy. It is not certain whether undergoing a hysterectomy for fibroids is a risk factor for developing symptomatic prolapse. Also, many women have several risk factors for prolapse, including parity, advancing age, and obesity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/19/12602?source=see_link&amp;anchor=H22#H22\">",
"     \"Overview of hysterectomy\", section on 'Pelvic organ prolapse'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In general, for subserosal or intramural fibroids, there are more minimally invasive options for hysterectomy than myomectomy. More women are candidates for vaginal and laparoscopic hysterectomy than laparoscopic myomectomy, and more surgeons have the skills for less invasive approaches to hysterectomy.",
"   </p>",
"   <p>",
"    Given these considerations, no overall recommendation can be made regarding myomectomy versus hysterectomy. Women who prefer definitive surgery require a hysterectomy. In contrast, those who desire uterine conservation should undergo myomectomy. For women who have, or are at increased risk for, pelvic organ prolapse, we suggest myomectomy rather than hysterectomy. Other women should choose the least invasive surgical approach that is available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H426525\">",
"    <span class=\"h1\">",
"     PREOPERATIVE EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H426761\">",
"    <span class=\"h2\">",
"     Informed consent",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with symptomatic fibroids should be counseled about other medical, interventional radiology, and surgical options for treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/41/20122?source=see_link&amp;anchor=H30#H30\">",
"     \"Chronic menorrhagia or anovulatory uterine bleeding\", section on 'Choosing a long-term treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/14/18666?source=see_link\">",
"     \"Overview of treatment of uterine leiomyomas (fibroids)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Potential complications of the procedure and the likelihood of recurrence of fibroids or symptoms should also be reviewed. (See",
"    <a class=\"local\" href=\"#H25049781\">",
"     'Complications'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H7665571\">",
"     'Persistent or new myomas'",
"    </a>",
"    below.) This discussion should be documented on the surgical consent form and in the medical record.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H426753\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;A thorough medical history is important to determine which fibroid-related symptoms are present (eg, heavy uterine bleeding, bulk symptoms) and whether these symptoms affect the patient's quality of life.",
"   </p>",
"   <p>",
"    The medical history should include questions regarding a personal or family history of bleeding disorders, as well as other medical comorbidities that may impact the ability to tolerate surgery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/4/10314?source=see_link\">",
"     \"Preoperative medical evaluation of the healthy patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H426745\">",
"    <span class=\"h2\">",
"     Pelvic examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;A thorough pelvic examination should be performed. On bimanual examination, the size, contour, and mobility of the uterus should be noted, along with any other findings (eg, adnexal mass, cervical mass). These findings impact the choice of preoperative imaging and aid surgical planning (eg, choosing a transverse or vertical incision).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H426729\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who are planning myomectomy should undergo imaging to confirm the presence of uterine leiomyomas rather than other pelvic pathology. In addition, incidental findings of other lesions (eg, ovarian cyst) may impact surgical planning.",
"   </p>",
"   <p>",
"    Imaging with ultrasonography rather than other modalities is sufficient for women in whom open myomectomy is planned. Ultrasound can confirm the presence of leiomyomas and their approximate number and location [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12346/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Magnetic resonance imaging is typically not necessary prior to open myomectomy, with the exception of women in whom leiomyomas must be differentiated from uterine sarcoma or adenomyosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/38/22121?source=see_link&amp;anchor=H1430514#H1430514\">",
"     \"Differentiating uterine leiomyomas (fibroids) from uterine sarcomas\", section on 'Imaging'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27191?source=see_link&amp;anchor=H7#H7\">",
"     \"Uterine adenomyosis\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Imaging of uterine leiomyomas is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/17/6426?source=see_link&amp;anchor=H5287506#H5287506\">",
"     \"Epidemiology, clinical manifestations, diagnosis, and natural history of uterine leiomyomas (fibroids)\", section on 'Imaging'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H623189\">",
"    <span class=\"h2\">",
"     Laboratory evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myomectomy is a procedure in which significant blood loss (&gt;300 mL) may occur. A baseline complete blood count is suggested for all patients undergoing this procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H426769\">",
"    <span class=\"h2\">",
"     Other testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormal bleeding is a symptom of uterine fibroids, but also of uterine cancer. Prior to myomectomy, endometrial sampling should be performed in all women with bleeding symptoms, particularly intermenstrual bleeding, who are older than 35 years or who have risk factors for endometrial cancer (",
"    <a class=\"graphic graphic_table graphicRef62089 \" href=\"UTD.htm?38/30/39403\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38744?source=see_link\">",
"     \"Evaluation of the endometrium for malignant or premalignant disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H426783\">",
"    <span class=\"h1\">",
"     PREOPERATIVE PREPARATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H623606\">",
"    <span class=\"h2\">",
"     Preparing for potential blood loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myomectomy may result in significant blood loss. Myomectomy does not usually result in significant blood loss, but risk factors for increased blood loss include large or multiple fibroids. For patients with an increased risk of significant blood loss, preoperative measures such as correction of anemia or autologous blood donation may reduce the likelihood of receiving a blood transfusion.",
"   </p>",
"   <p>",
"    A detailed discussion of measures to reduce blood loss associated with myomectomy can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/54/10088?source=see_link\">",
"     \"Techniques to reduce blood loss during abdominal or laparoscopic myomectomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H623653\">",
"    <span class=\"h2\">",
"     Reducing uterine size with GnRH agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preoperative use of gonadotropin releasing hormone (GnRH) agonists provides some short-term benefits for women undergoing myomectomy regarding blood loss and uterine size, but may increase the difficulty of surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12346/abstract/16\">",
"     16",
"    </a>",
"    ]. In the long-term, their use appears to increase the risk of persistent myomas.",
"   </p>",
"   <p>",
"    Myomectomy can usually be performed using a Pfannenstiel incision, or if slightly more access is needed, a Maylard incision. Compared with a large vertical incision (eg, to the umbilicus or above), these incisions decrease postoperative pain and improve scar cosmesis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12346/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/35/30265?source=see_link\">",
"     \"Principles of abdominal wall incisions\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For some women with large fibroids, a vertical incision may be required; however, use of GnRH agonists can reduce uterine size and allow use of a transverse or smaller vertical incision. A meta-analysis of 11 randomized trials demonstrated that pretreatment with a GnRH agonist compared with placebo or no treatment prior to abdominal myomectomy significantly reduced uterine size (uterine volume: 159 mL smaller; gestational size: 2.2 weeks less) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12346/abstract/16\">",
"     16",
"    </a>",
"    ]. The only trial that evaluated choice of incision found that GnRH agonist use was associated with fewer vertical incisions (0 of 13 versus 5 of 15) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12346/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The disadvantages of preoperative GnRH therapy, however, outweigh the advantages for most women. Randomized trials have not found that use of these agents reduces the risk of blood transfusion. Also, many surgeons report that these medications result in increased difficulty enucleating fibroids and small randomized trials have found that their use increases the risk of persistent myomas. Thus, we suggest",
"    <strong>",
"     not",
"    </strong>",
"    using GnRH agonist pretreatment for women undergoing open myomectomy. Most women can have an abdominal myomectomy through a large Pfannenstiel incision, even for very large fibroids. By dissecting the fascia off of the rectus muscles, both in the midline and laterally up to the umbilicus, the rectus muscles can be spread further laterally to give the surgeon more room to deliver the uterus. Use of these agents (GnRH) may be a reasonable option in women for whom treatment would allow a transverse rather than a vertical incision and who place a high priority on type of surgical incision. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/35/30265?source=see_link&amp;anchor=H19#H19\">",
"     \"Principles of abdominal wall incisions\", section on 'Pfannenstiel's incision'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A detailed discussion of the effect of GnRH agonists on blood loss during myomectomy can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/54/10088?source=see_link&amp;anchor=H1389439#H1389439\">",
"     \"Techniques to reduce blood loss during abdominal or laparoscopic myomectomy\", section on 'GnRH agonists'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1253844\">",
"    <span class=\"h2\">",
"     Prophylactic antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myomectomy is classified as a clean procedure, since it does not involve a vaginal or intestinal incision. The American College of Obstetricians and Gynecologists has advised that prophylactic antibiotics are not required for this procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12346/abstract/19\">",
"     19",
"    </a>",
"    ]. Other experts disagree, based upon the rationale that the surgical site infection risk is likely similar to hysterectomy, for which antibiotic prophylaxis is universally recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12346/abstract/20\">",
"     20",
"    </a>",
"    ]. There are no high quality data regarding the use of antibiotic prophylaxis in women undergoing myomectomy.",
"   </p>",
"   <p>",
"    In our practice, we give prophylactic antibiotics for abdominal myomectomy, since avoidance of pelvic infection with regard to fertility preservation may be an issue. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/58/934?source=see_link&amp;anchor=H6#H6\">",
"     \"Long-term complications of pelvic inflammatory disease\", section on 'Infertility'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1392339\">",
"    <span class=\"h2\">",
"     Thromboprophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients undergoing abdominal myomectomy (major surgery, defined as &gt;30 minutes duration) are at least at moderate risk for venous thromboembolism and require appropriate thromboprophylaxis, whether mechanical or pharmacologic. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=see_link\">",
"     \"Prevention of venous thromboembolic disease in surgical patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/55/39800?source=see_link&amp;anchor=H17332175#H17332175\">",
"     \"Overview of preoperative evaluation and preparation for gynecologic surgery\", section on 'Thromboprophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H624394\">",
"    <span class=\"h2\">",
"     Anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abdominal myomectomy is typically performed under general anesthesia, but regional anesthesia may be used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25049716\">",
"    <span class=\"h1\">",
"     PROCEDURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abdominal myomectomy is performed through a laparotomy. A transverse incision (eg, Pfannenstiel) is used whenever possible. (See",
"    <a class=\"local\" href=\"#H623653\">",
"     'Reducing uterine size with GnRH agonists'",
"    </a>",
"    above.) The basic steps of the procedure are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Apply measures to reduce blood loss",
"     </li>",
"     <li>",
"      Make uterine incision(s)",
"     </li>",
"     <li>",
"      Remove myomas",
"     </li>",
"     <li>",
"      Close uterine defects",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1390511\">",
"    <span class=\"h2\">",
"     Measures to reduce blood loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood loss during myomectomy can be prevented or decreased with mechanical or pharmacologic methods. Allogeneic blood transfusion can be avoided by using methods of autologous blood transfusion (autologous blood donation, intraoperative and postoperative blood salvage, or acute normovolemic [isovolemic] hemodilution).",
"   </p>",
"   <p>",
"    Techniques to reduce blood loss during myomectomy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/54/10088?source=see_link&amp;anchor=H1388946#H1388946\">",
"     \"Techniques to reduce blood loss during abdominal or laparoscopic myomectomy\", section on 'Intraoperative measures'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1522049\">",
"    <span class=\"h2\">",
"     Uterine incision",
"    </span>",
"    &nbsp;&mdash;&nbsp;The uterus is palpated to locate the leiomyomas. Careful planning and placement of uterine incisions can avoid inadvertent extension of the incision to the cornua or ascending uterine vessels.",
"   </p>",
"   <p>",
"    The uterine incisions may be either vertical or transverse. The common teaching has been to make vertical incisions, to prevent transection of the arcuate arteries of the uterus, which run transversely. However, avoiding these vessels is not feasible since myomas distort normal vascular architecture [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12346/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Anterior uterine incisions are associated with fewer adnexal adhesions than posterior incisions [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12346/abstract/22\">",
"     22",
"    </a>",
"    ]. However, if the fibroids are in the posterior uterine wall, it is usually preferable to make a posterior incision to remove than to go through the uterine cavity to remove them via an anterior incision.&nbsp;",
"   </p>",
"   <p>",
"    Many surgeons make a uterine incision at a location through which all or most of the myomas can be removed. The rationale for this is that limiting the number of adhesions reduces the likelihood of adhesions to the uterine serosa, although there are no data regarding the number of incisions and the risk of adhesions [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12346/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H427365\">",
"     'Adhesive disease'",
"    </a>",
"    below.) Use of a single incision, however, requires that tunnels be created within the myometrium to extract distant myomas. These myometrial defects can be difficult to close, interfering with hemostasis.",
"   </p>",
"   <p>",
"    Alternatively, an incision can be made directly over each myoma (or group of nearby or apposing myomas). This approach allows both easy removal of the myomas, as well as prompt closure of the myometrial defects to secure hemostasis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12346/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1366099\">",
"    <span class=\"h2\">",
"     Removal of myomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;The uterine incision is extended down through the myometrium and entire fibroid pseudocapsule (",
"    <a class=\"graphic graphic_figure graphicRef72235 \" href=\"UTD.htm?20/17/20757\">",
"     figure 3",
"    </a>",
"    ). The least vascular plane can be reached by extending this incision just deep to the capsule after the myoma is initially visualized. The myoma will then clearly be visible and may bulge slightly.",
"   </p>",
"   <p>",
"    Myomas are surrounded completely by a dense vascular layer supplying the myoma and no \"vascular pedicle\" exists at the base of the myoma, as demonstrated vascular corrosion casting and examination by electron microscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12346/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are many techniques to enucleate myomas. Many surgeons put traction on the myometrial edges with Allis clamps to expose the myoma (",
"    <a class=\"graphic graphic_figure graphicRef79302 \" href=\"UTD.htm?38/26/39333\">",
"     figure 4",
"    </a>",
"    ). The myomas are then extirpated by grasping them with a single tooth tenaculum or towel clamp (",
"    <a class=\"graphic graphic_figure graphicRef63325 \" href=\"UTD.htm?11/31/11765\">",
"     figure 5",
"    </a>",
"    ). The plane between the myometrium and myoma is typically dissected bluntly (eg, using a sponge or the back end of an empty knife handle) (",
"    <a class=\"graphic graphic_figure graphicRef74537 \" href=\"UTD.htm?20/55/21366\">",
"     figure 6",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7664470\">",
"    <span class=\"h2\">",
"     Closure of uterine defects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The uterine defects are closed with sutures in layers. If the myometrial defect is deep (&gt;2 cm), two layers may be needed to reapproximate the tissue and achieve hemostasis (",
"    <a class=\"graphic graphic_figure graphicRef53687 \" href=\"UTD.htm?29/0/29700\">",
"     figure 7",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef77177 \" href=\"UTD.htm?28/63/29686\">",
"     figure 8",
"    </a>",
"    ). In our practice, we use a size 0 polyglactin 910 (Vicryl&trade;) suture for the myometrium. The serosa is closed with a running suture (",
"    <a class=\"graphic graphic_figure graphicRef54185 \" href=\"UTD.htm?8/7/8308\">",
"     figure 9",
"    </a>",
"    ); we use size 2-0 polydioxanone (PDS&trade;), but any absorbable suture may be used. &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7664477\">",
"    <span class=\"h2\">",
"     Operative challenges",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H623747\">",
"    <span class=\"h3\">",
"     Large uterus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myomectomy can be performed safely for women with a large uterus (&ge;16 weeks size), but surgical skill and experience are required. As an example, a retrospective study of 91 women with uterine fibroids equal to or larger than 16 weeks size who underwent abdominal myomectomy reported an average operative duration of 236 minutes (range 120 to 390 minutes) and an average blood loss of 794 mL (range 50 to 3000 mL) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12346/abstract/24\">",
"     24",
"    </a>",
"    ]. Intraoperative blood salvage was used in women with a blood loss &gt;300 mL (70 women, 77 percent) and only 7 women (8 percent) received a blood transfusion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/54/10088?source=see_link&amp;anchor=H1388988#H1388988\">",
"     \"Techniques to reduce blood loss during abdominal or laparoscopic myomectomy\", section on 'Autologous blood transfusion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7664484\">",
"    <span class=\"h3\">",
"     Submucosal myomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hysteroscopic myomectomy is the procedure of choice for women with primarily intracavitary leiomyomas. For those with myomas in multiple locations including submucosal, abdominal myomectomy is preferred. Removal of submucosal myomas during abdominal myomectomy requires deep myometrial dissection. Often, the uterine cavity is entered during this process. In our practice, we repair the myometrium at the interface with the cavity, taking care to avoid entry of suture into the cavity, since this may cause a foreign body reaction and adhesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1387397\">",
"    <span class=\"h3\">",
"     Cervical or broad ligament myomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uterine leiomyomas originate within the myometrium, but, as they grow, may extend into or displace adjacent structures. Cervical or broad ligament myomas are a common finding. These lesions are often proximal to vital structures such as the ureter or major pelvic vessels.",
"   </p>",
"   <p>",
"    The first step in removing a cervical or broad ligament lesion is careful inspection of the peritoneum overlying the fibroid to identify a clear area where the peritoneum can be incised.&nbsp;With careful attention to staying in the proper surgical plane, the fibroid can be removed with traction and blunt dissection in a direction away from vital structures. Sharp dissection, especially where the tips of the instrument cannot be seen, should be avoided. Closure of the defect should also be carefully planned after identification of the ureter and uterine vessels, in order to avoid injury or ligation of the ureter or injury to vessels.&nbsp;If necessary, ligation of the uterine vessels may be performed to avoid bleeding. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25049781\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7664609\">",
"    <span class=\"h2\">",
"     Hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;The average volume of blood loss for abdominal myomectomy varies across studies from approximately 200 to 800 mL [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12346/abstract/13,14,24\">",
"     13,14,24",
"    </a>",
"    ]. In series of 100 or more abdominal myomectomy procedures, the blood transfusion rate has varied widely from 2 to 28 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12346/abstract/13,14,26\">",
"     13,14,26",
"    </a>",
"    ]. Increasing size and number of myomas, as well as entering the uterine cavity, are associated with increased blood loss [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12346/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prevention and management of blood loss during myomectomy are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/54/10088?source=see_link\">",
"     \"Techniques to reduce blood loss during abdominal or laparoscopic myomectomy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/18/43305?source=see_link\">",
"     \"Management of hemorrhage in gynecologic surgery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7664602\">",
"    <span class=\"h3\">",
"     Conversion to hysterectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe hemorrhage may be addressed with a number of techniques, including use of intraoperative blood salvage, uterine artery ligation, or conversion to hysterectomy. Approximately 1 to 4 percent of abdominal myomectomies are converted to hysterectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12346/abstract/12,28\">",
"     12,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7664617\">",
"    <span class=\"h2\">",
"     Fever and infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fever occurs within 48 hours after surgery in approximately 12 to 67 percent of women following myomectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12346/abstract/26,28,29\">",
"     26,28,29",
"    </a>",
"    ]. However, one retrospective study found that, compared with those undergoing hysterectomy, women who had a myomectomy had similar rates of fever (39 percent within 24 hours), but fewer localized findings (eg, urinary tract infection or pneumonia: 14 versus 31 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12346/abstract/29\">",
"     29",
"    </a>",
"    ]. Therefore, evaluation of fever after myomectomy in the absence of localizing symptoms may not be cost-effective. Proposed mechanisms for unexplained post-myomectomy fever include hematomas or release of inflammatory mediators at the evacuated myoma sites [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12346/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are few studies of specific sites of infection following abdominal myomectomy. Wound infection affects 2 to 5 percent of women after abdominal myomectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12346/abstract/26,28\">",
"     26,28",
"    </a>",
"    ]. A study of 250 myomectomy patients reported the most infections occurred in the urinary (46 percent) or respiratory tracts (38 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12346/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Evaluation and management of postoperative fever are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/46/19178?source=see_link\">",
"     \"Postoperative fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H427365\">",
"    <span class=\"h2\">",
"     Adhesive disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adhesion formation after myomectomy has been well documented. In a study (n = 45) in which second look laparoscopy was performed following abdominal or laparoscopic myomectomy, adhesions were found in 36 percent of women [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12346/abstract/30\">",
"     30",
"    </a>",
"    ]. Factors associated with adhesive disease were posterior location of a removed myoma and the presence of sutures. Adnexal adhesions, which may impact tubal fertility, were additionally associated with concurrent surgery (eg, ovarian cystectomy) and prior adhesive disease.",
"   </p>",
"   <p>",
"    A detailed discussion of methods of adhesion prevention can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/47/26359?source=see_link\">",
"     \"Preventing postoperative peritoneal adhesions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7666456\">",
"    <span class=\"h2\">",
"     Other complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Visceral injury is uncommon during abdominal myomectomy. As an example, in one series of 197 women who underwent the procedure, there was one cystotomy and two small bowel obstructions [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12346/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The evaluation and management of these and other complications, such as ileus, wound infection, or incisional hernia, are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/27/7609?source=see_link\">",
"     \"Urinary tract injury in gynecologic surgery: Evaluation and management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/46/14058?source=see_link\">",
"     \"Small bowel obstruction: Causes and management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/33/2586?source=see_link\">",
"     \"Postoperative ileus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/39/21113?source=see_link\">",
"     \"Abdominal surgical incisions: Prevention and treatment of complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1747014\">",
"    <span class=\"h1\">",
"     INPATIENT POSTOPERATIVE CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine postoperative care includes monitoring of a patient's hemodynamic and fluid status, pain control, and reintroducing normal diet and activity. Components of inpatient postoperative care following myomectomy include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Postoperative pain management initially with parenteral administration of analgesics. Patient-controlled anesthesia is also an option. This is transitioned to the oral route when a patient can tolerate oral intake, usually on the first postoperative day. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27546?source=see_link\">",
"       \"Management of postoperative pain\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Removal of the bladder catheter during the first 24 hours postoperatively. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/47/40697?source=see_link\">",
"       \"Placement and management of urinary bladder catheters\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Early feeding of a regular diet. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/33/2586?source=see_link&amp;anchor=H13#H13\">",
"       \"Postoperative ileus\", section on 'Prevention'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Ambulation and other measures to prevent pulmonary complications. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/51/13113?source=see_link\">",
"       \"Strategies to reduce postoperative pulmonary complications\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Evaluation and management of complications are discussed above. (See",
"    <a class=\"local\" href=\"#H25049781\">",
"     'Complications'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7664625\">",
"    <span class=\"h1\">",
"     FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;A woman is encouraged to resume her normal daily activities as quickly as is comfortable. Decisions regarding resumption of vaginal intercourse are made by the patient; there are no medical restrictions on sexual activity [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12346/abstract/31\">",
"     31",
"    </a>",
"    ]. Patients may return to work as soon as they have regained sufficient stamina and mobility.",
"   </p>",
"   <p>",
"    Routine postoperative instructions for patients can be found separately. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?27/27/28083?source=see_link\">",
"     \"Patient information: Care after gynecologic surgery (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We see patients for a follow-up visit at two weeks postoperatively. The follow-up visit includes an evaluation for potential complications and an examination of the abdomen and wound. We review the details of the surgery and pathology results with the patient. &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7665557\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7665564\">",
"    <span class=\"h2\">",
"     Relief of symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myomectomy has been reported to relieve symptoms in 80 percent of women [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12346/abstract/2,9\">",
"     2,9",
"    </a>",
"    ]. Unfortunately, many large series of abdominal myomectomies have not reported data for relief of symptoms, patient satisfaction, or quality-of-life following surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12346/abstract/26,32-34\">",
"     26,32-34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7665571\">",
"    <span class=\"h2\">",
"     Persistent or new myomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many women who undergo myomectomy will have leiomyomas upon subsequent evaluation. However, most of these women will not require additional treatment for fibroid-related symptoms. Surveillance for post-myomectomy myomas is not necessary, since imaging detects many clinically insignificant myomas. The outcome that is important to patients is the risk of recurrent symptoms that require additional treatment. &nbsp;",
"   </p>",
"   <p>",
"    Myomas detected after myomectomy, often referred to as recurrent, are more accurately referred to as persistent or newly developed. Myomas persist when they are not removed or incompletely removed at the time of surgery.",
"   </p>",
"   <p>",
"    Five to 10 years after myomectomy, 27 to 62 percent of women will have myomas detected by ultrasound [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12346/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. Considering the background prevalence of leiomyomas (77 percent in a post-hysterectomy study [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12346/abstract/38\">",
"     38",
"    </a>",
"    ]), it is not surprising that myomas continue to develop after excision.",
"   </p>",
"   <p>",
"    Post-myomectomy myomas are more likely in women who have multiple versus single myomas at time of surgery (74 versus 11 percent in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12346/abstract/39\">",
"     39",
"    </a>",
"    ]) and those who do not versus do have a pregnancy after myomectomy (30 versus 15 percent in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12346/abstract/36\">",
"     36",
"    </a>",
"    ]). Preoperative use of GnRH agonists is associated with an increase in the risk of postoperative myomas. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/54/10088?source=see_link&amp;anchor=H1389439#H1389439\">",
"     \"Techniques to reduce blood loss during abdominal or laparoscopic myomectomy\", section on 'GnRH agonists'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3250292\">",
"    <span class=\"h2\">",
"     Subsequent treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many women with myomas are asymptomatic, so the most important outcome is the need for subsequent treatment following myomectomy.",
"   </p>",
"   <p>",
"    After a first myomectomy, 10 to 25 percent of women will have a second major surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12346/abstract/37,39-42\">",
"     37,39-42",
"    </a>",
"    ]. The largest study (n = 568) was a nested case control study in which 21 percent of women who had undergone myomectomy (abdominal, laparoscopic, or hysteroscopic) had subsequent surgery within 1 to 10 years; the combination of surgical approaches limits the ability to apply these data to abdominal myomectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12346/abstract/10\">",
"     10",
"    </a>",
"    ]. Another retrospective study of 47 women who had undergone abdominal myomectomy reported that, at an average of seven-year follow-up, 34 percent had subsequent surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12346/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Risk factors for subsequent surgery are not well established. In one study, uterine size &lt;12 weeks was associated with an increased risk of a second surgery, while other data suggest that a larger uterus or multiple myomas are associated with a lower risk of re-operation [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12346/abstract/11,39\">",
"     11,39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no data regarding how many women require medical treatment for fibroids following myomectomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H427646\">",
"    <span class=\"h1\">",
"     CONCEPTION AND PREGNANCY AFTER MYOMECTOMY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1878381\">",
"    <span class=\"h2\">",
"     Interval to conception",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who undergo myomectomy with significant uterine disruption should wait several months before attempting to conceive; recommendations for this interval range from three to six months [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12346/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3949343\">",
"    <span class=\"h2\">",
"     Infertility",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a woman is having difficulty conceiving following a myomectomy, early assessment of the uterine cavity and fallopian tubes with a hysterosalpingogram is advisable [",
"    <a class=\"abstract\" href=\"UTD.htm?12/3/12346/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Issues of fertility and leiomyomas are discussed separately. (See",
"    <a class=\"local\" href=\"#H7945234\">",
"     'Infertility'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/60/30662?source=see_link\">",
"     \"Reproductive issues in women with uterine leiomyomas (fibroids)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H427523\">",
"    <span class=\"h2\">",
"     Uterine rupture during pregnancy following myomectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myomectomy appears to be associated with an increased risk of uterine rupture during subsequent pregnancy, but it is difficult to ascertain the degree of risk and whether opening the uterine cavity adds to this risk. Many experts advise cesarean delivery as a conservative approach.",
"   </p>",
"   <p>",
"    Uterine rupture during pregnancy following myomectomy is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/45/15065?source=see_link&amp;anchor=H25#H25\">",
"     \"Pregnancy in women with uterine leiomyomas (fibroids)\", section on 'Management of patients with prior myomectomy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7951810\">",
"    <span class=\"h2\">",
"     Myomectomy during pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myomectomy is performed rarely during pregnancy, and usually for the indication of intractable fibroid pain. In addition, in rare cases, myomectomy is required at the time of cesarean delivery to provide access to the uterine incision site.",
"   </p>",
"   <p>",
"    Antepartum and intrapartum myomectomy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/45/15065?source=see_link&amp;anchor=H23#H23\">",
"     \"Pregnancy in women with uterine leiomyomas (fibroids)\", section on 'Myomectomy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?20/20/20804?source=see_link\">",
"       \"Patient information: Uterine fibroids (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H427668\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Abdominal myomectomy (performed via laparotomy; also referred to as open myomectomy) is the surgical removal of leiomyomas from the uterus, leaving the uterus in place. (See",
"      <a class=\"local\" href=\"#H25049674\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common indications for abdominal myomectomy are abnormal uterine bleeding or bulk-related symptoms (eg,",
"      <span class=\"nowrap\">",
"       pelvic/abdominal",
"      </span>",
"      pain or pressure). Indications for which the benefit of myomectomy is unproven include: evaluation of pelvic malignancy (eg, ovarian or uterine cancer), infertility, and prevention of obstetric complications. (See",
"      <a class=\"local\" href=\"#H14328797\">",
"       'Indications'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7945019\">",
"       'Unproven indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women undergoing abdominal or laparoscopic myomectomy, we suggest",
"      <strong>",
"       not",
"      </strong>",
"      pretreating with GnRH agonists (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Use of these agents is a reasonable option in women for whom treatment would allow a transverse rather than a vertical incision and who place a high priority on type of surgical incision. (See",
"      <a class=\"local\" href=\"#H623653\">",
"       'Reducing uterine size with GnRH agonists'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/54/10088?source=see_link&amp;anchor=H1389439#H1389439\">",
"       \"Techniques to reduce blood loss during abdominal or laparoscopic myomectomy\", section on 'GnRH agonists'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In our practice, we use prophylactic antibiotics for this procedure, since intraabdominal infection may adversely affect fertility. (See",
"      <a class=\"local\" href=\"#H1253844\">",
"       'Prophylactic antibiotics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with bulk-related symptoms of uterine leiomyomas, the decision regarding procedure depends upon patient characteristics and preferences (see",
"      <a class=\"local\" href=\"#H748326\">",
"       'Bulk-related symptoms'",
"      </a>",
"      above): &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      The procedure of choice for women who desire future pregnancy is myomectomy.",
"     </li>",
"     <li>",
"      For women who do not wish to preserve fertility and do not prefer definitive surgery, the choice must be individualized. Uterine artery embolization and laparoscopic myomectomy are the least invasive options; eligibility for each of these procedures depends upon patient (and fibroid) characteristics. For patients who are candidates for either of these procedures, we suggest laparoscopic myomectomy rather than uterine artery embolization (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Women who place a high priority on avoiding abdominal incisions may reasonably choose embolization.",
"     </li>",
"     <li>",
"      For women who do not undergo an interventional radiology procedure and who have pelvic organ prolapse or have risk factors for prolapse (eg, increasing parity, obesity), we suggest myomectomy rather than hysterectomy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For women who prefer definitive surgery, hysterectomy is required. &nbsp;",
"     </li>",
"     <li>",
"      All other women should choose the least invasive surgical approach for which they are eligible and that is available to them (eg, abdominal myomectomy, laparoscopic hysterectomy, vaginal hysterectomy).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Blood loss during myomectomy can be prevented or decreased with mechanical or pharmacologic methods. Allogeneic blood transfusion can be avoided by using methods of autologous blood transfusion. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/54/10088?source=see_link\">",
"       \"Techniques to reduce blood loss during abdominal or laparoscopic myomectomy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Fever occurs within 48 hours after surgery in approximately 12 to 67 percent of women following myomectomy. Many women with post-myomectomy fever have not localized findings. (See",
"      <a class=\"local\" href=\"#H7664617\">",
"       'Fever and infection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adhesion formation occurs in approximately 36 percent of women after myomectomy. (See",
"      <a class=\"local\" href=\"#H427365\">",
"       'Adhesive disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Myomectomy relieves symptoms in 80 percent of women. The rate of subsequent surgery for fibroids following myomectomy is 21 to 34 percent. (See",
"      <a class=\"local\" href=\"#H7665557\">",
"       'Outcome'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12346/abstract/1\">",
"      Baird DD, Dunson DB, Hill MC, et al. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol 2003; 188:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12346/abstract/2\">",
"      Buttram VC Jr, Reiter RC. Uterine leiomyomata: etiology, symptomatology, and management. Fertil Steril 1981; 36:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12346/abstract/3\">",
"      Serden SP, Brooks PG. Treatment of abnormal uterine bleeding with the gynecologic resectoscope. J Reprod Med 1991; 36:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12346/abstract/4\">",
"      McLucas B, Chespak L, Kaminsky D. Myoma necrosis following Gelfoam embolization of uterine myomata. Minim Invasive Ther Allied Technol 2008; 17:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12346/abstract/5\">",
"      Reiter RC, Wagner PL, Gambone JC. Routine hysterectomy for large asymptomatic uterine leiomyomata: a reappraisal. Obstet Gynecol 1992; 79:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12346/abstract/6\">",
"      Pritts EA, Parker WH, Olive DL. Fibroids and infertility: an updated systematic review of the evidence. Fertil Steril 2009; 91:1215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12346/abstract/7\">",
"      Klatsky PC, Tran ND, Caughey AB, Fujimoto VY. Fibroids and reproductive outcomes: a systematic literature review from conception to delivery. Am J Obstet Gynecol 2008; 198:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12346/abstract/8\">",
"      Mara M, Maskova J, Fucikova Z, et al. Midterm clinical and first reproductive results of a randomized controlled trial comparing uterine fibroid embolization and myomectomy. Cardiovasc Intervent Radiol 2008; 31:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12346/abstract/9\">",
"      Broder MS, Goodwin S, Chen G, et al. Comparison of long-term outcomes of myomectomy and uterine artery embolization. Obstet Gynecol 2002; 100:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12346/abstract/10\">",
"      Thompson LB, Reed SD, McCrummen BK, et al. Leiomyoma characteristics and risk of subsequent surgery after myomectomy. Int J Gynaecol Obstet 2006; 95:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12346/abstract/11\">",
"      Stewart EA, Faur AV, Wise LA, et al. Predictors of subsequent surgery for uterine leiomyomata after abdominal myomectomy. Obstet Gynecol 2002; 99:426.",
"     </a>",
"    </li>",
"    <li>",
"     Viswanathan, M, Hartmann, K, McKoy, N, et al. Management of Uterine Fibroids: An Update of the Evidence. Evidence Report/Technology Assessment No. 154  AHRQ Publication No. 07-E011. Rockville, MD: Agency for Healthcare Research and Quality. July 2007. file://www.ahrq.gov/clinic/tp/uteruptp.htm (Accessed on November 12, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12346/abstract/13\">",
"      Sawin SW, Pilevsky ND, Berlin JA, Barnhart KT. Comparability of perioperative morbidity between abdominal myomectomy and hysterectomy for women with uterine leiomyomas. Am J Obstet Gynecol 2000; 183:1448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12346/abstract/14\">",
"      Iverson RE Jr, Chelmow D, Strohbehn K, et al. Relative morbidity of abdominal hysterectomy and myomectomy for management of uterine leiomyomas. Obstet Gynecol 1996; 88:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12346/abstract/15\">",
"      Dueholm M, Lundorf E, Hansen ES, et al. Accuracy of magnetic resonance imaging and transvaginal ultrasonography in the diagnosis, mapping, and measurement of uterine myomas. Am J Obstet Gynecol 2002; 186:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12346/abstract/16\">",
"      Lethaby A, Vollenhoven B, Sowter M. Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids. Cochrane Database Syst Rev 2001; :CD000547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12346/abstract/17\">",
"      Brown SR, Goodfellow PB. Transverse verses midline incisions for abdominal surgery. Cochrane Database Syst Rev 2005; :CD005199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12346/abstract/18\">",
"      Bustos L&oacute;pez HH, Miranda Rodr&iacute;guez JA, Kably Ambe A, et al. [Preoperative management of uterine leiomyomatosis using pituitary gonadotropin-releasing hormone analogues]. Ginecol Obstet Mex 1995; 63:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12346/abstract/19\">",
"      ACOG Committee on Practice Bulletins--Gynecology. ACOG practice bulletin No. 104: antibiotic prophylaxis for gynecologic procedures. Obstet Gynecol 2009; 113:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12346/abstract/20\">",
"      Mukhopadhaya N, De Silva C, Manyonda IT. Conventional myomectomy. Best Pract Res Clin Obstet Gynaecol 2008; 22:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12346/abstract/21\">",
"      Discepola F, Valenti DA, Reinhold C, Tulandi T. Analysis of arterial blood vessels surrounding the myoma: relevance to myomectomy. Obstet Gynecol 2007; 110:1301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12346/abstract/22\">",
"      Tulandi T, Murray C, Guralnick M. Adhesion formation and reproductive outcome after myomectomy and second-look laparoscopy. Obstet Gynecol 1993; 82:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12346/abstract/23\">",
"      Guarnaccia MM, Rein MS. Traditional surgical approaches to uterine fibroids: abdominal myomectomy and hysterectomy. Clin Obstet Gynecol 2001; 44:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12346/abstract/24\">",
"      West S, Ruiz R, Parker WH. Abdominal myomectomy in women with very large uterine size. Fertil Steril 2006; 85:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12346/abstract/25\">",
"      Walocha JA, Litwin JA, Miodoski AJ. Vascular system of intramural leiomyomata revealed by corrosion casting and scanning electron microscopy. Hum Reprod 2003; 18:1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12346/abstract/26\">",
"      LaMorte AI, Lalwani S, Diamond MP. Morbidity associated with abdominal myomectomy. Obstet Gynecol 1993; 82:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12346/abstract/27\">",
"      Sch&uuml;ring AN, Garcia-Rocha GJ, Schl&ouml;sser HW, et al. Perioperative complications in conventional and microsurgical abdominal myomectomy. Arch Gynecol Obstet 2011; 284:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12346/abstract/28\">",
"      Olufowobi O, Sharif K, Papaionnou S, et al. Are the anticipated benefits of myomectomy achieved in women of reproductive age? A 5-year review of the results at a UK tertiary hospital. J Obstet Gynaecol 2004; 24:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12346/abstract/29\">",
"      Rybak EA, Polotsky AJ, Woreta T, et al. Explained compared with unexplained fever in postoperative myomectomy and hysterectomy patients. Obstet Gynecol 2008; 111:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12346/abstract/30\">",
"      Dubuisson JB, Fauconnier A, Chapron C, et al. Second look after laparoscopic myomectomy. Hum Reprod 1998; 13:2102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12346/abstract/31\">",
"      Minig L, Trimble EL, Sarsotti C, et al. Building the evidence base for postoperative and postpartum advice. Obstet Gynecol 2009; 114:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12346/abstract/32\">",
"      Ikpeze OC, Nwosu OB. Features of uterine fibroids treated by abdominal myomectomy at Nnewi, Nigeria. J Obstet Gynaecol 1998; 18:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12346/abstract/33\">",
"      Sirjusingh A, Bassaw B, Roopnarinesingh S. The results of abdominal myomectomy. West Indian Med J 1994; 43:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12346/abstract/34\">",
"      Vercellini P, Maddalena S, De Giorgi O, et al. Determinants of reproductive outcome after abdominal myomectomy for infertility. Fertil Steril 1999; 72:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12346/abstract/35\">",
"      Fedele L, Parazzini F, Luchini L, et al. Recurrence of fibroids after myomectomy: a transvaginal ultrasonographic study. Hum Reprod 1995; 10:1795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12346/abstract/36\">",
"      Candiani GB, Fedele L, Parazzini F, Villa L. Risk of recurrence after myomectomy. Br J Obstet Gynaecol 1991; 98:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12346/abstract/37\">",
"      Aci&eacute;n P, Quereda F. Abdominal myomectomy: results of a simple operative technique. Fertil Steril 1996; 65:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12346/abstract/38\">",
"      Cramer SF, Patel A. The frequency of uterine leiomyomas. Am J Clin Pathol 1990; 94:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12346/abstract/39\">",
"      Hanafi M. Predictors of leiomyoma recurrence after myomectomy. Obstet Gynecol 2005; 105:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12346/abstract/40\">",
"      Malone LJ. Myomectomy: recurrence after removal of solitary and multiple myomas. Obstet Gynecol 1969; 34:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12346/abstract/41\">",
"      Buttram VC Jr. Uterine leiomyomata--aetiology, symptomatology and management. Prog Clin Biol Res 1986; 225:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12346/abstract/42\">",
"      Fauconnier A, Chapron C, Babaki-Fard K, Dubuisson JB. Recurrence of leiomyomata after myomectomy. Hum Reprod Update 2000; 6:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12346/abstract/43\">",
"      Tsuji S, Takahashi K, Imaoka I, et al. MRI evaluation of the uterine structure after myomectomy. Gynecol Obstet Invest 2006; 61:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/3/12346/abstract/44\">",
"      Wallach EE, Vlahos NF. Uterine myomas: an overview of development, clinical features, and management. Obstet Gynecol 2004; 104:393.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14195 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-27.109.116.13-B2EFA6BE5C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_3_12346=[""].join("\n");
var outline_f12_3_12346=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H427668\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25049674\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25049681\">",
"      PATIENT SELECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14328797\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7945019\">",
"      Unproven indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7945374\">",
"      - Evaluation of pelvic malignancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7945234\">",
"      - Infertility",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7945277\">",
"      - Prevention of obstetric complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14328804\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7944123\">",
"      MYOMECTOMY VERSUS OTHER TREATMENT APPROACHES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7950745\">",
"      Abnormal uterine bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H748326\">",
"      Bulk-related symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3251085\">",
"      - Women who desire future pregnancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H3251120\">",
"      - Choosing the least invasive approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H26149120\">",
"      Interventional radiology procedures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H26149127\">",
"      Myomectomy versus hysterectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H426525\">",
"      PREOPERATIVE EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H426761\">",
"      Informed consent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H426753\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H426745\">",
"      Pelvic examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H426729\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H623189\">",
"      Laboratory evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H426769\">",
"      Other testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H426783\">",
"      PREOPERATIVE PREPARATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H623606\">",
"      Preparing for potential blood loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H623653\">",
"      Reducing uterine size with GnRH agonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1253844\">",
"      Prophylactic antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1392339\">",
"      Thromboprophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H624394\">",
"      Anesthesia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25049716\">",
"      PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1390511\">",
"      Measures to reduce blood loss",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1522049\">",
"      Uterine incision",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1366099\">",
"      Removal of myomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7664470\">",
"      Closure of uterine defects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7664477\">",
"      Operative challenges",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H623747\">",
"      - Large uterus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7664484\">",
"      - Submucosal myomas",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1387397\">",
"      - Cervical or broad ligament myomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25049781\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7664609\">",
"      Hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7664602\">",
"      - Conversion to hysterectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7664617\">",
"      Fever and infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H427365\">",
"      Adhesive disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7666456\">",
"      Other complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1747014\">",
"      INPATIENT POSTOPERATIVE CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7664625\">",
"      FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7665557\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7665564\">",
"      Relief of symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7665571\">",
"      Persistent or new myomas",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3250292\">",
"      Subsequent treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H427646\">",
"      CONCEPTION AND PREGNANCY AFTER MYOMECTOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1878381\">",
"      Interval to conception",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3949343\">",
"      Infertility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H427523\">",
"      Uterine rupture during pregnancy following myomectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7951810\">",
"      Myomectomy during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H427668\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/14195\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/14195|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/16/30978\" title=\"figure 1\">",
"      Fibroid anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/32/27143\" title=\"figure 2\">",
"      Submucosal leiomyoma position",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/17/20757\" title=\"figure 3\">",
"      Myomectomy incision",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/26/39333\" title=\"figure 4\">",
"      Allis clamps on myometrium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/31/11765\" title=\"figure 5\">",
"      Towel clamp on myoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/55/21366\" title=\"figure 6\">",
"      Dissection of myoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/0/29700\" title=\"figure 7\">",
"      Closure of myomectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/63/29686\" title=\"figure 8\">",
"      Closure outer myometrium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/7/8308\" title=\"figure 9\">",
"      Serosal repair after myomectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/14195|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/30/39403\" title=\"table 1\">",
"      Risk factors endometrial cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/39/21113?source=related_link\">",
"      Abdominal surgical incisions: Prevention and treatment of complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/1/24601?source=related_link\">",
"      Approach to the patient with an adnexal mass",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/41/20122?source=related_link\">",
"      Chronic menorrhagia or anovulatory uterine bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/38/22121?source=related_link\">",
"      Differentiating uterine leiomyomas (fibroids) from uterine sarcomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/17/6426?source=related_link\">",
"      Epidemiology, clinical manifestations, diagnosis, and natural history of uterine leiomyomas (fibroids)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38744?source=related_link\">",
"      Evaluation of the endometrium for malignant or premalignant disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/53/32601?source=related_link\">",
"      Hysteroscopic myomectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/22/14698?source=related_link\">",
"      Laparoscopic approach to hysterectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/48/8970?source=related_link\">",
"      Laparoscopic myomectomy and other laparoscopic treatments for uterine leiomyomas (fibroids)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/58/934?source=related_link\">",
"      Long-term complications of pelvic inflammatory disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/18/43305?source=related_link\">",
"      Management of hemorrhage in gynecologic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/57/27546?source=related_link\">",
"      Management of postoperative pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/19/12602?source=related_link\">",
"      Overview of hysterectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/55/39800?source=related_link\">",
"      Overview of preoperative evaluation and preparation for gynecologic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41735?source=related_link\">",
"      Overview of the principles of medical consultation and perioperative medicine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/14/18666?source=related_link\">",
"      Overview of treatment of uterine leiomyomas (fibroids)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/27/28083?source=related_link\">",
"      Patient information: Care after gynecologic surgery (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?20/20/20804?source=related_link\">",
"      Patient information: Uterine fibroids (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/47/40697?source=related_link\">",
"      Placement and management of urinary bladder catheters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/46/19178?source=related_link\">",
"      Postoperative fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/33/2586?source=related_link\">",
"      Postoperative ileus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/45/15065?source=related_link\">",
"      Pregnancy in women with uterine leiomyomas (fibroids)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/4/10314?source=related_link\">",
"      Preoperative medical evaluation of the healthy patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/47/26359?source=related_link\">",
"      Preventing postoperative peritoneal adhesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=related_link\">",
"      Prevention of venous thromboembolic disease in surgical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/35/30265?source=related_link\">",
"      Principles of abdominal wall incisions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/24/16775?source=related_link\">",
"      Prolapsed uterine leiomyoma (fibroid)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/60/30662?source=related_link\">",
"      Reproductive issues in women with uterine leiomyomas (fibroids)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/14/10474?source=related_link\">",
"      Screening for ovarian cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/46/14058?source=related_link\">",
"      Small bowel obstruction: Causes and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/51/13113?source=related_link\">",
"      Strategies to reduce postoperative pulmonary complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/54/10088?source=related_link\">",
"      Techniques to reduce blood loss during abdominal or laparoscopic myomectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/43/42681?source=related_link\">",
"      The gynecologic history and pelvic examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/36/28233?source=related_link\">",
"      Treatment of primary dysmenorrhea in adult women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/27/7609?source=related_link\">",
"      Urinary tract injury in gynecologic surgery: Evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27191?source=related_link\">",
"      Uterine adenomyosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/60/22473?source=related_link\">",
"      Uterine leiomyoma (fibroid) embolization",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_3_12347="Causes of small bowel obstruction";
var content_f12_3_12347=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F53183&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F53183&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of small bowel obstruction",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Extrinsic lesions",
"       </td>",
"       <td class=\"subtitle1\">",
"        Intrinsic lesions",
"       </td>",
"       <td class=\"subtitle1\">",
"        Obstruction of normal bowel lumen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adhesions",
"       </td>",
"       <td>",
"        Congenital malformations",
"       </td>",
"       <td>",
"        Intussusception*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hernia",
"       </td>",
"       <td>",
"        Duplication, atresia, stenosis",
"       </td>",
"       <td>",
"        Gallstones",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Volvulus",
"       </td>",
"       <td>",
"        Neoplasm",
"       </td>",
"       <td>",
"        Feces or meconium",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Inflammatory stricture",
"       </td>",
"       <td>",
"        Bezoar",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Radiation enteritis",
"       </td>",
"       <td>",
"        Traumatic intramural hematoma",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * May be an instrinsic lesion serving as a lead point.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_3_12347=[""].join("\n");
var outline_f12_3_12347=null;
var title_f12_3_12348="Motor features PD PI";
var content_f12_3_12348=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F52492&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F52492&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Motor features of Parkinson disease",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Cardinal manifestations",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Tremor",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Bradykinesia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Rigidity",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Postural instability",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Other motor features",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Craniofacial",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Hypomimia (masked facial expression)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Decreased eye blinking",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Speech disturbances (hypokinetic dysarthria, hypophonia)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Dysphagia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Sialorrhea",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Visual",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Blurred vision",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Impaired contrast sensitivity",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Hypometric saccades",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Impaired vestibuloocular reflex",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Impaired upward gaze and convergence",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Lid apraxia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Musculoskeletal",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Micrographia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Dystonia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Myoclonus",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Stooped posture",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Kyphosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Scoliosis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Difficulty turning in bed",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Gait",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Shuffling, short-stepped gait",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Freezing",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Festination",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_3_12348=[""].join("\n");
var outline_f12_3_12348=null;
var title_f12_3_12349="Peak influenza activity";
var content_f12_3_12349=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F60877&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F60877&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 519px\">",
"   <div class=\"ttl\">",
"    Peak influenza activity, by month - United States, 1976-77 through 2010-11",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 499px; height: 290px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Centers for Disease Control and Prevention. The flu season. Available at: file://www.cdc.gov/flu/about/season/flu-season.htm. Accessed on September 21, 2011.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_3_12349=[""].join("\n");
var outline_f12_3_12349=null;
var title_f12_3_12350="Drug interactions between NRTIs and other drugs";
var content_f12_3_12350=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F50446&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F50446&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Drug interactions between NRTIs and other drugs (including antiretroviral drugs)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Concomitant drug class/name",
"       </td>",
"       <td class=\"subtitle1\">",
"        NRTI",
"       </td>",
"       <td class=\"subtitle1\">",
"        Effect on NRTI or concomitant drug concentrations",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dosage recommendations and clinical comments*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Antivirals",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Ganciclovir",
"        <br/>",
"        Valganciclovir",
"       </td>",
"       <td>",
"        Tenofovir (TDF)",
"       </td>",
"       <td>",
"        No data",
"       </td>",
"       <td>",
"        Serum concentrations of these drugs and/or TDF may be increased. Monitor for dose-related toxicities.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Zidovudine (ZDV)",
"       </td>",
"       <td>",
"        No significant pharmacokinetic effects",
"       </td>",
"       <td>",
"        Potential increase in hematologic toxicities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Ribavirin",
"       </td>",
"       <td>",
"        Didanosine (ddI)",
"       </td>",
"       <td>",
"        &uarr; intracellular ddI",
"       </td>",
"       <td>",
"        <strong>",
"         Contraindicated. Do not coadminister.",
"        </strong>",
"        Fatal hepatic failure and other ddI-related toxicities have been reported with coadministration.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Zidovudine (ZDV)",
"       </td>",
"       <td>",
"        Ribavirin inhibits phosphorylation of ZDV",
"       </td>",
"       <td>",
"        Avoid coadministration if possible or closely monitor virologic response and hematologic toxicities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Integrase inhibitor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Raltegravir (RAL)",
"       </td>",
"       <td>",
"        Tenofovir (TDF)",
"       </td>",
"       <td>",
"        RAL AUC &uarr; 49 percent, C",
"        <sub>",
"         max",
"        </sub>",
"        &uarr; 64 percent",
"       </td>",
"       <td>",
"        No dosage adjustment necessary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Narcotics/treatment for opioid dependence",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Buprenorphine",
"       </td>",
"       <td>",
"        Lamivudine (3TC), didanosine (ddI), tenofovir(TDF), zidovudine (ZDV)",
"       </td>",
"       <td>",
"        No significant effect",
"       </td>",
"       <td>",
"        No dosage adjustment necessary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"3\">",
"        Methadone",
"       </td>",
"       <td>",
"        Abacavir (ABC)",
"       </td>",
"       <td>",
"        Methadone clearance &uarr; 22 percent",
"       </td>",
"       <td>",
"        No dosage adjustment necessary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Stavudine (d4T)",
"       </td>",
"       <td>",
"        d4T AUC &darr; 23 percent and C",
"        <sub>",
"         max",
"        </sub>",
"        &darr; 44 percent",
"       </td>",
"       <td>",
"        No dosage adjustment necessary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Zidovudine (ZDV)",
"       </td>",
"       <td>",
"        ZDV AUC &uarr; 29-43 percent",
"       </td>",
"       <td>",
"        Monitor for ZDV-related adverse effects",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        NRTIs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Didanosine (ddI)",
"       </td>",
"       <td>",
"        Stavudine (d4T)",
"       </td>",
"       <td>",
"        No significant PK interaction",
"       </td>",
"       <td>",
"        <strong>",
"         Avoid coadministration.",
"        </strong>",
"        Additive toxicities of peripheral neuropathy, lactic acidosis, and pancreatitis seen with this combination.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tenofovir (TDF)",
"       </td>",
"       <td>",
"        ddI-EC AUC and C",
"        <sub>",
"         max",
"        </sub>",
"        &uarr; 48-60 percent",
"       </td>",
"       <td>",
"        <strong>",
"         Avoid coadministration",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Allopurinol",
"       </td>",
"       <td>",
"        Didanosine (ddI)",
"       </td>",
"       <td>",
"        <p>",
"         ddI AUC &uarr; 113 percent",
"        </p>",
"        <p>",
"         ddI AUC &uarr; 312 percent with renal impairment",
"        </p>",
"       </td>",
"       <td>",
"        <strong>",
"         Contraindicated. Do not coadminister.",
"        </strong>",
"        Potential for increased ddI-associated toxicities.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Protease inhibitors (PIs)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"3\">",
"        Atazanavir (ATV)",
"       </td>",
"       <td>",
"        Didanosine (ddI)",
"       </td>",
"       <td>",
"        With ddI-EC + ATV (with food): ddI AUC &darr; 34 percent; ATV no change",
"       </td>",
"       <td>",
"        Administer ATV with food&nbsp;two hours before or&nbsp;one hour after didanosine",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Tenofovir (TDF)",
"       </td>",
"       <td>",
"        <p>",
"         ATV AUC &darr; 25 percent and C",
"         <sub>",
"          min",
"         </sub>",
"         &darr; 23-40 percent (higher C",
"         <sub>",
"          min",
"         </sub>",
"         with RTV than without)",
"        </p>",
"        <p>",
"         TDF AUC &uarr; 24-37 percent",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Dose: ATV/r 300/100 mg daily coadministered with TDF 300 mg daily. Avoid concomitant use without RTV. If using TDF and H",
"         <sub>",
"          2",
"         </sub>",
"         receptor antagonist in ART-experienced patients, use ATV/r 400 mg/100 mg daily.",
"        </p>",
"        <p>",
"         Monitor for TDF-associated toxicity.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Zidovudine (ZDV)",
"       </td>",
"       <td>",
"        ZDV C",
"        <sub>",
"         min",
"        </sub>",
"        &darr; 30 percent, no change in AUC",
"       </td>",
"       <td>",
"        Clinical significance unknown",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Darunavir/ritonavir (DRV/r)",
"       </td>",
"       <td>",
"        Tenofovir (TDF)",
"       </td>",
"       <td>",
"        TDF AUC &uarr; 22 percent, C",
"        <sub>",
"         max",
"        </sub>",
"        &uarr; 24 percent and C",
"        <sub>",
"         min",
"        </sub>",
"        &uarr; 37 percent",
"       </td>",
"       <td>",
"        Clinical significance unknown. Monitor for TDF toxicity.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lopinavir/ritonavir (LPV/r)",
"       </td>",
"       <td>",
"        Tenofovir (TDF)",
"       </td>",
"       <td>",
"        <p>",
"         LPV/r AUC &darr; 15 percent",
"        </p>",
"        <p>",
"         TDF AUC &uarr; 34 percent",
"        </p>",
"       </td>",
"       <td>",
"        Clinical significance unknown. Monitor for TDF toxicity.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"3\">",
"        Tipranavir/ritonavir (TPV/r)",
"       </td>",
"       <td>",
"        Abacavir (ABC)",
"       </td>",
"       <td>",
"        ABC &darr; 35-44 percent with TPV/r 1250/100 mg twice per day",
"       </td>",
"       <td>",
"        Appropriate doses for this combination have not been established",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Didanosine (ddI)",
"       </td>",
"       <td>",
"        ddI-EC &darr; 10 percent and TPV C",
"        <sub>",
"         min",
"        </sub>",
"        &darr; 34 percent with TPV/r 1250/100 mg twice per day",
"       </td>",
"       <td>",
"        Separate doses by at least&nbsp;two hours",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Zidovudine (ZDV)",
"       </td>",
"       <td>",
"        ZDV AUC &darr; 31-43 percent and C",
"        <sub>",
"         max",
"        </sub>",
"        &darr; 46-51 percent with TPV/r 1250/100 mg twice per day",
"       </td>",
"       <td>",
"        Appropriate doses for this combination have not been established",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     3TC: lamivudine; ABC: abacavir; ATV: atazanavir; AUC: area under the plasma concentration-time curve; C",
"     <sub>",
"      max",
"     </sub>",
"     : maximum plasma concentration; C",
"     <sub>",
"      min",
"     </sub>",
"     : minimum plasma concentration; d4T: stavudine; ddI: didanosine; EC: enteric coated; NRTI: nucleoside reverse transcriptase inhibitor; PI: protease inhibitor; PK: pharmacokinetic; RAL: raltegravir; TDF: tenofovir; ZDV: zidovudine.",
"     <br>",
"      * For additional information see Lexi-Comp drug interactions program included with UpToDate.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Updated January 10, 2011.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_3_12350=[""].join("\n");
var outline_f12_3_12350=null;
var title_f12_3_12351="Nomogram for BMI";
var content_f12_3_12351=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F65305&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F65305&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 473px\">",
"   <div class=\"ttl\">",
"    Nomogram for determining body mass index",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 453px; height: 511px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The nomogram is used by placing a ruler or other straight edge between the body weight in kilograms or pounds (the left-hand line) and the height in centimeters or inches (the right-hand line). The body mass index is read from the middle of the scale, in metric units.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_3_12351=[""].join("\n");
var outline_f12_3_12351=null;
